

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

# **BMJ Open**

## **COVID-19** seroprevalence among workers of a Comprehensive Cancer Center in Catalonia, Spain.

Journal:	BMJ Open
Manuscript ID	bmjopen-2021-056637
Article Type:	Original research
Date Submitted by the Author:	27-Aug-2021
Complete List of Authors:	Peremiquel-Trillas , Paul; Catalan Institute of Oncology, Tobacco Control Unit Saura-Lazaro, Anna; Catalan Institute of Oncology, Tobacco Control Unit Benavente Moreno, Yolanda Casabonne, Delphinne; Catalan Institute of Oncology Loureiro, Eva; Catalan Institute of Oncology Cabrera, Sandra; Catalan Institute of Oncology Duran, Angela; Catalan Institute of Oncology Garrote, Lidia; Catalan Institute of Oncology Brao, Immaculada; Catalan Institute of Oncology Galán, Maica; Catalan Institute of Oncology Galán, Maica; Catalan Institute of Oncology Soler, Francesc; Catalan Institute of Oncology Julia, Joaquim; Catalan Institute of Oncology Cortasa, Dolça; Catalan Institute of Oncology Domínguez, Maria Ángeles; Bellvitge University Hospital Albasanz-Puig, Adaia; Catalan Institute of Oncology Gudiol, Carlota; Catalan Institute of Oncology Ramírez, Dolors; Catalan Institute of Oncology Muniesa, Joan; Catalan Institute of Oncology Muniesa, Joan; Catalan Institute of Oncology Muñoz-Montplet, Carles; Catalan Institute of Oncology Rivas, Juan; Catalan Institute of Oncology Rivas, Juan; Catalan Institute of Oncology Calle, Candela; Catalan Institute of Oncology Cancer-Pont, Dolors; Hospital Duran i Reynals, Alemany, L.; Institut Catala d' Oncologia, Fernandez, Esteve; Catalan Institute of Oncology, Tobacco Control Unit
Keywords:	COVID-19, Adult oncology < ONCOLOGY, Epidemiology < INFECTIOUS DISEASES, Epidemiology < ONCOLOGY

## SCHOLARONE<sup>™</sup> Manuscripts

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies



*I*, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.



## **COVID-19 seroprevalence among workers of a Comprehensive Cancer Center in Catalonia, Spain.**

Paula Peremiquel-Trillas\*, Anna Saura-Lázaro\*, Yolanda Benavente-Moreno, Delphine Casabonne, Eva Loureiro, Sandra Cabrera, Angela Durán, Lidia Garrote, Inmaculada Brao, Jordi Trelis, Maica Galán, Francesc Soler, Joaquim Julià, Dolça Cortasa, M. Angeles Domínguez, Adaia Albasanz-Puig, Carlota Gudiol, Dolors Ramírez, Joan Muniesa, Juan Pedro Rivas, Carles Muñoz-Montplet, Ana Sedano, Àngel Plans, Beatriz Calvo-Cerrada, Candela Calle, Ana Clopés, Dolors Carnicer-Pont<sup>†</sup>, Laia Alemany<sup>†</sup>, Esteve Fernández<sup>†</sup>

\*Contributed equally

<sup>†</sup>Joint senior authors

#### **Authors' affiliations**

PPT	Cancer Epidemiology Research Programme, Cancer Epidemiology and Prevention Department, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain; Epidemiology and Public Health Programme, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain; CIBER in epidemiology and public health (CIBERESP), Madrid, Spain; School of Medicine and Clinical Sciences, Universitat de Barcelona, Barcelona, Spain. @PeremiquelPaula. ORCID: 0000-0002-8636-1725
ASL	Cancer Epidemiology Research Programme, Cancer Epidemiology and Prevention Department, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain; Epidemiology and Public Health Programme, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain. 0000-0001-9742-2725
YBM	Cancer Epidemiology Research Programme, Cancer Epidemiology and Prevention Department, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain; Epidemiology and Public Health Programme, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain; CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain. ORCID: 0000-0003-1422-4614
DC	Cancer Epidemiology Research Programme, Cancer Epidemiology and Prevention Department, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain; Epidemiology and Public Health Programme, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain; CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain. ORCID: 0000-0002-7874-3707
EL	Computer Science Services, Technology & Physics, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain; Computational Science and Artificial Intelligence, Faculty of Computer Science of Coruña, University of Coruña (UDC), Coruña, Spain.
SC	Research Nursing Department, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain. @scabrerajaime. ORCID: 0000-0003-3013-8812
AD	Nursing Department, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain.
LG	Nursing Department, Institut Català d'Oncologia – Badalona (ICO), Badalona, Spain.
IB	Nursing Department, Institut Català d'Oncologia – Girona (ICO), Girona, Spain
JT	Palliative Care Department and Medical Director, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain. @JordiTrelis.
MG	Esofagogastric Tumours Functional Unit and Medical Director, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain.
FS	Pharmacy Service and Medical Director, Institut Català d'Oncologia – Girona (ICO), Girona, Spain
JJT	Palliative Care Department and Medical Director. Institut Català d'Oncologia (ICO) Badalona, Badalona, Spain. @drjjulia. ORCI: 0000-0002-1462-3167
DC	Medical Director, Institut Català d'Oncologia - Tarragona/Terres de l'Ebre, Tarragona (ICO).
MADL	Microbiology Department. Hospital Universitari de Bellvitge; Infectious Diseases Programme, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL); Department of Pathology Experimental Therapeutics, Universitat de Barcelona, Barcelona, Spain.
AAP	Infectious Disease Department, Hospital Universitari de Bellvitge, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain. ORCID: 0000-0001-9852-5574
CG	Infectious Disease Department, Hospital Universitari de Bellvitge, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain. @Carlotasway3. ORCID: 0000-0003-3095-4422

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

2	
3	
4	
5	
6 7	
6 7 8	
9	
) 10	
11	
12	
13	
14	
15	
16	
1/	
10	
20	
20	
22	
23	
24	
12 13 14 15 16 17 18 19 20 21 22 23 24 25	
26 27	
27	
28 20	
29 30	
31	
32	
32 33 34	
34	
35	
36 37	
37	
38 39	
40	
41	
42	
43	
44	
45	
46	
47	
48 49	
49 50	
50	
52	
53	
54	
55	
56	
57	
58	

59 60

1

DR Preventive Medicine Unit, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain.

- JM Computer Science Services, Technology & Physics Department, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain.
- JPR Computer Science Services, Technology & Physics Department, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain.
- CMM Technology and Physics Department, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain; Medical Physics and Radiation Protection Department, Institut Català d'Oncologia (ICO) – Girona, Girona, Spain; Department of Medical Sciences, Universitat de Girona, Girona, Spain. @CMunozMontplet. ORCID: 0000-0002-7324-8889
- AS Human Resources Department, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain.
- AC Scientific Direction, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain. ORCID: 0000-0002-1857-362X
- BCC Occupational Health Unit, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain.
- CC General Direction, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain. @CandelaCalle.
- AP Occupational Health Unit, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain. ORCID: 0000-0003-3199-0361
- DCP Cancer Prevention and Control Programme, Cancer Epidemiology and Prevention Department, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Spain; Epidemiology and Public Health Programme, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain. ORCID: 0000-0002-3475-8704
- LA Cancer Epidemiology Research Programme, Cancer Epidemiology and Prevention Department, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain; Epidemiology and Public Health Programme, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain; CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain. ORCID: 0000-0003-0945-6015
- EF Cancer Prevention and Control Programme, Cancer Epidemiology and Prevention Department, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain; Epidemiology and Public Health Programme, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain; School of Medicine and Clinical Sciences, Universitat de Barcelona, Barcelona, Spain; CIBER of Respiratory Diseases (CIBERES).
   @StvFdz. ORCID: 0000-0003-4239-723X

#### Word counts.

Abstract: 292. Main text: 3,626. One figure, three tables, one supplementary table.

*Correspondence to:* Prof. Esteve Fernández, MD, MPH, PhD. Tobacco Control Unit, Cancer Prevention and Control Programme, Institut Català d'Oncologia (ICO). Avinguda de la Granvia de l'Hospitalet, 199-203, 08908 L'Hospitalet de Llobregat, Barcelona, Spain. Phone: +34 93 2607345. E-mail: <u>efernandez@iconcologia.net</u> (Prof. E. Fernández).

#### ABSTRACT

**Objectives** Cancer patients are at higher risk for severe COVID-19 infection. COVID-19 surveillance of workers in oncological centres is crucial to assess infection burden and prevent transmission. We estimate the SARS-CoV-2 seroprevalence among health care workers (HCW) of a comprehensive cancer centre in Catalonia, Spain, and analyse its association with sociodemographic characteristics, exposure factors and behaviours.

**Design** Cross-sectional study (21<sup>st</sup> May – 26<sup>th</sup> June 2020)

Setting A comprehensive cancer centre in Catalonia, Spain,

**Participants** All HCW (N=1,969) were invited to complete an online self-administered epidemiological survey and to provide a blood sample for SARS-CoV-2 antibodies detection.

**Primary outcome measure** Prevalence (%) and 95% confidence intervals (CI) of seropositivity together with adjusted prevalence ratios (aPR) and 95%CI were estimated.

**Results** A total of 1,266 HCW filled the survey (participation rate: 64.0%) and 1,238 underwent serological testing (97.8%). The median age was 43.7 years (p25-p75: 34.8-51.0 years), 76.0% were female, 52.0% were nursing or medical staff, and 79.0% worked on-site during the pandemic period. SARS-CoV-2 seroprevalence was 8.9% (95%CI: 7.44-10.63), with no differences by age and sex. No significant differences in terms of seroprevalence were observed between onsite workers and teleworkers. Seropositivity was associated with living with a person with COVID-19 (aPR: 3.86, 95%CI: 2.49-5.98). Among on-site workers, seropositive participants were twofold more likely to be nursing or medical staff. Nursing and medical staff working in a COVID-19 zone showed a higher seroprevalence than other staff (aPR: 2.45, 95% CI: 1.08-5.52).

**Conclusions** At the end of the first wave of the pandemic in Spain, SARS-CoV-2 seroprevalence among ICO HCW was lower than the reported in other Spanish hospitals. The main risk factors were sharing household with infected people and contact with COVID-19 patients and colleagues. Strengthening preventive measures and health education among HCW is fundamental.

**Keywords** SARS-CoV-2; COVID-19; seroprevalence; antibody; health care workers; epidemiology.

### **ARTICLE SUMMARY**

### Strenghts and limitations

- This study is the first seroepidemiological study with such a large sample size settled in an oncological health centre and has had a high response rate (64.3%)
- Questionnaire completeness was very high, with no variables presenting more than 5% of missing values.
- Some recall bias is possible as the data for the correlates of SARS-CoV-2 infection rely on a self-administered questionnaire. Also, results regarding the accomplishment of preventive measures, might be overestimated.
- Response and perception biases must be considered, as well as complacency bias.
- Answers reported in the questionnaire could be influenced by the participants' knowledge regarding their COVID status.

## Highlights

- First SARS-CoV-2 health care workers seroprevalence study in an oncological monographic centre
- Health care workers seroprevalence knowledge may help hospitals to characterize risk and reduce the risk of infection.
- Protecting HWC health is of paramount importance for reducing morbidity and mortality, reducing transmission, and maintaining the health system capacity
- Strengthening preventive measures among health care workers is fundamental in oncological settings.

#### INTRODUCTION

Frontline health care workers (HCW) dealing with COVID-19 have higher exposure to SARS-CoV-2 than the general population (1) and they can contribute to the spread of COVID-19 as per their exposure to vulnerable patients. Data regarding the prevalence of SARS-CoV-2 infections in HCW are scarce, variable, and characterized by underlying limitations related to the lack of information on tests performance (2). The European Centre for Disease Prevention and Control (ECDC) has analysed surveillance data with known HCW status from 15 countries in Europe, reporting an overall percentage of HCW among COVID-19 cases of 23.0% but no data on prevalence by workplace or speciality is available (3). In Spain the HCW have been highly affected: a total amount of 40,921 cases among HCW were already officially notified by the 11<sup>th</sup> of May 2021(4) at the end of the third wave.

Cancer patients are vulnerable, presenting a high risk for COVID-19 infection and more severe outcomes due to their immunosuppression status (5). The pandemic has presented unprecedented professional and personal challenges for the oncology community (6). Data are lacking on the seroprevalence of SARS-CoV-2 among HCW in oncological centres. The present study aims to estimate the seroprevalence of SARS-CoV-2 and associated sociodemographic and behavioural risk factors among workers of the Catalan Institute of Oncology (ICO), a Comprehensive Cancer Centre comprised of four hospitals in Catalonia (Spain), covering around 40% of the adult population in Catalonia (7).

#### PARTICIPANTS AND METHODS

#### Study design and setting

A cross-sectional study including blood sample collection and a self-administered questionnaire was conducted between 21<sup>st</sup> May and 26<sup>th</sup> June 2020 in the four ICO centres (L'Hospitalet de Llobregat, Badalona, Tarragona/Terres de l'Ebre and Girona).

The study population were HCW delivering care and services to patients (directly or indirectly), and support staff, including those who do not deliver care but work in other tasks within the hospital. A total of 1,969 employees of ICO were invited to participate in the study through an email that allowed access to the study information. The inclusion criteria were: a)

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

to be an active worker during the epidemic period, (1<sup>st</sup>February - 26<sup>th</sup>June 2020) and b) to be aged  $\geq$ 18years. The participants filled in an online epidemiological questionnaire and were scheduled for serology testing by the Occupational Health Department. 1,266 HCW filled in the online epidemiological questionnaire (participation rate: 64.3%) and 1,238 of them (97.8%) underwent a serology test. Three participants with inconclusive serological results were excluded. The final analysis included 1,235 participants (**Figure 1**).

Figure 1 about here

to perteries only

#### Epidemiological questionnaire and study variables

An epidemiological questionnaire was programmed online to collect information regarding sociodemographic characteristics, working information, compliance of personal protective equipment (PPE) measures at work, at home and history of previous COVID-19 infection.

Sociodemographic characteristics included information on age and sex and ICO centre of recruitment, presence of comorbidities, smoking history, pregnancy and cohabitants.

Work-related conditions included the professional category, teleworking status, type of shift, working on a COVID19 zone, contact with COVID-19 cases, contact with biological samples and reporting to be exposed to COVID-19.

In relation to PPE measures at work, participants were asked about feeling protected with PPE and compliance of PPE measures. In respect of preventive measures at home, participants were asked about using face mask when shopping, shower and clothes changing after work or upon home arrival and hand cleaning. Among those participants reporting cohabitants, information about COVID-19 cases and protective measures were also collected. Participants were also asked about the type of transport used to go to work.

Participants were asked about a previous diagnose (and date) of COVID-19 by rRT-PCR or serology, as well as reporting COVID-19 compatible symptoms, and the type of symptoms.

#### SARS-CoV-2 laboratory testing

Serum samples from participants at L'Hospitalet, Girona and Tarragona/Terres de l'Ebre were studied at the Microbiology Department of Hospital de Bellvitge; whereas samples from health-care workers at ICO Badalona were analysed at the MetroNord Regional Clinical Laboratory. Detection of SARS-CoV-2 antibodies was carried out using the quantitative SARS-CoV-2 S1/S2 IgG LIAISON® test (DiaSorin, Vercelli, Italy) on the LIAISON XL platform, following the manufacturer's instructions. This test discriminates among negative (<12AU/mL; with 3.8 as IgG detection limit), equivocal (12.0–15.0AU/mL) and positive (>15.0AU/mL) subjects. In those cases in which a) IgG anti S1/S2 quantification was higher than the limit of detection (i.e.>3.8AU/mL) but did not reach the limit of discrimination (i.e.<15AU/mL) and/or b) when the healthcare workers answered the questionnaire saying that he or she had been diagnosed of COVID-19 but IgG anti S1/S2 where lower than 15

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

AU/ml, an additional serological study was performed using a different antigen (N) as a target. In this case, a SARS-CoV-2 IgG test (Abbott Diagnostics, Sligo, Ireland) was run on an Architect i2000 platform. This test discriminates among negative (<1.4Index (S/C)) and positive ( $\geq$ 1.4Index (S/C)) subjects.

#### **Case definition**

A seropositive case of SARS-CoV-2 was defined as seropositivity to IgG independently of previous self-reported results.

#### **Patient and Public Involvement**

No patient involved

#### **Statistical analysis**

Crude global and by subgroups SARS-CoV-2 seroprevalences and their 95% confidence intervals (CI) were calculated. Differences in the distribution of study variables between seropositive and seronegative participants were assessed by means of chi-squared test for categorical variables, and parametric or non-parametric tests were performed for normal and non-normal continuous variables, respectively. Prevalence ratios (PR) and 95% confidence intervals (CI) were estimated using Poisson regression models with robust variance(8). Prevalence ratios were adjusted (aPR) for statistically significant variables in the bivariate analysis and those considered relevant for the study design. Thus, adjusted models include sex, ICO centre of recruitment, age, type of HCW, teleworking and cohabitants. Linear trends of number of symptoms among those reporting COVID-19 compatible symptoms when rRT-PCR was performed was assessed by fitting the model with the ordinal variable as a continuous. *P*-values were based on 2-sided hypothesis tests and considered significant at p<0.05. All analyses were conducted by using Stata version 16.0 (StataCorp LP, College Station, Texas).

#### **Ethical considerations**

The present study was approved by the Hospital Universitari de Bellvitge Ethics Committee (PR205/20). The study follows the Helsinki Declaration and subsequent amendments, and Spanish data confidentiality laws (General data protection regulation Organic Law 3/2018, the EU General data protection Regulation 2016/679 and Law 14/2007 for biomedical

research). All participants signed an informed consent form after receiving information of the study and prior to obtaining biological samples. The biological material obtained was kept at ICO and processed under the appropriate measures in order to preserve the confidentiality of the results and data.

#### RESULTS

A total of 1,235 HCW with serological results (Figure 1) were included in the analysis: 76.0% were female, the median age was 43.7 years (p25-p75: 34.8-51.0 years), 52.2% were nursing or medical staff and 18.6% of the participants teleworked full-time during the study period (Table 1). No differences in baseline characteristics between the participants' teleworking and the rest were found (data not shown). Up to 14.7% of the participants reported at least one comorbidity. Regarding smoking habits, 16.0% were current smokers and 28.2% reported to be former smokers (Table 1). Seven women were pregnant and none of them showed seropositivity.

The overall crude SARS-CoV-2 seroprevalence was 8.9% (95%CI: 7.44-10.63), with no statistically significant differences by neither age group nor sex, and the seroprevalence for nursing and medical staff was 11.6% (95%CI: 9.37-14.34). After fully adjustment, the main determinants of higher seroprevalence included working at ICO Girona compared to workers at ICO L'Hospitalet (aPR: 1.52, 95%CI: 0.97-2.38), and nursing or medical staff compared to other groups (aPR: 2.04, 95%CI: 1.33-3.14) (**Table 1**).

		BMJ Oper	1	jope	
Table 1. Sociodemographic characterist	ics associated with SARS-CoV-2	positive serology among stu	dy participants (N=1,235).	bmjopen-2021- J by copyright,	
	Total participants	SARS-CoV-2 seroprevalence	Prevalence (95%CI)	<sup>6</sup> bmjopen-2021-05663 pon 21 by copyright, including for	aPR (95% CI
	n (%)	n (%)		on 2 ng fe	
Study participants	1,235	110	8.91 (7.44-10.63)	4 <u>1</u>	
Sex				April 2022 82 Enseignement uses related to to	
Male	291 (23.6)	27 (24.5)	9.28 (6.44-13.20)	eigi reli	REF
Female	939 (76.0)	83 (75.5)	8.84 (7.18-10.83)	atec <b>19</b> .82	0.82 (0.53-1.2
Age [median, (p25-p75)]	43.7 (34.8-51.0)	42.8 (32.0-50.1)			0.99 (0.97-1.0
<35 years	313 (25.3)	33 (30.0)	10.54 (7.59-14.46)	vnlc t Su tex	REF
35-49 years	566 (45.8)	47 (42.7)	8.30 (6.29-10.88)	t ar	0.85 (0.55-1.3
>49 years	356 (28.8)	30 (27.3)	8.43 (5.95-11.80)	/nloaded from http://b Superieur (ABES) . text and data mining,	0.88 (0.53-1.4
ICO Center				rom r (A	
ICO L'Hospitalet	885 (71.7)	73 (66.4)	8.25 (6.61-10.25)		REF
ICO Girona	204 (16.5)	29 (26.4)	14.22 (10.06-19.72)	ning	1.52 (0.97-2.3
ICO Badalona	134 (10.9)	7 (6.4)	5.22 (2.51-10.56)	J, A	0.54 (0.25-1.1
ICO Tarragona / Terres de l'Ebre	12 (1.0)	1 (0.9)	8.33 (1.16-41.38)	April 2022: 02 Enseignement Superieur (ABES) . uses related to text and data mining, Al training, and similar technologies.	1.07 (0.15-7.8
Professional category				bmj.c	
Nursing staff <sup>1</sup>	380 (30.8)	43 (39.0)	11.32 (8.50-14.92)	nd	REF
Medical Staff <sup>2</sup>	265 (21.5)	32 (29.1)	12.08 (8.67-16.58)	sim:	1.07 (0.65-1.7
Middle and superior technicians	285 (23.1)	14 (12.7)	4.91 (2.93-8.13)	ı June ilar te	0.41 (0.22-0.7
Service staff <sup>3</sup>	114 (9.2)	2 (1.8)	7.02 (3.55-13.42)	e 13 chn	0.69 (0.31-1.54
Watchmen	21 (1.7)	8 (7.3)	9.52 (2.39-31.16)	, 20 olo	0.74 (0.17-3.2
Administratives	129 (10.4)	8 (7.3)	6.20 (3.13-11.92)	25 a gie	0.54 (0.25-1.1
Other	20 (1.6)	1 (0.9)	5.00 (0.70-28.26)	10.03	0.50 (0.07-3.7
Nursing or medical staff <sup>4</sup>	645 (52.2)	75 (68.2)	11.63 (9.37-14.34)	Agenc∂.001	2.04 (1.33-3.14
Other staff <sup>s</sup>	569 (46.1)	33 (30.0)	5.80 (4.15-8.05)	Bibliographique.56	REF
Telework				ogra	
Never/Occasionally	981 (79.4)	86 (78.1)	8.77 (7.15-10.71)	iphi	REF
Always	230 (18.6)	23 (20.9)	10.00 (6.72-14.63)	<b>द्र</b> ).56	1.60 (0.98-2.59

e 13 of 30		BMJ Open		bmjopen-2021 d by copyright	
Table 1 (continued)	Total participants	SARS-CoV-2	Prevalence (95%CI)	-2021-056637 on 21 April 2022. Downl Enseignement S	aPR (95% CI) <sup>8</sup>
		seroprevalence		51ud	
Shift work	545 (44.1)	40 (47 0)	0.00 (6.06.11.7)	' on	DEE
Morning	545 (44.1)	49 (45.0)	8.99 (6.86-11.7)	1 21 for	REF
Evening	140 (11.3)	10 (9.1)	7.14 (3.88-12.77)	us Ep	0.56 (0.34-0.93)
Split shift (morning-evening)	417 (33.8)	38 (34.5)	9.11 (6.7-12.28)	es r	0.88 (0.57-1.37)
Night	88 (7.1)	10 (9.1)	11.36 (6.22-19.86)	elan ela	0.95 (0.46-1.96)
Other	25 (2)	3 (2.7)	12 (3.92-31.32)		1.15 (0.35-3.75)
Comorbidities <sup>6</sup>				ent to t	
None	1,054 (85.3)	99 (90.0)	9.39 (7.77-11.31)	nlo: Sul	REF
Yes	181 (14.7)	11 (10.0)	6.08 (3.4-10.64)	ed to text and d	0.67 (0.36-1.25)
Smoking history				d di	
Never	650 (52.6)	80 (72.7)	12.31 (9.99-15.07)	ata	REF
Past	348 (28.2)	22 (20.0)	6.32 (4.20-9.42)	ABES	0.57 (0.35-0.93)
Current	198 (16.0)	8 (7.3)	4.04 (2.03-7.87)	<b>i i i i i i i i i i</b>	0.38 (0.18-0.79)
Cohabitants				• •	
Yes	1,119 (90.6)	95 (86.0)	8.49 (6.99-10.27)	Al training	REF
No	104 (8.4)	15 (13.6)	14.42 (8.88-22.57)	<b>D</b> .04	1.48 (0.83-2.66)
Numbers do not always sum up the total aPR: adjusted Prevalence Ratio, CI: Con <sup>1</sup> Nursing staff: nurses and nursing assist <sup>2</sup> Medical staff: resident physicians and s <sup>3</sup> Service staff: security, maintenance, cle <sup>4</sup> Nurses, nursing assistants, resident phy <sup>5</sup> Middle and superior technicians, securi <sup>6</sup> Comorbidities: hypertension, obesity (I disorders. <sup>7</sup> Chi-squared test for categorical variabl <sup>8</sup> Adjusted for sex, age (continuous), ICC	afidence Interval, p25: 25% percent ants. specialists. eaning and kitchen. rsicians and specialists. (ty, maintenance, cleaning, kitcher BMI≥30), heart disease, liver dise es (Fisher's exact test corrected for	ntile, p75: 75% percentile. n, watchmen, administrative ase, diabetes, chronic respira or continuity) and median tes	, and other. atory disease, renal disease, can	m/ on June 13, ; d similar techno	sorders and other immunolo
				e Bibliographiqu	

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

Seroprevalence among on-site workers was 8.8% (95%CI:7.15-10.71) (Table 2). Onsite workers were younger, mostly health care workers, and reported more frequently rRT-PCR previous to serology than teleworkers but no differences were observed in sex, self-reported comorbidities, smoking history, cohabiting with COVID-19 positive case between them and teleworkers (data not shown). Among this group (N=981) of professionals who never or occasionally teleworked SARS-CoV-2 seropositivity was not associated with not working in a COVID-19 zone (aPR: 1.29, 95%CI: 0.81-2.06), nor being in contact with COVID-19 biological samples (aPR: 1.30, 95%CI: 0.77-2.20) nor being in contact with patient with COVID-19 (aPR: 1.09, 95%CI: 0.66-1.79) were associated with SARS-CoV-2 positivity (Table 2). On-site nursing or medical staff who worked in a COVID zone had twofold SARS-CoV-2 seroprevalence than others who did not work in COVID zone (aPR: 2.45, 95%CI: 1.08-5.52). Seropositivity was higher among those who referred being exposed by interacting with colleagues (aPR: 3.26, 95%CI: 1.49-7.15). On-site workers who self-reported symptoms of COVID-19 were almost 10-fold more likely to be seropositive than those who did not (aPR: 9.5, 95%CI: 5.34-17.03). Most of on-site workers were highly adherent to the recommendation of hand hygiene at work. Hand-washing before eating or working were followed by more than 97% of on-site workers, whereas around 24% of them reported not hand hygiene after working or a low frequency of hand washing during the workday. In relation to protective measures at work 17.4% of the on-site workers did not feel protected with PPE and 12.1% did not use PPE with confirmed or suspicious COVID-19 cases. In reference to colleagues' behaviour, 2m safety distance from colleagues when having lunch was reported to be unfollowed by 14.1% (Table 2).

#### BMJ Open

	by copyright, ir .).	2021-0			
	Total participants	SARS-CoV-2 seroprevalence	Prevalence (95%CI)	, Q	Adjusted PR (95% CI) <sup>3</sup>
	n (%)	n (%)	for	21	(/ 2 / 2 / 2 / )
On-site workers	981 (79.4)	86 (78.1)	8.77 (7.15-10.71) g	April 0.56	
Type of transport to work			es r	nse	
Private	751 (76.6)	66 (76.7)	8.79 (6.96-11.04) 🧧	2022. eignei	REF
Public	154 (15.7)	15 (17.4)	9.74 (5.95-15.54) <b>6</b>		1.32 (0.74-2.36
Private and Public	35 (3.6)	2 (2.3)	5.71 (1.43-20.19) <b>6</b>	Dow	0.63 (0.15-2.58
Walking	37 (3.8)	3 (3.5)	8.11 (2.63-22.34)	Sul 0.89	0.57 (0.14-2.35
Working in a COVID-19 zone			an	aded	
No	398 (40.6)	29 (33.7)	7.29 (5.11-10.29)	d fr	REF
Yes	545 (55.6)	55 (63.9)	10.09 (7.83-12.92)	ur (Al	1.29 (0.81-2.06
Type of and COVID zone <sup>1</sup>			B. B.	BEC	
Non-assisting HCW & never worked in a COVID-19 zone	148 (15.1)	7 (8.0)	4.73 (2.27-9.6) ng		REF
Non-assisting HCW & ever worked in a COVID-19 zone	230 (23.4)	13 (15.1)	5.65 (3.31-9.5)	://bmjope	1.12 (0.44-2.82
Assisting HCW & never worked in a COVID-19 zone	244 (24.9)	22 (25.6)	9.02 (6.01-13.32) <b>fa</b>	ope	1.81 (0.77-4.26
Assisting HCW & ever worked in a COVID-19 zone	311 (31.7)	40 (46.5)	9.02 (6.01-13.32) faining	0.006	2.45 (1.08-5.52
<i>p-trend</i>				, <u>ä</u> ,	0.26
Contact with COVID-19 cases			and		
No	333 (33.9)	23 (26.7)	6.91 (4.63-10.18) 10.63 (8.29-13.54)	20	REF
Yes	536 (54.6)	57 (66.3)	10.63 (8.29-13.54)	9.07 مے 0.07	1.30 (0.77-2.20
Contact with COVID-19 biological samples					
No	646 (65.9)	51 (59.3)	7.89 (6.05-10.24)	1	REF
Yes	282 (28.7)	30 (34.9)	10.64 (7.54-14.81) 🔒	2025 0.17	1.09 (0.66-1.79
Reporting to be exposed to COVID-19 by interacting with colleagues at work			7.89 (6.05-10.24) 10.64 (7.54-14.81)	••	
No	242 (24.7)	66 (76.7)	2.89 (1.38-5.95)	ger	REF
Yes	608 (62.0)	7 (8.1)	10.86 (8.62-13.59)	Agence 0.0001	3.26 (1.49-7.1
Reporting COVID-19 compatible symptoms					
No	623 (63.5)	15 (17.4)	2.41 (1.46-3.96)	Bibliog	REF
Yes	306 (31.2)	68 (79.1)	22.22 (17.91-27.23)	<u>a</u> 0.0001	9.53 (5.34-17.0

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

		BMJ Open	⅓ by copyright,	bmjopen-2021-05	
Table 2 (continued)			right, in	·2021-05	
	Total participants	SARS-CoV-2 seroprevalence	Prevalence (95%CI)	Sp-value <sup>2</sup>	Adjusted PR (95% CI) <sup>3</sup>
Not following protection measures at work			g fo	on 2	
Felt protected with PPE	132 (17.4)	12 (16.9)	9.09 (5.23-15.34) g	► 0.83	0.98 (0.51-1.88)
Colleagues cover themselves with their elbows when sneezing/coughing	155 (15.8)	21 (24.4)	13.55 (9.00-19.90)	0.83 April 0.01	1.70 (1.01-2.87
2m safety distance from colleagues during lunch	127 (14.1)	12 (15.6)	9.45 (5.44-15.91)	<b>N</b> 0.71	1.06 (0.56-1.99
Use of PPE with confirmed or suspicious COVID-19 patients	79 (12.1)	7 (10.45)	8.86 (4.28-17.46) <b>6</b>		1.01 (0.45-2.26)
PPE removal safety	48 (7.3)	3 (4.6)	6.25 (2.03-17.68)	0.33 0.21 0.62	0.54 (0.17-1.74)
Personal use of mask	34 (3.5)	1 (1.2)	2.94 (0.41-18.17)	0.21	0.41 (0.06-2.99)
Colleagues use of surgical mask	7 (0.7)	1 (1.2)	14.29 (1.96-58.12) og	0.62	1.68 (0.23-12.29
Not following hand hygiene at work			ta r	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	
$\leq$ 7 times during workday	233 (23.8)	15 (17.4)	6.44 (3.92-10.41)	0.13	0.71 (0.39-1.28)
After money, phone and other personal tools manipulation	175 (17.8)	16 (18.6)	9.14 (5.67-14.41)	0.89	1.00 (0.58-1.74
Every time entering in a new workspace	102 (10.4)	5 (5.8)	4.90 (2.05-11.25)	0.14 0.37 0.67	0.55 (0.22-1.37)
Before working	21 (2.1)	3 (3.5)	14.29 (4.67-36.17)	<b>9</b> 0.37	1.72 (0.54-5.47)
After finishing the workday	17 (1.7)	1 (1.2)	5.88 (0.82-32.09) jig		0.65 (0.09-4.72)
Before eating	9 (0.9)	2 (2.3)	22.22 (5.59- 57.95) <b>a</b>	0.16	2.67 (0.65-10.94
umbers do not always sum up the total due to some missing val- R: Prevalence Ratio, CI: Confidence Interval, HCW: Health Can Assisting HCW: nurses, nursing assistants, resident physicians a Chi-squared test. Adjusted for sex, age (continuous), ICO centre, care staff, telework	re Workers. and specialists; other	-	ilar	on June 13, 2025 at <i>A</i>	
				vgence Bibliographique de l	
For peer	review only - http://	l. /bmjopen.bmj.com/sit	e/about/guidelines.xhtml	de I	

Concerning the correlates of seropositivity according to household factors for all participants (**Table 3**), seropositivity was associated with living with a COVID-19 positive person (aPR: 3.86, 95%CI: 2.49-5.98). Up to 17.3% of the participants did not take a shower nor changed clothes upon arrival, but the majority (99.0%) did hand hygiene upon arrival. The least followed hand hygiene home practices were after money, phone and other personal tools manipulation as well as after nose blowing (23.5% and 22.7%). However, not following protection measures or hand hygiene at home were associated to a higher SARS-CoV-2 for occreation with seroprevalence.

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Table 3. Household factors associated with SARS-CoV-2 positive serology among study participants (n=1,235). SARS-CoV-2 **Total participants** seroprevalence Adjusted PR (95% CI)<sup>3</sup> Prevalence (95%CI) n (%) n (%) 8.91 (7.44-10.63) 1.235 110 **Study participants Cohabitants with COVID-191** 52 (54.7) 5.82 (4.46-7.56) 894 (79.9) REF No 34 (35.8) 24.11 (17.76-31.86) 141 (12.60) 3.86 (2.49-5.97) Yes Cohabitants cover themselves with their elbow when sneezing 158 (14.1) 18 (18.9) 11.39 (7.29-17.37) REF No 919 (82.1) 0.73 (0.43-1.22) 73 (76.8) 7.94 (6.36-9.88) Yes Not following protection measures at home<sup>4</sup> Use of face mask when shopping 17 (1.4) 2(1.8)11.76 (2.95-36.86) 0.98(0.24-4.05)*Shower and clothes changing* 214 (17.3) 20 (18.2) 9.35 (6.11-14.05) 1.02 (0.62-1.69) afterwork or upon home arrival Not following hand hygiene at home<sup>4</sup> 12(1)2(1.8)16.67 (4.19-47.76) 1.59 (0.39-6.60) Upon arrival 9 (8.2) 60 (4.9) 15.00 (7.99-26.4) 1.55(0.77-3.12)Before eating After money, phone and other 290 (23.5) 27 (24.6) 9.31 (6.46-13.24) 1.01 (0.65-1.58) personal tools manipulation 110 (8.9) 8 (7.3) 7.27 (3.68-13.88) 0.78 (0.38-1.61) *After cleaning* 

25 (22.7)

Numbers do not always sum up the total due to some missing values (none of the categories present more than 5% of missing values). PR: Prevalence Ratio, CI: Confidence Interval.

280 (22.7)

<sup>1</sup>Analyses performed among those participants who reported having cohabitants (n=1,119).

<sup>2</sup> Chi-squared test.

After nose blowing

1 2 3

4 5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

43

44 45 46 <sup>3</sup> Adjusted for sex, age (continuous), ICO center, care staff, telework and cohabitants.

<sup>4</sup> Unfollowing the measures of protection and hand hygiene recommendations.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

8.93 (6.1-12.88)

nologies

3, 2025 at Agence Bibliographique

del

0.93 (0.58-1.48)

Page 19 of 30

#### **BMJ** Open

Clinical characteristics were collected for those participants (*N*=469) who reported a rRT-PCR performed previous to serology (**Suppl. table 1**). The majority of the patients with a positive serology and reporting a positive rRT-PCR presented compatible COVID-19 symptoms (74.4%). Among seropositive patients, the most common symptoms were arthromyalgia, cough, headache, asthenia and anosmia. Reporting a positive rRT-PCR when presenting compatible symptoms, was associated with a threefold higher prevalence of seropositivity (aPR: 3.10, 95%CI: 1.78-5.31). An increased number of compatible symptoms was also associated with a higher seroprevalence (aPR: 7.4, 95%CI: 1.78-5.31, for presenting 4 or more symptoms as compared to no symptoms).

#### DISCUSSION

Despite the impact of COVID-19 in oncological patients (9), there are no SARS-CoV-2 seroprevalence studies in comprehensive cancer centres. The global SARS-CoV-2 seroprevalence was 8.9%, lower than expected, owing to the presumed higher risk among HCW. Also, it was lower than the reported estimates in two studies performed among HCW in Catalonia between March-April and May 2020, showing a seroprevalence of 11.2% (10) and 10.3% (11) respectively. In both cases, the seroprevalence was higher than in the general population, estimated to be of a maximum of 7.4% in the Barcelona metropolitan area when the study was conducted (12), but lower than expected among these highly exposed populations. Seroprevalence studies interpretation must be related to the average COVID-19 prevalence at the time of blood collection, and both of the mentioned studies were carried out earlier in time than ours, which was performed approximately one month later (21st May-26th June 2020), and specifically two months after the first-wave peak in Catalonia (23<sup>th</sup> March) (13). An explanation for this lower seroprevalence in our Centre concerns the participation: all active HCW, regardless their teleworking status during the previous months or work absenteeism, were invited to participate, and most did (64%). In contrast, García-Basteiro's (10) and Barallat's (11) studies comprised general hospitals (10,11) and primary health care centers (11) in which the incidence could be higher than in a cancer monographic centre.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

In comparison with other Spanish seroprevalence studies, our estimate was even lower. A study performed among 2,509 HCW in the Alcorcón Hospital (Madrid), in April 2020, found a seroprevalence of 31.6% (14). A partial explanation for this large prevalence was the higher

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

exposure to the virus in this particular geographical area during the first wave of the epidemic. The largest population-based cross-sectional study in Spain, conducted from April 27<sup>th</sup> to May 11<sup>th</sup> to estimate the seroprevalence of SARS-CoV-2 infection showed a nationwide prevalence of 5.0% in adults, being of 6.8% in Barcelona and 11.5% in the Madrid region (12).

Other countries also reported the SARS-CoV-2 seroprevalence status of HCW, but with a quite broad range of outcomes and no specificity of HCW in oncological premises. Seroprevalence rates among HCW in Germany, Denmark and Belgium were low (1.6%, 4.0% and 6.4%, respectively) (15–17). These studies were conducted during early stages of the epidemic, and therefore, they supposed that infection was community-acquired. Also, the Belgian study, with a sample size of almost 30,000 HCW, notes that the high availability of PPE, high standards of infection prevention, and PCR screening in symptomatic staff, coupled with contact tracing and quarantine, might explain the relatively low seroprevalence (17). An study performed in Lombardy region, Italy (18), one of the regions most hit by the first epidemic wave, showed a seroprevalence of 7.4% (3.8-11.0%), similar to the observed in the Catalan studies (10,11). Sweden and the UK were the two European countries reporting the highest seropositivity rates among HCW: 19.1% and between 18.0% and 45.3%, respectively (19–21). In the UK, this high seroprevalence was settled in London during the week with the highest number of new cases in the city in the first wave, with around 15% seropositivity among the general population. In the USA, the prevalence of infection among HCW was 10.7%, despite high variation, as low as 1.1% in California (22) to 13.7% in New York State (23).

The differences observed among different countries and healthcare settings may be explained not only because of the period when the study was performed, but also by the seroprevalence (and the transmission rates) in the community, and the COVID policies stablished (social distancing, hand hygiene, and use of PPEs). Nonetheless, all the seroprevalence estimates among HCW were substantially higher than those reported in the general population of each geographical area during the same study period, firmly suggesting an occupational health hazard among HCW.

Despite SARS-CoV-2 seropositivity rate in oncological HCW has significant implications for oncological patients, scant research has been done. Some of the few studies performed, showed seroprevalence rates at huge variation. The lowest SARS-CoV-2 antibodies rates in

#### **BMJ** Open

oncological HCW (1% and 3.6%) were found in Thuringia (Germany) (24) and Vienna (Austria) (25), both areas with a low COVID-19 incidence during the first wave. The highest prevalence (21.2%) was reported in England between March and June 2020, among 70 workers, all patient-facing oncology staff, which may explain the high prevalence (26). All of those studies were based on small sample sizes (<70 participants) in oncological wards, but none, to the best of our knowledge, was conducted in monographic oncological hospitals or comprehensive cancer centres.

In our study, no differences in seroprevalence according to sex, age and presence of comorbidities were found. Current or past smoking was however inversely associated to SARS-CoV-2 seroprevalence. Early studies in selected cohorts of COVID-19 patients showed a paradoxical higher risk of SARS-CoV-2 infection among non-smokers (27) whilst ever smokers showed higher risk of COVID-19 progression, including severity of the disease, Intensive Care Unit admission and death (27,28). The reported prevalence of current smokers in this survey (16.5%) is lower than that reported in the periodical smoking surveys in our centres (ranging 21-26% in 2017-2019, unpublished data) probably due to underreporting of smoking or lack of reporting.

It is worth mentioning that, unlike most of the other published seroepidemiological studies among HCW, the present study was performed among all the HCW of the institution, regardless they did full-time telework during the study period (21.6%). No differences by telework were found, and among all study participants the main factor associated with SARS-CoV-2 seropositivity was living with a COVID-19 case, with a three times higher probability. This finding supports the importance of community dissemination of the infection also for HCWs. Similarly, the Belgian study suggested that neither being directly involved in clinical care nor working in a COVID-19 unit increased the likelihood of being seropositive, while having a suspected COVID-19 household contact did(17).

To avoid the spread of the disease, the only available and effective measures among health care workers during the first and second wave of the epidemic, have been hand hygiene, the use of mask and, when indicated, the use of complete PPE, physical distancing, patients' isolation, contact tracing of cases to quarantine their close contacts and screening them, as well as community based interventions such as screening of high-risk populations, mass quarantine and social or mobility restrictions (29). After December 2020 with the

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

authorization of first COVID-19 vaccinations, vaccines to prevent disease have become another useful tool, currently under implementation (30).

An increased risk of infection among HCW has been attributed to direct, close and long-time exposure to large numbers of infected patients, especially those involving certain practices such as intubations or contact with aerosols and body secretions (29,31). Other relevant factors that could contribute to increase the probability of infection among HCW are shortage of PPE (32) and work intensity and lack of rest (due to staff shortages) together with inadequate infection control training (33). Also, it has been observed that most of the HCW infected were working in general wards or first level emergency response departments (32).

Our study shows that among on-site HCW in an oncological centre, working as medical care staff (nursing, nursing assistant, resident physicians and specialists) in COVID-19 areas stood out as one of the main factors associated with developing SARS-CoV-2 antibodies. Published results regarding the possibility of in-hospital infection among HCW and transmission at work are controversial. Some studies did not find any relation between working in COVID unit or professional category with seropositivity (10,18). Korth et al. showed that seroprevalence was higher in the intermediate-risk group (daily non-COVID-19 patient contact) compared to the high-risk group (daily contact to COVID-19 patients on the designated wards and on the intensive care units) (OR: 0.2; p=0.13) (15). A study from Denmark showed that HCW working in COVID-19 wards had a significantly higher seroprevalence than other frontline health-care workers working in hospitals (RR: 1.7; p<0.001). Also, a Swedish study found that seroprevalence was strongly associated with patient-related work (16), COVID-19 patient contact (OR: 1.43, p<0.005), and occupation (as being an assisting nurse, OR: 3.7; p<0.005) (19).

In our study, the HCW who reported being exposed to COVID-19 by other colleagues presented an almost four-fold probability of being seropositive. Most of the HCW declared to follow the protective measures at the workplace. The moments with less accomplishment were at the end of the workday and after tools' manipulation, with no differences according to protective measures and hand hygiene. No differences in seroprevalence were found according to protective measures and hand hygiene.

Contact with colleagues at work is a potentially dangerous situation for transmission among HCW as well as the relaxation of protective measures at the end of the day. Therefore,

patients with COVID-19 might not be the main source of SARS-CoV-2 infection for HCW, and HCW could be exposed to non-suspected COVID-19 patients, infected family members, social contacts, and colleagues, as a result of the pandemic community transmission (34).

Protecting HWC health is of paramount importance for reducing morbidity and mortality, reducing transmission, and maintaining the health system capacity (35). Thus international health authorities recommend screening strategies for SARS-CoV-2 infection in exposed or high-risk HCW (36) as well as massive COVID-19 vaccination (37).

Significant differences exist in SARS-CoV-2 testing between countries, and existing programmes focus on screening symptomatic rather than asymptomatic staff. Published studies point out the fact that screening should be performed regardless of the absence of typical symptoms for COVID-19 disease. It has been demonstrated that seroconversion can occur in HCW who have suffered no previous symptoms of SARS-CoV-2 infection (38,39) as asymptomatic transmission is very relevant in SARS-CoV-2 spread (40,41). Thus, the approach for mass testing of both symptomatic and asymptomatic HCW could mitigate workforce depletion by unnecessary quarantine, reduce spread in atypical, mild, or asymptomatic cases; and protect patients and health-care workforce.

Among the potential limitations of the study, some recall bias is possible as the data for the correlates of SARS-CoV-2 infection rely on a self-administered questionnaire. Also, response and perception biases have to be considered, as well as complacency bias. Results, especially those regarding the accomplishment of preventive measures, might be overestimated. Answers reported in the questionnaire could be influenced by the participants' knowledge regarding their COVID status. However, this study is the first seroepidemiological study with such a large sample size settled in an oncological health centre. The sufficient sample size and high response rate (64.3%) are strengths of the study, although information regarding non-participants was not collected, and we cannot disregard a potential participation bias. Questionnaire completeness was very high, with no variables presenting more than 5% of missing values.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

In conclusion, SARS-CoV-2 seroprevalence among ICO HCW was lower than the reported in other Catalan hospitals, but higher than among the general population living in the area. Whereas the main risk factor was living with infected people, contact with COVID-19 patients and other colleagues were associated with SARS-CoV-2 infection. Knowing the

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

seroprevalence rate and follow-up evaluation of persistence may help hospitals to characterize the staff at risk, rationalize their placement, prioritize the use of PPE, thereby potentially reducing the risk of infection. Follow-up studies to evaluate long term durability of antibodies among HCW will be of interest, after the introduction of COVID-19 vaccination among HCW, to better promote infection control in this group. Strengthening preventive measures and health education among HCW is fundamental, especially in oncological departments and centres.

to perteries only

#### **BMJ** Open

**Contributors** EF, DCP, AP, CC, AC and AS contributed to study design. SC, AD, LG, IB, JT, MG, FS, JJT, DC, AS, BC, DR and AP accrued participants and care for blood collection at ICO centres. Laboratory analyses were coordinated by MADL. The questionnaire was designed by DCP and EF, and revised by PPT, ASL, YB, DC, AP, and LA. Questionnaire's implementation was done by EL, JM, JPR, CMM. Data were analysed by YB and DC. PPT, ASL, YB, DC, LA, and EF interpreted the initial results and designed the tables. All authors contributed to interpretation of results. The first draft of the manuscript was prepared by PPT and ASL. PPT, ASL, YB, DC, LA, DC and EF were the main contributors to the writing of the manuscript. All authors assisted in manuscript review. The co-senior authors had full access to all the data in the study for interpretation and had final responsibility for manuscript generation and review, and the decision to submit for publication. EF is the guarantor.

**Funding** This work was supported by the Catalan Institute of Oncology. PPT is partially supported by the Instituto de Salud Carlos III (ISCIII), Government of the Kingdom of Spain, co-funded by FEDER funds/European Regional Development Fund (ERDF) - a way to build Europe (CM19/00216). The Ministry of Universities and Research, Government of Catalonia partly supports EF and DCP (2017SGR319) and PPT, AS, YBM, DC and LA (2017SGR1085). We thank CERCA Programme / Generalitat de Catalunya for institutional support.

**Competing interests** JJ received research funding from Kyowa Kirin and from Angelini Pharma for congress attendance. The Cancer Epidemiology Research Programme has received grants from Merck & Co., Roche, GSK, IDT, Hologic, and Seegene.

**Acknowledgments** The authors acknowledge all the health care workers who participated in the study as well as all the ICO staff involved in the logistics of the different aspects of the study.

Data availability statement No additional data available

## REFERENCES

- 1. Ng K, Poon BH, Kiat Puar TH, Shan Quah JL, Loh WJ, Wong YJ, et al. COVID-19 and the Risk to Health Care Workers: A Case Report. Annals of internal medicine. 2020 Jun 2;172(11):766–7.
- 2. Lahner E, Dilaghi E, Prestigiacomo C, Alessio G, Marcellini L, Simmaco M, et al. Prevalence of Sars-Cov-2 infection in health workers (HWs) and diagnostic test performance: the experience of a teaching hospital in central Italy. International Journal of Environmental Research and Public Health. 2020 Jun 2;17(12):1–12.
- 3. Risk factors and risk groups [Internet]. [cited 2021 Mar 19]. Available from: https://www.ecdc.europa.eu/en/covid-19/latest-evidence/epidemiology
- 4. Informe sobre la situación de COVID-19 en personal sanitario en España. España; 2020 May.
- 5. Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: A multicenter study during the COVID-19 outbreak. Cancer Discovery. 2020 Jun 1;10(6):783.
- 6. Leung MST, Lin SG, Chow J, Harky A. COVID-19 and Oncology: Service transformation during pandemic. Cancer Medicine. 2020 Oct 18;9(19):7161–71.
- 7. Institut Català d'Oncologia [Internet]. [cited 2021 Mar 19]. Available from: http://ico.gencat.cat/ca/l\_institut/
- 8. Barros AJD, Hirakata VN. Alternatives for logistic regression in cross-sectional studies: An empirical comparison of models that directly estimate the prevalence ratio. BMC Medical Research Methodology. 2003 Oct 20;3:1–13.
- 9. Richards M, Anderson M, Carter P, Ebert BL, Mossialos E. The impact of the COVID-19 pandemic on cancer care. Nature Cancer. 2020 Jun;1(6):565–7.
- 10. Garcia-Basteiro AL, Moncunill G, Tortajada M, Vidal M, Guinovart C, Jiménez A, et al. Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital. Nature Communications. 2020 Dec 1;11(1):1–9.
- 11. Barallat J, Fernández-Rivas G, -Sánchez B Q, Martinez-Caceres. Seroprevalence of SARS-CoV-2 IgG Specific Antibodies among Healthcare Workers in the Northern Metropolitan Area of Barcelona, Spain, after the first pandemic wave.
- 12. Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda M, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. The Lancet. 2020 Aug 22;396(10250):535–44.
- COVID-19 data and indicators. Sistemes d'Informació dels Serveis d'Atenció Primària-SISAP, Institut Català de la Salut, Departament de Salut, Generalitat de Catalunya. [Internet]. 2020 [cited 2021 Mar 19]. Available from: http://eines.portalics/covid/
- 14. Galán MAI, Velasco M, Casas MAL, Goyanes MAJ, Rodríguez-Caravaca G, Losa JE, et al. SARS-CoV-2 Seroprevalence among all workers in a teaching hospital in Spain: Unmasking the risk. medRxiv. medRxiv; 2020. p. 2020.05.29.20116731.
- Korth J, Wilde B, Dolff S, Anastasiou OE, Krawczyk A, Jahn M, et al. SARS-CoV-2specific antibody detection in healthcare workers in Germany with direct contact to COVID-19 patients. Journal of Clinical Virology. 2020 Jul 1;128:104437.
- Iversen K, Bundgaard H, Hasselbalch RB, Kristensen JH, Nielsen PB, Pries-Heje M, et al. Risk of COVID-19 in health-care workers in Denmark: an observational cohort study. The Lancet Infectious Diseases. 2020;20(12):1401–8.
- Steensels D, Oris E, Coninx L, Nuyens D, Delforge ML, Vermeersch P, et al. Hospital-Wide SARS-CoV-2 Antibody Screening in 3056 Staff in a Tertiary Center in Belgium. JAMA - Journal of the American Medical Association. 2020;324(2):195–7.


1 2		
3	18	Sotgiu G, Barassi A, Miozzo M, Saderi L, Piana A, Orfeo N, et al. SARS-CoV-2 specific
4	10.	serological pattern in healthcare workers of an Italian COVID-19 forefront hospital.
5		BMC Pulmonary Medicine. 2020;20(1):1–6.
6 7	19	Rudberg AS, Havervall S, Månberg A, Jernbom Falk A, Aguilera K, Ng H, et al. SARS-
8	17.	CoV-2 exposure, symptoms and seroprevalence in healthcare workers in Sweden. Nature
9		Communications. 2020 Dec 1;11(1):1–8.
10	20	Pallett SJC, Rayment M, Patel A, Fitzgerald-Smith SAM, Denny SJ, Charani E, et al.
11	20.	Point-of-care serological assays for delayed SARS-CoV-2 case identification among
12		health-care workers in the UK: a prospective multicentre cohort study. The Lancet
13		Respiratory Medicine. 2020;8(9):885–94.
14	21	
15 16	21.	Houlihan CF, Vora N, Byrne T, Lewer D, Heaney J, Moore DA, et al. SARS-CoV-2 virus and antibodies in front-line Health Care Workers in an acute hospital in London:
10		1
18		Preliminary results from a longitudinal study. medRxiv. medRxiv; 2020. p.
19	22	2020.06.08.20120584. Pront Zawadzki M. Fridman D. Bahingan BA. Zahn M. Chay C. Carman B. et al. SARS
20	22.	Brant-Zawadzki M, Fridman D, Robinson PA, Zahn M, Chau C, German R, et al. SARS-
21		CoV-2 antibody prevalence in health care workers: Preliminary report of a single center
22	22	study. PLoS ONE. 2020 Nov 1;15(11 November).
23	23.	Moscola J, Sembajwe G, Jarrett M, Farber B, Chang T, McGinn T, et al. Prevalence of
24 25		SARS-CoV-2 Antibodies in Health Care Personnel in the New York City Area. JAMA -
26	24	Journal of the American Medical Association. 2020;324(9):893–5.
27	24.	Epstude J, Harsch IA. Seroprevalence of COVID-19 antibodies in the cleaning and
28		oncological staff of a municipal clinic Seroprävalenz von COVID-19-Antikörpern beim
29		Raumpflegepersonal und beim Personal einer onkologischen Station in einer
30	25	kommunalen Klinik. 2020;15:5–9.
31	25.	Fuereder T, Berghoff AS, Heller G, Haslacher H, Perkmann T, Strassl R, et al. SARS-
32 33		CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a
33		tertiary care centre during the COVID-19 pandemic. ESMO Open. 2020 Sep
35	•	2;5(5):e000889.
36	26.	Favara DM, Cooke A, Doffinger R, McAdam K, Corrie P, Ainsworth NL. COVID-19
37		Serology in Oncology Staff Study: Understanding SARS-CoV-2 in the Oncology
38		Workforce. Vol. 33, Clinical Oncology. Elsevier Ltd; 2021. p. e61–3.
39	27.	Simons D, Shahab L, Brown J, Perski O. The association of smoking status with SARS-
40 41		CoV-2 infection, hospitalisation and mortality from COVID-19: A living rapid evidence
41	• •	review with Bayesian meta-analyses (version 11). Qeios. 2021 Mar 2;
43	28.	Patanavanich R, Glantz SA. Smoking is associated with COVID-19 progression: A meta-
44		analysis. Vol. 22, Nicotine and Tobacco Research. Oxford University Press; 2020. p.
45		1653–6.
46	29.	Chou R, Dana T, Buckley DI, Selph S, Fu R, Totten AM. Epidemiology of and Risk
47		Factors for Coronavirus Infection in Health Care Workers: A Living Rapid Review. Vol.
48		173, Annals of internal medicine. NLM (Medline); 2020. p. 120-36.
49 50	30.	Coronavirus disease (COVID-19): Vaccines [Internet]. [cited 2021 Mar 19]. Available
50		from: https://www.who.int/news-room/q-a-detail/coronavirus-disease-(covid-19)-
52		vaccines
53	31.	Nguyen LH, Drew DA, Joshi AD, Guo CG, Ma W, Mehta RS, et al. Risk of COVID-19
54		among frontline healthcare workers and the general community: A prospective cohort
55		study. medRxiv. medRxiv; 2020. p. 2020.04.29.20084111.
56 57	32.	Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138
57 58		Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan,
59		China. JAMA - Journal of the American Medical Association. 2020 Mar
60		17;323(11):1061–9.
		2

 Wang J, Zhou M, Liu F. Reasons for healthcare workers becoming infected with novel coronavirus disease 2019 (COVID-19) in China. Vol. 105, Journal of Hospital Infection. W.B. Saunders Ltd; 2020. p. 100–1.

- Bielicki JA, Duval X, Gobat N, Goossens H, Koopmans M, Tacconelli E, et al. Monitoring approaches for health-care workers during the COVID-19 pandemic. Vol. 20, The Lancet Infectious Diseases. Lancet Publishing Group; 2020. p. e261–7.
- 35. The Lancet. COVID-19: protecting health-care workers. Vol. 395, The Lancet. Lancet Publishing Group; 2020. p. 922.
- COVID-19 Prioritization of Diagnostic Testing. https://www.idsociety.org/globalassets/idsa/public-health/covid-19-prioritization-of-dx-testing.pdf. Accessed March 19, 2021.
- 37. The Importance of COVID-19 Vaccination for Healthcare Personnel | CDC [Internet]. [cited 2021 Mar 19]. Available from: https://www.cdc.gov/coronavirus/2019ncov/vaccines/recommendations/hcp.html
- Black JRM, Bailey C, Przewrocka J, Dijkstra KK, Swanton C. COVID-19: the case for health-care worker screening to prevent hospital transmission. The Lancet. 2020;395(10234):1418–20.
- Rivett L, Sridhar S, Sparkes D, Routledge M, Jones NK, Forrest S, et al. Screening of healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-19 transmission. eLife. 2020;9:1–20.
- 40. Shields AM, Faustini SE, Perez-Toledo M, Jossi S, Aldera E, Allen JD, et al. SARS-CoV-2 seroconversion in health care workers. medRxiv. medRxiv; 2020. p. 2020.05.18.20105197.
- Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, et al. Presumed Asymptomatic Carrier Transmission of COVID-19. Vol. 323, JAMA - Journal of the American Medical Association. American Medical Association; 2020. p. 1406–7.

#### Figure 1

Participants' flowchart in the seroprevalence survey, Catalan Institute of Oncology. 21<sup>st</sup> May-26<sup>th</sup> June 2020; Spain.



	<u>v</u>	σ
BMI	Open 🦉 .	<u>n</u>
	c ·	
Supplementary Table 1. Clinical characteristics associated with SARS-CoV-2 positive sero	logy among those who report rRT-PCR p	₽evious to study serology
(n=469).	rig	20

(n=469).	Total participants n (%)	SARS-CoV-2 seroprevalence n (%)	Prevalence (95%CI)	2021-05663; ight, includ p-v2lud	Adjusted PR (95% CI)
Reported rRT-PCR previous to serology	469 (38.0)	86 (78.2)	18.34 (15.08-22.11)	ding	
Result of previous rRT-PCR				for	
Negative	397 (84.6)	27 (31.0)	6.80 (4.70-9.74)	use segentii	REF
Positive	72 (15.4)	59 (68.6)	81.94 (71.31-89.23)	<09.000 <09.000 re	12.15 (7.54-19.57)
Number of symptoms(mean, standard deviation) None	1.65 (2.10) 217 (46.3)	3.08 (2.61) 21 (24.0)	9.68 (6.39-14.4)	9022. D 91a@dme <0	REF
One	61 (13)	7 (8.1)	11.48 (5.56-22.21)	owr to t	1.13 (0.48-2.67)
2-3	109 (23.2)	22 (25.6)	20.18 (13.66-28.78)	Downloaded ment Supetter d to text and 0	2.03 (1.10-3.73)
≥-5 ≥4	81 (17.3)	35 (40.7)	43.21 (32.87-54.18)	ande <0760	4.33 (2.48-7.59)
∠4 p-trend (among exposed)	81 (17.3)	33 (40.7)	45.21 (52.07-54.10)	verur Seur dar	4.33 (2.48-7.39) <0.001
Reporting COVID-19 compatible symptoms when rRT-PCR was performed				om http: (ABES) Ita minir	01002
No	217 (46.3)	21 (24.0)	9.68 (6.39-14.4)	19, /	REF
Yes	251 (53.5)	64 (74.4)	25.5 (20.48-31.27)	<0 <b>4</b> 01	2.49 (1.51-4.10)
COVID-19 symptoms				://bmjopen. · ∧¶?traini <0traini	
Headache	126 (26.9)	36 (41.9)	28.57 (21.35-37.08)	<0 <b>月</b> 01	1.87 (1.20-2.93)
Cough	119 (25.4)	37 (43.0)	31.09 (23.42-39.97)	<0 ឆ្នំ 01 💆	2.25 (1.44-3.52)
Asthenia	110 (23.5)	36 (41.9)	32.73 (24.6-42.04)		2.38 (1.53-3.72)
Arthromyalgia	80 (17.1)	57 (66.0)	36.25 (26.47-47.31)	<0 <b>30</b> 01 <b>9</b>	2.32 (1.47-3.67)
Low-grade fever (37.3°C-38°C)	73 (15.6)	26 (30.2)	35.62 (25.5-47.21)	<0 <b>80</b> 01 ⊑	2.71 (1.67-4.39)
Odynophagia	64 (13.6)	14 (16.3)	21.88 (13.39-33.65)	ine 13, 2 0 0 0 0	1.18 (0.65-2.13)
Diarrhoea	58 (12.4)	16 (18.6)	27.59 (17.62-40.43)		1.47 (0.83-2.60)
Anosmia	42 (9)	33 (38.4)	78.57 (63.65-88.48)	<0 <b>8</b> 00125	6.09 (3.86-9.60)
Dyspnoea	40 (8.5)	11 (12.8)	27.50 (15.91-43.2)	0 <b>1</b> 42 Be	1.56 (0.81-3.00)
<i>Fever (&gt;38°C)</i>	28 (6)	15 (17.4)	53.57 (35.4-70.84)	<0.001 <b>P</b>	3.06 (1.71-5.46)
Nausea / vomiting	17 (3.6)	6 (7)	35.29 (16.75-59.66)	0.07 <b>enc</b>	1.86 (0.80-4.36)
Skin lesions	8 (1.7)	1 (1.2)	12.50 (1.72-53.86)	0.66 <b>ö</b>	0.74 (0.10-5.38)
Pneumonia	3 (0.6)	2 (2.3)	66.67 (15.27-95.69)	0.03	2.99 (0.71-12.63)
Myoclonus	2 (0.4)	0		0.50 <b>g</b>	

Numbers do not always sum up the total due to some missing values (none of the categories present more than 5% of missing values). PR: Prevalence Ratio, CI: Confidence Interval. <sup>1</sup> Chi-squared test for categorical variables (Fisher's exact test corrected for continuity) and median test for continuous variables. <sup>2</sup> Adjusted for sex, age (continuous), ICO center, care staff, telework and cohabitants. For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Page	31	of	30
------	----	----	----

		BMJ Open BMJ Open BMJ Open BMJ Open BMJ Open	
	STI	ຼຼຼ 호 ROBE 2007 (v4) Statement—Checklist of items that should be included in reports of cress-sectional studies 으 영	
Section/Topic	ltem #	Recommendation	Reported on page
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract ឆ្ក្រី ញុង្គ្	3
		(b) Provide in the abstract an informative and balanced summary of what was done and what was figurd	3
Introduction		anei late	
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any prespecified hypotheses 폭융 이	5
Methods		State specific objectives, including any prespecified hypotheses	
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, www-up, and data collection	5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	5
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers Give diagnostic criteria, if	7
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7
Bias	9	Describe any efforts to address potential sources of bias	
Study size	10	Explain how the study size was arrived at	5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which good by swere chosen and why	7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8
		(b) Describe any methods used to examine subgroups and interactions	8
		(c) Explain how missing data were addressed	8
		(c) Explain how missing data were addressedExplain how missing data were addressed(d) If applicable, describe analytical methods taking account of sampling strategyExplain how missing data were addressed	NA
		(e) Describe any sensitivity analyses     a       a     a       a     a       a     a       a     a       a     a	NA

		BMJ Open BMJ Open BMJ Open BMJ Open BMJ Open BMJ Open	Page
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, exangine of or eligibility,	9
		confirmed eligible, included in the study, completing follow-up, and analysedES(b) Give reasons for non-participation at each stageTC	9
		(c) Consider use of a flow diagram	6
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information of the social of	9
		(b) Indicate number of participants with missing data for each variable of interest	9
Outcome data	15*	Report numbers of outcome events or summary measures	12
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision are so that the state of the state	12
		(b) Report category boundaries when continuous variables were categorized	9
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses 🛱 🛱	15
Discussion		ning S)	
Key results	18	Summarise key results with reference to study objectives	17
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	21
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	17
Generalisability	21	Discuss the generalisability (external validity) of the study results	21
Other information		arte	
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, by original study on which the present article is based	22

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine ab/ Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www. above-statement.org.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

aphique de l

# **BMJ Open**

## **COVID-19** seroprevalence among workers of a Comprehensive Cancer Center in Catalonia, Spain.

Journal:	BMJ Open
Manuscript ID	bmjopen-2021-056637.R1
Article Type:	Original research
Date Submitted by the Author:	15-Feb-2022
Complete List of Authors:	Peremiquel-Trillas , Paul; Catalan Institute of Oncology, Tobacco Control Unit Saura-Lazaro, Anna; Catalan Institute of Oncology, Tobacco Control Unit Benavente Moreno, Yolanda; Institut Català d'Oncologia Casabonne, Delphine; Catalan Institute of Oncology Loureiro, Eva; Catalan Institute of Oncology Cabrera, Sandra; Catalan Institute of Oncology Duran, Angela; Catalan Institute of Oncology Garrote, Lidia; Catalan Institute of Oncology Brao, Immaculada; Catalan Institute of Oncology Galán, Maica; Catalan Institute of Oncology Galán, Maica; Catalan Institute of Oncology Soler, Francesc; Catalan Institute of Oncology Domínguez, Maria Ángeles; Bellvitge University Hospital Albasanz-Puig, Adaia; Catalan Institute of Oncology Gudiol, Carlota; Catalan Institute of Oncology Ramírez-Tarruella, Dolors; Catalan Institute of Oncology Rivas, Juan; Catalan Institute of Oncology Runiesa, Joan; Catalan Institute of Oncology Calvo-Cerrada, Beatriz; Catalan Institute of Oncology Calvo-Cerrada, Beatriz; Catalan Institute of Oncology Calle, Candela; Catalan Institute of Oncology Carnicer-Pont, Dolors; Hospital Duran i Reynals, Alemany, L.; Institut Catala d' Oncologia, Fernandez, Esteve; Catalan Institute of Oncology, Tobacco Control Unit
<b>Primary Subject Heading</b> :	Epidemiology
Secondary Subject Heading:	Infectious diseases, Oncology
Keywords:	Adult oncology < ONCOLOGY, Epidemiology < INFECTIOUS DISEASES, COVID-19, Epidemiology < ONCOLOGY

1	
2	
3	
4	
5	<b>SCHOLARONE</b> <sup>™</sup>
6	Manuscripts
7	Manuscripts
8	
9	
10	
11	
12	
13	
14	
15	
16 17	
18 19	
20	
20	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40 41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59 60	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
00	

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies



*I*, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.



# COVID-19 among workers of a Comprehensive Cancer Center between first and second epidemic waves (2020): a seroprevalence study in Catalonia, Spain.

## 4 Paula Peremiquel-Trillas\*, Anna Saura-Lázaro\*, Yolanda Benavente-Moreno, Delphine

5 Casabonne, Eva Loureiro, Sandra Cabrera, Angela Durán, Lidia Garrote, Inmaculada Brao,

6 Jordi Trelis, Maica Galán, Francesc Soler, Joaquim Julià, Dolça Cortasa, M. Angeles

7 Domínguez, Adaia Albasanz-Puig, Carlota Gudiol, Dolors Ramírez, Joan Muniesa, Juan

8 Pedro Rivas, Carles Muñoz-Montplet, Ana Sedano, Àngel Plans, Beatriz Calvo-Cerrada,

9 Candela Calle, Ana Clopés, Dolors Carnicer-Pont<sup>†</sup>, Laia Alemany<sup>†</sup>, Esteve Fernández<sup>†</sup>

10 \*Contributed equally

11 <sup>†</sup>Joint senior authors

## 12 Authors' affiliations

PPT	Cancer Epidemiology Research Programme, Cancer Epidemiology and Prevention Department, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain; Epidemiology and Public Health Programme, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain; CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain; School of Medicine and Clinical Sciences, Universitat de Barcelona, Barcelona, Spain. @PeremiquelPaula. ORCID: 0000-0002-8636-1725
ASL	Cancer Epidemiology Research Programme, Cancer Epidemiology and Prevention Department, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain; Epidemiology and Public Health Programme, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain. 0000-0001-9742-2725
YBM	Cancer Epidemiology Research Programme, Cancer Epidemiology and Prevention Department, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain; Epidemiology and Public Health Programme, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain; CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain. ORCID: 0000-0003-1422-4614
DC	Cancer Epidemiology Research Programme, Cancer Epidemiology and Prevention Department, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain; Epidemiology and Public Health Programme, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain; CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain. ORCID: 0000-0002-7874-3707
EL	Computer Science Services, Technology & Physics, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain; Computational Science and Artificial Intelligence, Faculty of Computer Science of Coruña, University of Coruña (UDC), Coruña, Spain.
SC	Research Nursing Department, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain. @scabrerajaime. ORCID: 0000-0003-3013-8812
AD	Nursing Department, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain.
LG	Nursing Department, Institut Català d'Oncologia – Badalona (ICO), Badalona, Spain.
IB	Nursing Department, Institut Català d'Oncologia – Girona (ICO), Girona, Spain.
JT	Palliative Care Department and Medical Director, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain. @JordiTrelis.
MG	Esofagogastric Tumours Functional Unit and Medical Director, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain.
FS	Pharmacy Service and Medical Director, Institut Català d'Oncologia - Girona (ICO), Girona, Spain.
JJT	Palliative Care Department and Medical Director. Institut Català d'Oncologia (ICO) Badalona, Badalona, Spain. @drjjulia. ORCID: 0000-0002-1462-3167
DC	Medical Director, Institut Català d'Oncologia -Tarragona/Terres de l'Ebre, Tarragona (ICO).
MADL	Microbiology Department. Hospital Universitari de Bellvitge; Infectious Diseases Programme, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL); Department of Pathology Experimental Therapeutics, Universitat de Barcelona, Barcelona, Spain.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

## BMJ Open

2
3
4
5
6
7
, 8
•
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
23 24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58

13

14

15

16

17

18

59 60

I	AAP	Infectious Disease Department, Hospital Universitari de Bellvitge, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain. CIBER of Infectious Diseases (CIBERINFEC), Madrid, Spain. ORCID: 0000-0001-9852-5574.
(	CG	Infectious Disease Department, Hospital Universitari de Bellvitge, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain. CIBER of Infectious Diseases (CIBERINFEC), Madrid, Spain. @Carlotasway3. ORCID: 0000-0003-3095-4422
Ι	OR	Preventive Medicine Unit, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain.
J	М	Computer Science Services, Technology & Physics Department, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain.
J	PR	Computer Science Services, Technology & Physics Department, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain.
(	СММ	Technology and Physics Department, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain; Medical Physics and Radiation Protection Department, Institut Català d'Oncologia (ICO) – Girona, Girona, Spain; Department of Medical Sciences, Universitat de Girona, Girona, Spain. @CMunozMontplet. ORCID: 0000-0002-7324-8889.
A	AS	Human Resources Department, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain.
P	AC	Scientific Direction, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain. ORCID: 0000-0002- 1857-362X.
I	BCC	Occupational Health Unit, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain.
	CC	General Direction, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain. @CandelaCalle.
A	ĄР	Occupational Health Unit, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain. ORCID: 0000- 0003-3199-0361.
Ι	DCP	Cancer Prevention and Control Programme, Cancer Epidemiology and Prevention Department, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Spain; Epidemiology and Public Health Programme, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain. ; CIBER of Respiratory Diseases (CIBERES). ORCID: 0000-0002-3475-8704.
Ι	LA	Cancer Epidemiology Research Programme, Cancer Epidemiology and Prevention Department, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain; Epidemiology and Public Health Programme, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain; CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain. ORCID: 0000-0003-0945-6015.
H	ΞF	Cancer Prevention and Control Programme, Cancer Epidemiology and Prevention Department, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain; Epidemiology and Public Health Programme, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain; School of Medicine and Clinical Sciences, Universitat de Barcelona, Barcelona, Spain; CIBER of Respiratory Diseases (CIBERES). @StvFdz. ORCID: 0000-0003-4239-723X.
W	/ord co	ounts.
А	bstract	t: 296. Main text: 3,309. One figure, three tables, supplementary information.
Pı G	reventi ranvia	<i>condence to:</i> Prof. Esteve Fernández, MD, MPH, PhD. Tobacco Control Unit, Cancer ion and Control Programme, Institut Català d'Oncologia (ICO). Avinguda de la de l'Hospitalet, 199-203, 08908 L'Hospitalet de Llobregat, Barcelona, Spain. Phone: 2607345. Twitter: @StvFdz E-mail: <u>efernandez@iconcologia.net</u> (Prof. E. Fernández).

# ABSTRACT Objectives Cancer patients are at higher risk for severe COVID-19 infection. COVID-19

surveillance of workers in oncological centres is crucial to assess infection burden and prevent
transmission. We estimate the SARS-CoV-2 seroprevalence among health care workers
(HCW) of a comprehensive cancer centre in Catalonia, Spain, and analyse its association with
sociodemographic characteristics, exposure factors and behaviours.

- **Design** Cross-sectional study ( $21^{st}$  May  $26^{th}$  June 2020).
- 26 Setting A comprehensive cancer centre (Institut Català d'Oncologia) in Catalonia, Spain.

27 Participants All HCW (*N*=1,969) were invited to complete an online self-administered
28 epidemiological survey and provide a blood sample for SARS-CoV-2 antibodies detection.

Primary outcome measure Prevalence (%) and 95% confidence intervals (CI) of
seropositivity together with adjusted prevalence ratios (aPR) and 95%CI were estimated.

**Results** A total of 1,266 HCW filled the survey (participation rate: 64.0%) and 1,238 underwent serological testing (97.8%). The median age was 43.7 years (p25-p75: 34.8-51.0 years), 76.0% were female, 52.0% were nursing or medical staff, and 79.0% worked on-site during the pandemic period. SARS-CoV-2 seroprevalence was 8.9% (95%CI: 7.44-10.63), with no differences by age and sex. No significant differences in terms of seroprevalence were observed between onsite workers and teleworkers. Seropositivity was associated with living with a person with COVID-19 (aPR: 3.86, 95%CI: 2.49-5.98). Among on-site workers, seropositive participants were twofold more likely to be nursing or medical staff. Nursing and medical staff working in a COVID-19 area showed a higher seroprevalence than other staff (aPR: 2.45, 95% CI: 1.08-5.52).

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

**Conclusions** At the end of the first wave of the pandemic in Spain, SARS-CoV-2 42 seroprevalence among Institut Català d'Oncologia HCW was lower than the reported in other 43 Spanish hospitals. The main risk factors were sharing household with infected people and 44 contact with COVID-19 patients and colleagues. Strengthening preventive measures and health 45 education among HCW is fundamental.

46 Keywords SARS-CoV-2; COVID-19; seroprevalence; antibody; health care workers;
 47 epidemiology.

## 48 ARTICLE SUMMARY

## 49 Strenghts and limitations

- Seroepidemiological study with a large sample size settled in a monographic oncological health centre.
- Questionnaire completeness was very high, with no variables presenting more than 5% of missing values.
- Recall bias is possible as the data for the correlates of SARS-CoV-2 infection rely on a
   self-administered questionnaire.
  - The accomplishment of preventive measures might be overestimated: response and perception biases must be considered, as well as complacency bias.
    - Answers reported in the questionnaire could be influenced by the participants' knowledge regarding their COVID status.

## 61 INTRODUCTION

Frontline health care workers (HCW) dealing with COVID-19 have higher exposure to SARS-CoV-2 than the general population (1), and they can contribute to the spread of COVID-19 as per their exposure to vulnerable patients. Since the beginning of the pandemic, several studies have been published on SARS-CoV-2 infections prevalence in HCW, although with diverse results. A meta-analysis of 49 studies, including 127,480 health care workers, showed that the overall seroprevalence of SARS-CoV-2 antibodies in the European region was 8.5% (2). HCW in Spain have been highly affected: a total amount of 154,636 cases among HCW were already officially notified by December 2, 2021 at the onset of the sixth pandemic wave (4).

Cancer patients are vulnerable, presenting a high risk for COVID-19 infection and more severe outcomes due to their immunosuppression status (5). The pandemic has presented unprecedented professional and personal challenges for the oncology community (6). Data are lacking on the seroprevalence of SARS-CoV-2 among HCW in oncological centres, and small sample sizes limit the few published studies. The present study aims to estimate the seroprevalence of SARS-CoV-2 and associated sociodemographic and behavioural risk factors among workers of the Catalan Institute of Oncology (ICO), a Comprehensive Cancer Centre comprised of four hospitals in Catalonia (Spain), covering around 40% of the adult population in Catalonia (7).

1 2							
2 3 4	79						
5 6 7	80	PARTICIPANTS AND METHODS					
8 9 10	81	Study design and setting					
10 11 12	82	A cross-sectional study including blood sample collection and a self-administered					
13	83	questionnaire was conducted between 21st May and 26th June 2020 in the four ICO centres					
14 15 16	84	(L'Hospitalet de Llobregat, Badalona, Tarragona/Terres de l'Ebre and Girona).					
17 18	85	The study population were HCW delivering care and services to patients (directly or indirectly)					
19 20	86	and support staff, including those who do not deliver care but work in other tasks within the					
21	87	hospital. A total of 1,969 employees of ICO were invited to participate in the study through an					
22 23	88	email that allowed access to the study information. The inclusion criteria were: a) to be an					
24 25	89	active worker during the epidemic period, (1st February - 26th June 2020) and b) to be aged					
26	90	$\geq$ 18 years. The participants filled in an online epidemiological questionnaire and were					
27 28	91	scheduled for serology testing by the Occupational Health Department. 1,266 HCW filled in					
29 30 31	92	the online epidemiological questionnaire (participation rate: 64.3%) and 1,238 of them (97.8%)					
	93	underwent a serology test. Three participants with inconclusive serological results were					
32 33	94	excluded. The final analysis included 1,235 participants (Figure 1).					
34 35 36	95	Figure 1 about here					
37 38 39	96						
40 41	97	Epidemiological questionnaire and study variables					
42 43	98	An epidemiological questionnaire was programmed online to collect information regarding					
44	99	sociodemographic characteristics, working information, compliance of personal protective					
45 46	100	equipment (PPE) measures at work, at home and history of previous COVID-19 infection					
47 48	101	(Supplemental Material). The questionnaire was developed based on previous					
49 50	102	epidemiological studies conducted within the ICO centres, and a modified version was used in					
51	103	another seroprevalence study performed among university personnel of the University of					
52 53 54	104	Barclona (8).					
55 56	105	Sociodemographic characteristics included information on age and sex, ICO centre of					
57 58 59 60	106	recruitment, presence of comorbidities, smoking history, pregnancy and cohabitants.					

107 Work-related conditions included the professional category, teleworking status, type of shift,
108 working on a COVID-19 area, contact with COVID-19 cases, contact with biological samples
109 and reporting to be exposed to COVID-19.

Concerning PPE measures at work, participants were asked about feeling protected with PPE and compliance with PPE measures. Regarding the application of preventive measures outside the working setting, participants were asked if they got a shower after leaving the workplace or when arriving home, if they changed clothes after work or upon home arrival, as well as about hand washing and use of face mask when shopping. Information about COVID-19 cases and protective measures were also collected among those participants reporting cohabitants. Participants were also asked about the type of transport used to go to work. 

Participants were asked about a previous diagnosis of COVID-19 performed by rRT-PCR or
 serology test and date of diagnosis, as well as reporting COVID-19 compatible symptoms, and
 the type of symptoms.

## 28 29 120 SARS-CoV-2 laboratory testing

Serum samples from participants at L'Hospitalet, Girona and Tarragona/Terres de l'Ebre were studied at the Microbiology Department of Hospital de Bellvitge and samples from health-care workers at ICO Badalona were analysed at the MetroNord Regional Clinical Laboratory, using the same procedures and techniques in both laboratories. Detection of SARS-CoV-2 antibodies was carried out using the quantitative SARS-CoV-2 S1/S2 IgG LIAISON® test (DiaSorin, Vercelli, Italy) on the LIAISON XL platform, following the manufacturer's instructions. This test discriminates among negative (<12AU/mL; with 3.8 as IgG detection limit), equivocal (12.0–15.0AU/mL) and positive (>15.0AU/mL) subjects. In those cases in which a) IgG anti S1/S2 quantification was higher than the limit of detection (i.e.>3.8AU/mL) but did not reach the limit of discrimination (i.e.<15AU/mL) and/or b) when the HCW answered the questionnaire saying that he or she had been diagnosed of COVID-19 but IgG anti S1/S2 where lower than 15 AU/ml, an additional serological study was performed using a different antigen (N) as a target. In this case, a SARS-CoV-2 IgG test (Abbott Diagnostics, Sligo, Ireland) was run on an Architect i2000 platform. This test discriminates among negative ( $\leq 1.4$ Index (S/C)) and positive  $(\geq 1.4$  Index (S/C)) subjects. 

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

**BMJ** Open

## 137 Case definition

A seropositive case of SARS-CoV-2 was defined as seropositivity to IgG independently ofprevious self-reported results.

## 140 Patient and Public Involvement

141 No patient was involved in the study.

## 142 Statistical analysis

Crude global and by subgroups SARS-CoV-2 seroprevalence and 95% confidence intervals (CI) were calculated. Differences in the distribution of study variables between seropositive and seronegative participants were assessed using chi-squared test for categorical variables, and parametric or non-parametric tests were performed for normal and non-normal continuous variables, respectively. Prevalence ratios (PR) and 95% confidence intervals (CI) were estimated using Poisson regression models with robust variance (9). Prevalence ratios were adjusted (aPR) for statistically significant variables in the bivariate analysis and those considered relevant for the study design. Thus, adjusted models included sex, ICO centre of recruitment, age, type of HCW, teleworking and cohabitants. Linear trends for variables with ordinal categories was based in the likelihood ratio test of the model with the ordinal variable as a continuous one. P-values were based on 2-sided hypothesis tests and considered significant at p < 0.05. All analyses were conducted using Stata version 16.0 (StataCorp LP, College Station, Texas).

## 156 Ethical considerations

The present study was approved by the Hospital Universitari de Bellvitge Ethics Committee (PR205/20). The study follows the Helsinki Declaration and subsequent amendments, and Spanish data confidentiality laws (General data protection regulation Organic Law 3/2018, EU General data protection Regulation 2016/679 and Law 14/2007 for biomedical research). All participants signed an informed consent form after receiving information of the study and prior to obtaining biological samples. The biological material obtained was kept at ICO and processed under the appropriate measures to preserve the confidentiality of the results and data.

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

## **RESULTS**

A total of 1,235 HCW with serological results (Figure 1) were included in the analysis: 76.0%
were female, the median age was 43.7 years (p25-p75: 34.8-51.0 years), 52.2% were nursing
or medical staff, and 18.6% of the participants teleworked full-time during the study period
(Table 1). Up to 14.7% of the participants reported at least one comorbidity. Regarding
smoking habits, 16.0% were current smokers, and 28.2% reported to be former smokers (Table
1). Seven women were pregnant, and none of them showed seropositivity.

The overall crude SARS-CoV-2 seroprevalence was 8.9% (95%CI: 7.44-10.63), with no statistically significant differences by neither age group nor sex, and the seroprevalence for nursing and medical staff was 11.6% (95%CI: 9.37-14.34). After fully adjustment, the main determinants of higher seroprevalence included working at ICO Girona compared to workers at ICO L'Hospitalet (aPR: 1.52, 95%CI: 0.97-2.38), and nursing or medical staff compared to other groups (aPR: 2.04, 95%CI: 1.33-3.14) (**Table 1**).

8. For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

reliez onz

Page 11 of 33

**3** 13

## BMJ Open

of 33		BMJ Open		mjop by co	
able 1. Sociodemographic characteristic	cs associated with SARS-CoV-2 p	ositive serology among study	y participants (N=1,235).	bmjopen-2021-0566 d by copyright, inclu	
	Total participants	SARS-CoV-2 seroprevalence	Prevalence (95%CI)	omjopen-2021-056637 on 21 April 2022. Downloaded from http://bmjope by copyright, including for uses related to text and data mining, AI trai	aPR (95% CI)
	n (%)	n (%)		on 2 ng fo	
Study participants	1,235	110	8.91 (7.44-10.63)		
Sex				pril Ens ses	
Male	291 (23.6)	27 (24.5)	9.28 (6.44-13.20)	20) religi	REF
Female	939 (76.0)	83 (75.5)	8.84 (7.18-10.83)	atec <u>0.82</u>	0.82 (0.53-1.28
Age [median, (p25-p75)]	43.7 (34.8-51.0)	42.8 (32.0-50.1)			0.99 (0.97-1.01
<35 years	313 (25.3)	33 (30.0)	10.54 (7.59-14.46)	vnlc t Su tex	REF
35-49 years	566 (45.8)	47 (42.7)	8.30 (6.29-10.88)	bade t ar	0.85 (0.55-1.34
>49 years	356 (28.8)	30 (27.3)	8.43 (5.95-11.80)	nd d $0.5$	0.88 (0.53-1.46
ICO Center				rom r (A lata	
ICO L'Hospitalet	885 (71.7)	73 (66.4)	8.25 (6.61-10.25)		REF
ICO Girona	204 (16.5)	29 (26.4)	14.22 (10.06-19.72)	t <mark>tp://</mark> S) .	1.52 (0.97-2.38
ICO Badalona	134 (10.9)	7 (6.4)	5.22 (2.51-10.56)	g, A	0.54 (0.25-1.19
ICO Tarragona / Terres de l'Ebre	12 (1.0)	1 (0.9)	8.33 (1.16-41.38)	<b>D D</b>	1.07 (0.15-7.83
Professional category				.bmj.com/ on ing, and simil	
Nursing staff <sup>1</sup>	380 (30.8)	43 (39.0)	11.32 (8.50-14.92)	ind	REF
Medical Staff <sup>2</sup>	265 (21.5)	32 (29.1)	12.08 (8.67-16.58)	sim V OI	1.07 (0.65-1.76
Middle and superior technicians	285 (23.1)	14 (12.7)	4.91 (2.93-8.13)	n June 13, ilar techn	0.41 (0.22-0.77
Service staff <sup>3</sup>	114 (9.2)	2 (1.8)	7.02 (3.55-13.42)	e 13 chn	0.69 (0.31-1.54
Porter	21 (1.7)	8 (7.3)	9.52 (2.39-31.16)	, 2025 Iologie	0.74 (0.17-3.24
Administratives	129 (10.4)	8 (7.3)	6.20 (3.13-11.92)	125 a	0.54 (0.25-1.16
Other	20 (1.6)	1 (0.9)	5.00 (0.70-28.26)	~ U U3	0.50 (0.07-3.71
Nursing or medical staff <sup>4</sup>	645 (52.2)	75 (68.2)	11.63 (9.37-14.34)	Agence 0.001	2.04 (1.33-3.14
Other staff <sup>5</sup>	569 (46.1)	33 (30.0)	5.80 (4.15-8.05)	Bibliographique 0.56	REF
Felework				ogra	
Never/Occasionally	981 (79.4)	86 (78.1)	8.77 (7.15-10.71)	phic	REF
Always	230 (18.6)	23 (20.9)	10.00 (6.72-14.63)	<b>Jue</b> 0.56	1.60 (0.98-2.59

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

		BMJ Open		bmjopen-2021. 1 by copyright	
able 1 (continued)					
	Total participants	SARS-CoV-2 seroprevalence	Prevalence (95%CI)	-056637 on 21 April Ens	aPR (95% CI) <sup>8</sup>
hift work		•		37 on ding t	
Morning	545 (44.1)	49 (45.0)	8.99 (6.86-11.7)	n 21 J for	REF
Evening	140 (11.3)	10 (9.1)	7.14 (3.88-12.77)		0.56 (0.34-0.93)
Split shift (morning-evening)	417 (33.8)	38 (34.5)	9.11 (6.7-12.28)	April Ense	0.88 (0.57-1.37)
Night	88 (7.1)	10 (9.1)	11.36 (6.22-19.86)	2022. 0.83	0.95 (0.46-1.96)
Other	25 (2)	3 (2.7)	12 (3.92-31.32)	0.83 eigneme	1.15 (0.35-3.75)
Comorbidities <sup>6</sup>				Downloaded botto text and o	
None	1,054 (85.3)	99 (90.0)	9.39 (7.77-11.31)	t Su	REF
Yes	181 (14.7)	11 (10.0)	6.08 (3.4-10.64)	tan per 0.15	0.67 (0.36-1.25)
moking history		<b>`</b> ,		ieu ieu d d	· · · · · ·
Never	650 (52.6)	80 (72.7)	12.31 (9.99-15.07)	from ur (At data	REF
Past	348 (28.2)	22 (20.0)	6.32 (4.20-9.42)		0.57 (0.35-0.93)
Current	198 (16.0)		4.04 (2.03-7.87)	ning . 0.0002	
Cohabitants				у, А	,
Yes	1,119 (90.6)	95 (86.0)	8.49 (6.99-10.27)	jop I tra	REF
No	104 (8.4)	15 (13.6)	14.42 (8.88-22.57)	0.04	1.48 (0.83-2.66)
Current         Cohabitants         Yes         No         mbers do not always sum up the total due         adjusted Prevalence Ratio, CI: Confide         trising staff: nurses and nursing assistants         edical staff: resident physicians and spec         rvice staff: security, maintenance, cleani         urses, nursing assistants, resident physici         iddle and superior technicians, security, to         pmorbidities: hypertension, obesity (BMI)         orders.         ti-squared test for categorical variables (figured for sex, age (continuous), ICO ce	e to some missing values (none ence Interval, p25: 25% percent s. tialists. ing and kitchen. ians and specialists.	e of the categories present mo tile, p75: 75% percentile.	re than 5% of missing values).	tp://bmjopen.bmj.com/ on June 1: S) . Al training, and similar tech	
urses, nursing assistants, resident physici iddle and superior technicians, security, pomorbidities: hypertension, obesity (BMI orders. hi-squared test for categorical variables (fi ljusted for sex, age (continuous), ICO ce	maintenance, cleaning, kitchen $I \ge 30$ ), heart disease, liver disea Fisher's exact test corrected for	, porter, administrative, and o se, diabetes, chronic respirate continuity) and median test	other. ory disease, renal disease, cance for continuous variables.	nologies.	orders and other

Seroprevalence among on-site workers was 8.8% (95%CI: 7.15-10.71) (Table 2). Onsite workers were younger, mostly health care workers, and reported more frequently rRT-PCR previous to serology than teleworkers, but no differences were observed in sex, self-reported comorbidities, smoking history, cohabiting with COVID-19 positive case between them and teleworkers (Supplemental Material). Among this group (N=981) of professionals who never or occasionally teleworked SARS-CoV-2 seropositivity was not associated with not working in a COVID-19 area (aPR: 1.29, 95%CI: 0.81-2.06), nor being in contact with COVID-19 biological samples (aPR: 1.30, 95%CI: 0.77-2.20) nor being in contact with patients with COVID-19 (aPR: 1.09, 95%CI: 0.66-1.79) were associated with SARS-CoV-2 positivity (Table 2). On-site nursing or medical staff who worked in a COVID area had twofold SARS-CoV-2 seroprevalence than others who did not work in COVID area (aPR: 2.45, 95%CI: 1.08-5.52). Seropositivity was higher among those whom referred being exposed by interacting with colleagues (aPR: 3.26, 95%CI: 1.49-7.15). On-site workers who self-reported symptoms of COVID-19 were almost 10-fold more likely to be seropositive than those who did not (aPR: 9.5, 95%CI: 5.34-17.03). Most of the on-site workers were highly adherent to the recommendation of hand hygiene at work. Hand washing before eating or working, were followed by more than 97% of on-site workers, whereas around 24% of them reported not hand hygiene after working or a low frequency of handwashing during the workday. In relation to protective measures at work, 17.4% of the on-site workers did not feel protected with PPE, and 12.1% did not use PPE with confirmed or suspicious COVID-19 cases. About colleagues' behaviour, 2m safety distance from colleagues when having lunch was reported to be unfollowed by 14.1% (Table 2). 

45 46

	Total participants	SARS-CoV-2 seroprevalence	nclu	bmiopen-2021-056637- -value <sup>2</sup>	Adjusted PR
	n (%)	n (%)	-	6n 2	(95% CI) <sup>3</sup>
On-site workers	981 (79.4)	86 (78.1)		<b></b>	
Type of transport to work			es	pril	
Private	751 (76.6)	66 (76.7)	8.79 (6.96-11.04) eg	2022.	REF
Public	154 (15.7)	15 (17.4)	9.74 (5.95-15.54) <b>atem</b>	2	1.32 (0.74-2.36)
Private and Public	35 (3.6)	2 (2.3)	5.71 (1.43-20.19) <b>6</b>	Dov	0.63 (0.15-2.58)
Walking	37 (3.8)	3 (3.5)	8.11 (2.63-22.34) <b>5</b>	Downloaded from 0.14	0.57 (0.14-2.35)
Working in a COVID-19 area		·	8.11 (2.03-22.34) Xt an	iade	,
No	398 (40.6)	29 (33.7)	7.29 (5.11-10.29) de	¢d f	REF
Yes	545 (55.6)	55 (63.9)	10.09 (7.83-12.92) a 🛱 🏹	<b>0</b> .14	1.29 (0.81-2.06)
Type of and COVID area <sup>1</sup>			a Be	2	
Non-assisting HCW & never worked in a COVID-19 area	148 (15.1)	7 (8.0)	4.73 (2.27-9.6)		REF
Non-assisting HCW & ever worked in a COVID-19 area	230 (23.4)	13 (15.1)	5.65 (3.31-9.5)	bm m	1.12 (0.44-2.82)
Assisting HCW & never worked in a COVID-19 area	244 (24.9)	22 (25.6)	5.65 (3.31-9.5) A fraining 9.02 (6.01-13.32) 12.86 (9.57-17.07)		1.81 (0.77-4.26)
Assisting HCW & ever worked in a COVID-19 area	311 (31.7)	40 (46.5)	12.86 (9.57-17.07)	0.006	2.45 (1.08-5.52)
p-trend			, íg,	<u>n</u>	0.26
Contact with COVID-19 cases			6.91 (4.63-10.18) 10.63 (8.29-13.54)	//bmiopen.bmi.com/ on June	
No	333 (33.9)	23 (26.7)	6.91 (4.63-10.18)	2	REF
Yes	536 (54.6)	57 (66.3)	10.63 (8.29-13.54) a	ة 0.07 ي	1.30 (0.77-2.20)
Contact with COVID-19 biological samples			r te	une	
No	646 (65.9)	51 (59.3)	7.89 (6.05-10.24)	 ພ	REF
Yes	282 (28.7)	30 (34.9)	10.64 (7.54-14.81) 🔒	-	1.09 (0.66-1.79)
Reporting to be exposed to COVID-19 by interacting with colleagues at work			7.89 (6.05-10.24) 10.64 (7.54-14.81)	0.17 2025 at A	
No	242 (24.7)	66 (76.7)	2.89 (1.38-5.95)	t Agence<0.0001	REF
Yes	608 (62.0)	7 (8.1)	10.86 (8.62-13.59)	<u> </u>	3.26 (1.49-7.15
Reporting COVID-19 compatible symptoms				Bib	
No	623 (63.5)	15 (17.4)	2.41 (1.46-3.96)	Bibliograf <i>&lt; 0.0001</i>	REF
Yes	306 (31.2)	68 (79.1)	22.22 (17.91-27.23)	a<0.0001	9.53 (5.34-17.03

Page 15 of 33

	Total participants	SARS-CoV-2 seroprevalence	Prevalence (95%Cla	66 37 <i>p-value</i> <sup>2</sup>	Adjusted PR (95% CI) <sup>3</sup>
Not following protection measures at work			g fo	n 2	
Felt protected with PPE	132 (17.4)	12 (16.9)	9.09 (5.23-15.34) or	$\frac{1}{P}$ 0.83	0.98 (0.51-1.88
Colleagues cover themselves with their elbows when sneezing/coughing	155 (15.8)	21 (24.4)	13.55 (9.00-19.90) Tree:	pril 0.01 20	1.70 (1.01-2.87
2m safety distance from colleagues during lunch	127 (14.1)	12 (15.6)	9.45 (5.44-15.91) ar	0.71	1.06 (0.56-1.99
Use of PPE with confirmed or suspicious COVID-19 patients	79 (12.1)	7 (10.45)	8.86 (4.28-17.46) <b>b</b> ment	<b>Dov</b> 0.63	1.01 (0.45-2.26
PPE removal safety	48 (7.3)	3 (4.6)	6.25 (2.03-17.68) 🔄 🖉	<b>no</b> 0.33	0.54 (0.17-1.74
Personal use of mask	34 (3.5)	1 (1.2)	2.94 (0.41-18.17) a e	ade 0.21	0.41 (0.06-2.99
Colleagues use of surgical mask	7 (0.7)	1 (1.2)	14.29 (1.96-58.12) a l	<b>d</b> 0.62	1.68 (0.23-12.2
lot following hand hygiene at work			ata A	om	
≤7 times during workday	233 (23.8)	15 (17.4)	6.44 (3.92-10.41)	0.13	0.71 (0.39-1.28
After money, phone and other personal tools manipulation	175 (17.8)	16 (18.6)	9.14 (5.67-14.41) <b></b>	0.89	1.00 (0.58-1.74
Every time entering in a new workspace	102 (10.4)	5 (5.8)	4.90 (2.05-11.25)	0.14 0.37	0.55 (0.22-1.37
Before working	21 (2.1)	3 (3.5)	14.29 (4.67-36.17)	<b>0.37</b>	1.72 (0.54-5.47
After finishing the workday	17 (1.7)	1 (1.2)	5.88 (0.82-32.09) <b>j</b>	0.67	0.65 (0.09-4.72
Before eating	9 (0.9)	2 (2.3)	22.22 (5.59- 57.95) <b>g</b>	<u>o</u> 0.16	2.67 (0.65-10.9

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

m/ on June 13, 2025 at Agence Bibliographique de l

d by copyrig bmjopen-20;

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

Concerning the correlates of seropositivity according to household factors for all participants (Table 3), seropositivity was associated with living with a COVID-19 positive person (aPR: 3.86, 95%CI: 2.49-5.98). Up to 17.3% of the participants did not take a shower nor change clothes upon home arrival, but the majority (99.0%) did hand hygiene. The least followed hand hygiene home practices were after money, phone and other personal tools manipulation, and after nose blowing, coughing or sneezing (23.5% and 22.7%). However, not following protection measures or hand hygiene at home were associated with a higher SARS-CoV-2 seroprevalence.

Clinical characteristics were collected for those participants (*N*=469) who reported a rRT-PCR performed previous to serology (Supplemental material). The majority of the patients with a positive serology and reporting a positive rRT-PCR presented compatible COVID-19 symptoms (74.4%). Among seropositive patients, the most common symptoms were arthromyalgia, cough, headache, asthenia and anosmia. Reporting a positive rRT-PCR when presenting compatible symptoms was associated with a threefold higher prevalence of seropositivity (aPR: 3.10, 95%CI: 1.78-5.31). An increased number of compatible symptoms was also associated with a higher seroprevalence (aPR: 7.4, 95%CI: 1.78-5.31, for presenting four or more symptoms compared to no symptoms).

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

	RS-CoV-2 positive serology	among study participan	ts (n=1,235).	-056637 or , including	
	<b>Total participants</b> <i>n</i> (%)	SARS-CoV-2 seroprevalence n (%)	Prevalence (95%CI)	g fogulue p-gulue p-gulue	Adjusted PR (95% CI
tudy participants	1,235	110	8.91 (7.44-10.63)	i S S	
Cohabitants with COVID-19 <sup>1</sup>				2022. eigne relate	
No	894 (79.9)	52 (54.7)	5.82 (4.46-7.56)	eme led	REF
Yes	141 (12.60)	34 (35.8)	24.11 (17.76-31.86)	< <b>ହ୍</b> ରିନ୍ଦ୍ରିଞ୍ଚି	3.86 (2.49-5.97)
Cohabitants cover themselves with their lbow when sneezing				nloade Super ext an	
No	158 (14.1)	18 (18.9)	11.39 (7.29-17.37)	ieu d d	REF
Yes	919 (82.1)	73 (76.8)	7.94 (6.36-9.88)		0.73 (0.43-1.22)
ot following protection measures at ome <sup>4</sup>				ı <mark>http:</mark> BES) minir	
Use of face mask when shopping	17 (1.4)	2 (1.8)	11.76 (2.95-36.86)	<b>4</b> .67	0.98 (0.24-4.05)
Shower and clothes changing afterwork or upon home arrival	214 (17.3)	20 (18.2)	9.35 (6.11-14.05)	Attraining; and stimil	1.02 (0.62-1.69)
ot following hand hygiene at home <sup>4</sup>				inin <mark>b</mark>	
Upon arrival	12 (1)	2 (1.8)	16.67 (4.19-47.76)	∯.35 <u>∃</u>	1.59 (0.39-6.60)
Before eating	60 (4.9)	9 (8.2)	15.00 (7.99-26.4)	8.09 <mark>8</mark>	1.55 (0.77-3.12)
After money, phone and other personal tools manipulation	290 (23.5)	27 (24.6)	9.31 (6.46-13.24)	stinila 53 <b>U</b>	1.01 (0.65-1.58)
After cleaning	110 (8.9)	8 (7.3)	7.27 (3.68-13.88)	8.53E	0.78 (0.38-1.61)
After nose blowing	280 (22.7)	25 (22.7)	8.93 (6.1-12.88)	1990 ne	0.93 (0.58-1.48)

#### DISCUSSION

Despite the impact of COVID-19 in oncological patients (10), there are scarce SARS-CoV-2 seroprevalence studies in comprehensive cancer centres with large sample sizes. The global SARS-CoV-2 seroprevalence was 8.9% during the first wave of the COVID-19 pandemic, lower than expected, owing to the presumed higher risk among HCW. Also, it was lower than the reported estimates in two studies performed among HCW in Catalonia between March-April and May 2020, showing a seroprevalence of 11.2% (11) and 10.3% (12), respectively. In all cases, the seroprevalence was higher than in the general population, estimated to be of a maximum of 7.4% in the Barcelona metropolitan area when the study was conducted (13). Seroprevalence studies interpretation must be related to the average COVID-19 prevalence at the time of blood collection. Both of the mentioned studies were carried out earlier than ours, which was performed approximately one month later (21<sup>st</sup> May-26<sup>th</sup> June 2020), and two months after the first-wave peak in Catalonia (23<sup>th</sup> March) (14). Another explanation for this lower seroprevalence in our Centre concerns the participation: all active HCW, regardless of their teleworking status during the previous months or work absenteeism, were invited to participate, and most did (64%). In contrast, García-Basteiro's (11) and Barallat's (12) studies comprised general hospitals (10,11) and primary health care centers (12) in which the incidence could be higher than in a monographic cancer centre. 

Several studies regarding COVID-19 infections in HCW in Spain have been published, although showing diverse results. In a tertiary-care hospital in Mallorca, with low regional seroprevalence in the general population (<2%), the prevalence of infected HCW (n=2,210) was 2.8%(15). Varona et al. performed a cross-sectional study evaluating 6.038 employees from the healthcare system of 17 hospitals across four regions in Spain (Madrid, Catalonia, Galicia and Castilla-Leon), showing an 11% seropositivity for SARS-CoV-2 IgG (16). Finally, other studies in Madrid, reported a seroprevalence between 16.6% and 36.5% among HCW in areas with high COVID-19 prevalence (17-19). These studies revealed seroprevalence of SARS-CoV-2 IgG antibodies in HCW tend to be higher than in the general population, at variance according to regional COVID-19 incidence. 

The prevalence of SARS-CoV-2 antibodies among HCW has been increasingly investigated in many other countries showing a broad range of outcomes. So far, two systematic reviews estimated an overall seroprevalence of SARS-CoV-2 antibodies of 8.7% and 8.0% among 127,480 HCW and 168,200 HCW, respectively, before vaccination started (2,20). 

Seroprevalence was higher in studies conducted in North America (12.7%) compared with those conducted in Europe (8.5%), Africa (8.2) and Asia (4%) (2).

In Europe, seroprevalence rates among HCW in Germany, Denmark and Belgium were low (1.6%, 4.0% and 6.4%, respectively) (21-23). These studies were conducted during early stages of the epidemic, and therefore, they derived that infection was community-acquired. Also, the Belgian study, with a sample size of almost 30,000 HCW, notes that the high availability of PPE, high standards of infection prevention, and PCR screening in symptomatic staff, coupled with contact tracing and quarantine, might explain the relatively low seroprevalence (23). An study performed in Lombardy, Italy (24), one of the Italian regions most hit by the first epidemic wave, showed a seroprevalence of 7.4% (3.8-11.0%), similar to the observed in the Catalan studies (11,12). Sweden and the UK were the two European countries reporting the highest seropositivity rates among HCW: 19.1% and between 18.0% and 45.3%, respectively (25–27). In the UK, this high seroprevalence was settled in London during the week with the highest number of new cases in the city in the first wave, with around 15% seropositivity among the general population. In the USA, the prevalence of infection among HCW was 10.7%, despite high variation, as low as 1.1% in California (28) to 13.7% in New York State (29). 

Despite SARS-CoV-2 seropositivity rate in oncological HCW has significant implications for oncological patients, scant research has been done. The only study published with a large sample size was in Tokyo, Japan, and it showed a very low seroprevalence of 0.67% among 1,190 HCW. It was performed at the end of the first wave in Japan, between the 3<sup>rd</sup> of August and the 30<sup>th</sup> of October 2020, so this may explain the lower seroprevalence compared with our estimation. A French study performed among 663 HCW and 1,011 cancer patients, after the end of the first wave, showed also low seroprevalence both for HCW and patients (1.8% and 1.7%, respectively) (30). Other studies that have been published were based on small sample sizes and showed very variable seroprevalence rates (22,31–35). 

In our study, we found no differences in HCW seroprevalence according to sex, age and presence of comorbidities. Current or past smoking was however inversely associated to SARS-CoV-2 seroprevalence. Early studies in selected cohorts of COVID-19 patients showed a paradoxical higher risk of SARS-CoV-2 infection among non-smokers (36) whilst ever smokers showed higher risk of COVID-19 progression, including severity of the disease, Intensive Care Unit admission and death (27,28). 

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

It is worth mentioning that, unlike most of the other published seroepidemiological studies among HCW, the present study was performed among all the HCW of the institution, regardless they did full-time telework during the study period (21.6%). No differences by telework were found, and among all study participants the main factor associated with SARS-CoV-2 seropositivity was living with a COVID-19 case, with a times higher probability, similarly to what has been described in other studies (2,20). This finding supports the importance of community dissemination of the infection also for HCWs. 

Our study shows that among on-site HCW in an oncological centre, working as medical care staff (nursing, nursing assistant, resident physicians and specialists) in COVID-19 areas stood out as one of the main factors associated with developing SARS-CoV-2 antibodies. Published results regarding the possibility of in-hospital infection among HCW and transmission at work are controversial. Some studies did not find any relation between working in COVID unit or professional category with seropositivity (11,24) whereas other studies reported that seroprevalence was strongly associated with patient related-work (16,22,25,38). 

Contact with colleagues at work is potentially a risky situation for transmission among HCW as well as the relaxation of protective measures at the end of the working day. In our study, the on-site HCW who reported being exposed to COVID-19 by other colleagues presented an almost four-fold probability of being seropositive. Most of the HCW declared to follow the protective measures at the workplace, and no differences in seroprevalence were found according to protective measures and hand hygiene. 

Protecting HWC health is of paramount importance for reducing morbidity and mortality, reducing transmission, and maintaining the health system capacity (39). Thus international health authorities recommend screening strategies for SARS-CoV-2 infection in exposed or high-risk HCW (40) as well as massive COVID-19 vaccination (41). 

Significant differences exist in SARS-CoV-2 testing between countries, and existing programmes focus on screening symptomatic rather than asymptomatic staff. Published studies point out the fact that screening should be performed regardless of the absence of typical symptoms for COVID-19 disease. It has been demonstrated that seroconversion can occur in HCW who have suffered no previous symptoms of SARS-CoV-2 infection (42,43) as asymptomatic transmission is very relevant in SARS-CoV-2 spread (44,45). Thus, the approach for mass testing of both symptomatic and asymptomatic HCW could mitigate 

382 workforce depletion by unnecessary quarantine, reduce spread in atypical, mild, or
383 asymptomatic cases; and protect patients and health-care workforce.

Among the potential limitations of the study, some recall bias is possible as the data for the correlates of SARS-CoV-2 infection rely on a self-administered questionnaire. Also, response and perception biases must be considered, as well as complacency bias. Results, especially those regarding the accomplishment of preventive measures, might be overestimated. Answers reported in the questionnaire could be influenced by the participants' knowledge regarding their COVID status. However, this study is the first seroepidemiological study with such a large sample size settled in an oncological health centre. The sufficient sample size and high response rate (64.3%) are strengths of the study, although information regarding non-participants was not collected, and we cannot disregard a potential participation bias. However, the distribution by age and sex was similar between participants and non-participants and a possible reason for no participation is that professionals from ICO-Badalona had previously participated in a HCW county seroprevalence survey (12). Also, the fact that the information of the study and the questionnaire was published online and sent by e-mail, as well as the short period of time stablished to respond to it, could have limited the participation. Questionnaire completeness was very high, with no variables presenting more than 5% of missing values.

In conclusion, SARS-CoV-2 seroprevalence among ICO HCW at the end of the first wave of the pandemic was lower than the reported in other Catalan hospitals, but higher than among the general population living in the area. Whereas the main risk factor was living with infected people, among on-site workers, contact with colleagues was associated with SARS-CoV-2 infection. Knowing the seroprevalence rate and follow-up evaluation of persistence may help hospitals to characterize the staff at risk, rationalize their placement, prioritize the use of PPE, thereby potentially reducing the risk of infection. Follow-up studies to evaluate long term durability of antibodies among HCW will be of interest, after the introduction of COVID-19 vaccination among HCW, to better promote infection control in this group. Strengthening preventive measures and health education among HCW is fundamental, especially in oncological departments and centres.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

Contributors EF, DCP, AP, CC, AC and AS contributed to study design. SC, AD, LG, IB, JT, MG, FS, JJT, DC, AS, BC, DR and AP accrued participants and care for blood collection at ICO centres. Laboratory analyses were coordinated by MADL. The questionnaire was designed by DCP and EF, and revised by PPT, ASL, YB, DC, AP, and LA. Questionnaire's implementation was done by EL, JM, JPR, CMM. Data were analysed by YB and DC. PPT, ASL, YB, DC, LA, and EF interpreted the initial results and designed the tables. All authors contributed to interpretation of results. The first draft of the manuscript was prepared by PPT and ASL. PPT, ASL, YB, DC, LA, DC and EF were the main contributors to the writing of the manuscript. All authors assisted in manuscript review. The co-senior authors had full access to all the data in the study for interpretation and had final responsibility for manuscript generation and review, and the decision to submit for publication. EF is the guarantor.

Funding This work was supported by the Catalan Institute of Oncology. PPT is partially supported by the Instituto de Salud Carlos III (ISCIII), Government of the Kingdom of Spain, co-funded by FEDER funds/European Regional Development Fund (ERDF) - a way to build Europe (CM19/00216). The Ministry of Universities and Research, Government of Catalonia partly supports EF and DCP (2017SGR319) and PPT, AS, YBM, DC and LA (2017SGR1085). We thank CERCA Programme / Generalitat de Catalunya for institutional support. 

Competing interests JJ received research funding from Kyowa Kirin and from Angelini Pharma for congress attendance. The Cancer Epidemiology Research Programme has received grants from Merck & Co., Roche, GSK, IDT, Hologic, and Seegene. 

Acknowledgments The authors acknowledge all the health care workers who participated in the study as well as all the ICO staff involved in the logistics of the different aspects of the study. 

Data availability statement No additional data available 

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

1 2			
2 3 4	434	REFI	ERENCES
5 6 7	435 436	1.	Ng K, Poon BH, Kiat Puar TH, Shan Quah JL, Loh WJ, Wong YJ, et al. COVID-19 and the Risk to Health Care Workers: A Case Report. Annals of internal medicine.
8 9	437 438	2.	2020 Jun 2;172(11):766–7. Galanis P, Vraka I, Fragkou D, Bilali A, Kaitelidou D. Seroprevalence of SARS-CoV-2
10	439		antibodies and associated factors in healthcare workers: a systematic review and meta-
11	440	2	analysis. J Hosp Infect. 2021 Feb;108:120–34.
12 13	441 442	3.	Informe sobre la situación de COVID-19 en personal sanitario en España. España; 2020.
14	442	4.	Centro de Coordinación de Alertas y, Emergencias Sanitarias. Actualización no 517.
15	444	4.	Enfermedad por el coronavirus (COVID-19). 03.12.2021 [Internet]. [cited 2022 Feb 1].
16	445		Available from:
17 18	446		https://www.sanidad.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/docu
19	447		mentos/Actualizacion 517 COVID-19.pdf
20	448	5.	Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more
21	449		vulnerable to SARS-CoV-2: A multicenter study during the COVID-19 outbreak.
22 23	450		Cancer Discovery. 2020 Jun 1;10(6):783.
23	451	6.	Leung MST, Lin SG, Chow J, Harky A. COVID-19 and Oncology: Service
25	452		transformation during pandemic. Cancer Medicine. 2020 Oct 18;9(19):7161–71.
26	453	7.	Institut Català d'Oncologia [Internet]. [cited 2021 Mar 19]. Available from:
27	454	0	http://ico.gencat.cat/ca/l_institut/
28 29	455	8.	Videla S, Otero A, Martí S, Domínguez MÁ, Fabrellas N, Delgado-Hito MP, et al.
30	456		Prevalence of SARS-CoV-2 Infection at the University of Barcelona during the Third
31	457		COVID-19 Pandemic Wave in Spain. Int J Environ Res Public Health. 2021
32	458 459	9.	Jan;18(12):6526. Barros AJD, Hirakata VN. Alternatives for logistic regression in cross-sectional
33 34	460	9.	studies: An empirical comparison of models that directly estimate the prevalence ratio.
35	461		BMC Medical Res Methodol. 2003 Oct 20;3:1–13.
36	462	10.	Richards M, Anderson M, Carter P, Ebert BL, Mossialos E. The impact of the COVID-
37	463	10.	19 pandemic on cancer care. Nature Cancer. 2020 Jun;1(6):565–7.
38	464	11.	Garcia-Basteiro AL, Moncunill G, Tortajada M, Vidal M, Guinovart C, Jiménez A, et
39 40	465		al. Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a
41	466		large Spanish reference hospital. Nature Comm. 2020 Dec 1;11(1):1–9.
42	467	12.	Barallat J, Fernández-Rivas G, -Sánchez B Q, Martinez-Caceres. Seroprevalence of
43	468		SARS-CoV-2 IgG Specific Antibodies among Healthcare Workers in the Northern
44 45	469		Metropolitan Area of Barcelona, Spain, after the first pandemic wave. PLoS One. 2020
46	470	10	Dec 28;15(12):e0244348.
47	471	13.	Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda M, et
48	472		al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-
49 50	473 474	14.	based seroepidemiological study. The Lancet. 2020 Aug 22;396(10250):535–44. COVID-19 data and indicators. Sistemes d'Informació dels Serveis d'Atenció Primària-
50 51	474 475	14.	SISAP, Institut Català de la Salut, Departament de Salut, Generalitat de Catalunya.
52	473 476		[Internet]. 2020 [cited 2021 Mar 19]. Available from: http://eines.portalics/covid/
53	477	15.	Rodriguez A, Arrizabalaga-Asenjo M, Fernandez-Baca V, Lainez MP, Al Nakeeb Z,
54	478	10.	Garcia JD, et al. Seroprevalence of SARS-CoV-2 antibody among healthcare workers
55 56	479		in a university hospital in Mallorca, Spain, during the first wave of the COVID-19
57	480		pandemic. Int J Infect Dis. 2021 Apr;105:482–6.
58			<b>*</b> *
59			
60			


1 2			
3	481	16.	Varona JF, Madurga R, Peñalver F, Abarca E, Almirall C, Cruz M, et al.
4	482	10.	Seroprevalence of SARS-CoV-2 antibodies in over 6000 healthcare workers in Spain.
5	483		Int J Epidemiol. 2021 May 17;50(2):400–9.
6 7	484	17.	Galán MI, Velasco M, Casas ML, Goyanes MJ, Rodríguez-Caravaca G, Losa JE, et al.
8	485	17.	SARS-CoV-2 Seroprevalence Among All Workers in a Teaching Hospital in Spain:
9	486		Unmasking The Risk [Internet]. medRxiv; 2020 [cited 2022 Feb 2]. p.
10	487		2020.05.29.20116731. Available from:
11	488		https://www.medrxiv.org/content/10.1101/2020.05.29.20116731v1
12	489	18.	Pérez-García F, Pérez-Zapata A, Arcos N, De la Mata M, Ortiz M, Simón E, et al.
13	490	10.	Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection among hospital
14 15	491		workers in a severely affected institution in Madrid, Spain: A surveillance cross-
16	492		sectional study. Infect Control Hosp Epidemiol. 2021 Jul;42(7):803–9.
17	493	19.	Cantero M, Millán-Pérez R, Muñez E, Gómez-Lozano N, Anel-Pedroche J, Parra LM,
18	494	17.	et al. SARS-COV-2 seroprevalence among all healthcare workers in a tertiary hospital
19	495		in Spain. Infectious Diseases. 2022 Jan 2;54(1):8–15.
20	496	20.	Kayı İ, Madran B, Keske Ş, Karanfil Ö, Arribas JR, Pshenichnaya N, et al. The
21 22	497		seroprevalence of SARS-CoV-2 antibodies among health care workers before the era of
23	498		vaccination: a systematic review and meta-analysis. Clin Microbiol Infect. 2021
24	499		Sep;27(9):1242–9.
25	500	21.	Korth J, Wilde B, Dolff S, Anastasiou OE, Krawczyk A, Jahn M, et al. SARS-CoV-2-
26	501		specific antibody detection in healthcare workers in Germany with direct contact to
27	502		COVID-19 patients. J Clin Virol. 2020 Jul 1;128:104437.
28 29	503	22.	Iversen K, Bundgaard H, Hasselbalch RB, Kristensen JH, Nielsen PB, Pries-Heje M, et
30	504		al. Risk of COVID-19 in health-care workers in Denmark: an observational cohort
31	505		study. Lancet Infect Dis. 2020;20(12):1401–8.
32	506	23.	Steensels D, Oris E, Coninx L, Nuyens D, Delforge ML, Vermeersch P, et al. Hospital-
33	507		Wide SARS-CoV-2 Antibody Screening in 3056 Staff in a Tertiary Center in Belgium.
34	508		JAMA. 2020;324(2):195–7.
35 36	509	24.	Sotgiu G, Barassi A, Miozzo M, Saderi L, Piana A, Orfeo N, et al. SARS-CoV-2
37	510		specific serological pattern in healthcare workers of an Italian COVID-19 forefront
38	511		hospital. BMC Pulmonary Med. 2020;20(1):1–6.
39	512	25.	Rudberg AS, Havervall S, Månberg A, Jernbom Falk A, Aguilera K, Ng H, et al.
40	513		SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in
41	514		Sweden. Nature Comm. 2020 Dec 1;11(1):1–8.
42 43	515	26.	Pallett SJC, Rayment M, Patel A, Fitzgerald-Smith SAM, Denny SJ, Charani E, et al.
44	516		Point-of-care serological assays for delayed SARS-CoV-2 case identification among
45	517		health-care workers in the UK: a prospective multicentre cohort study. Lancet Resp
46	518	<i></i>	Med. 2020;8(9):885–94.
47	519	27.	Houlihan CF, Vora N, Byrne T, Lewer D, Heaney J, Moore DA, et al. SARS-CoV-2
48 49	520		virus and antibodies in front-line Health Care Workers in an acute hospital in London:
49 50	521		Preliminary results from a longitudinal study [pre-print]. Available:
51	522	• •	medhttps://www.medrxiv.org/content/10.1101/2020.06.08.20120584v1
52	523	28.	Brant-Zawadzki M, Fridman D, Robinson PA, Zahn M, Chau C, German R, et al.
53	524		SARS-CoV-2 antibody prevalence in health care workers: Preliminary report of a
54	525	•	single center study. PLoS ONE. 2020 Nov 1;15.
55 56	526	29.	Moscola J, Sembajwe G, Jarrett M, Farber B, Chang T, McGinn T, et al. Prevalence of
56 57	527 529		SARS-CoV-2 Antibodies in Health Care Personnel in the New York City Area. JAMA
58	528		2020;324(9):893–5.
59			
60			

1			
2			
3 4	529	30.	Ladoire S, Goussot V, Redersdorff E, Cueff A, Ballot E, Truntzer C, et al.
4 5	530		Seroprevalence of SARS-CoV-2 among the staff and patients of a French cancer centre
6	531		after first lockdown: The canSEROcov study. Eur J Cancer. 2021 May 1;148:359–70.
7	532	31.	Favara DM, McAdam K, Cooke A, Bordessa-Kelly A, Budriunaite I, Bossingham S, et
8	533		al. SARS-CoV-2 Infection and Antibody Seroprevalence among UK Healthcare
9	534		Professionals Working with Cancer Patients during the First Wave of the COVID-19
10	535		Pandemic. Clin Oncol. 2021 Oct;33(10):667–75.
11	536	32.	Epstude J, Harsch IA. Seroprevalence of COVID-19 antibodies in the cleaning and
12 13	537		oncological staff of a municipal clinic. GMS Hyg Infect Control. 2020;15:5–9.
14	538	33.	Fuereder T, Berghoff AS, Heller G, Haslacher H, Perkmann T, Strassl R, et al. SARS-
15	539		CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at
16	540		a tertiary care centre during the COVID-19 pandemic. ESMO Open. 2020 Sep
17	541		2;5(5):e000889.
18	542	34.	Fong D, San Nicolò KO, Alber M, Mitterer M. Evaluating the longitudinal
19	543		effectiveness of preventive measures against COVID-19 and seroprevalence of IgG
20 21	544		antibodies to SARS-CoV-2 in cancer outpatients and healthcare workers. Wien Klin
21	545		Wochenschr. 2021 Apr;133(7–8):359–63.
23	546	35.	Marra A, Generali D, Zagami P, Cervoni V, Gandini S, Venturini S, et al.
24	547		Seroconversion in patients with cancer and oncology health care workers infected by
25	548		SARS-CoV-2. Ann Oncol. 2021 Jan;32(1):113–9.
26	549	36.	Simons D, Shahab L, Brown J, Perski O. The association of smoking status with
27	550		SARS-CoV-2 infection, hospitalisation and mortality from COVID-19: A living rapid
28 29	551		evidence review with Bayesian meta-analyses (version 11). Qeios. 2021 Mar 2;
29 30	552	37.	Patanavanich R, Glantz SA. Smoking is associated with COVID-19 progression: A
31	553	071	meta-analysis. Vol. 22, Nicotine and Tobacco Research. Oxford University Press; 2020.
32	554		p. 1653–6.
33	555	38.	Korth J, Wilde B, Dolff S, Anastasiou OE, Krawczyk A, Jahn M, et al. SARS-CoV-2-
34	556	200	specific antibody detection in healthcare workers in Germany with direct contact to
35	557		COVID-19 patients. J Clin Virol. 2020;128:104437.
36	558	39.	The Lancet. COVID-19: protecting health-care workers. COVID-19 Prioritization of
37 38	559	27.	Diagnostic Testing. Lancet. 2020;395: 922.
39	560	41.	The Importance of COVID-19 Vaccination for Healthcare Personnel. CDC [Internet].
40	561		[cited 2021 Mar 19]. Available from: https://www.cdc.gov/coronavirus/2019-
41	562		ncov/vaccines/recommendations/hcp.html
42	563	42.	Black JRM, Bailey C, Przewrocka J, Dijkstra KK, Swanton C. COVID-19: the case for
43	564	.2.	health-care worker screening to prevent hospital transmission. Lancet.
44	565		2020;395(10234):1418–20.
45 46	566	43.	Rivett L, Sridhar S, Sparkes D, Routledge M, Jones NK, Forrest S, et al. Screening of
40	567	13.	healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in
48	568		COVID-19 transmission. eLife. 2020;9:1–20.
49	569	44.	Shields AM, Faustini SE, Perez-Toledo M, Jossi S, Aldera E, Allen JD, et al. SARS-
50	570	• • •	CoV-2 seroprevalence and asymptomatic viral carriage in healthcare workers: a cross-
51	571		sectional study. Thorax. 2020 Dec;75(12):1089-1094.
52	572	45.	Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, et al. Presumed Asymptomatic Carrier
53 54	573	τ <i>Э</i> .	Transmission of COVID-19. JAMA. 2020;323:1406–7.
54 55	574		1100000000000000000000000000000000000
56	574		
57			
58			
59			

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

## Figure 1

Participants' flowchart in the seroprevalence survey, Catalan Institute of Oncology. 21<sup>st</sup> May-26<sup>th</sup> June 2020; Spain.



## SUPPLEMENTARY MATERIAL

Accompanying the manuscript:

## COVID-19 among workers of a Comprehensive Cancer Center between first and second epidemic waves (2020): a seroprevalence study in Catalonia, Spain.

**Contents:** 

- •
- •
- •

The information of the inform

## Epidemiologic and behaviour questionnaire - ICO-Sero-COVID Study

I give my consent to participate in the study of seroprevalence of SARS-Cov-2 infection among ICO workers and related companies, which includes responding to an epidemiological survey with information on working conditions and obtaining a nasopharyngeal smear (to perform PCR test for virus detection) and/or to obtain blood sample by venipuncture (to perform serological tests for antibody determination and plasma cryopreservation at ICO biobank)

1 = Yes; 2 = No.

Thank you for participating in the COVID-19 seroprevalence survey among ICO workers. All informations provided below will be treated confidentially, and all resulting results will be anonymized, with no individual data identifying participants.

## A. Socio-demographic data.

Socio-demographic data.
Name string variable.
Last name1 string variable.
Last name2 string variable.
Last name2 string variable.
CIP string variable.
Socio-demographic data.
Numeric variable.
Son NI numeric variable.
Socio-active and the string variable.
CIP string variable.
Socio-active and the string variable and the s

- **B.** Exposure and occupational safety measures data.

  - - c. Hepatopathy numeric variable (1 = Yes; 2 = No).
    - d. Nephropathy numeric variable (1 = Yes; 2 = No).
    - e. Active Cancer numeric variable (1 = Yes; 2 = No).
    - f. **Immunosuppression** numeric variable (1 = Yes; 2 = No).
    - **Diabetes mellitus** numeric variable (1 = Yes; 2 = No). g.
    - h. **Pregnancy** numeric variable (1 = Yes; 2 = No).
  - 17. Have you had contact with patients with COVID-19 infection at ICO? numeric variable (1 = Yes; 2 = No).
  - **18.** Have you had contact with samples of COVID-19 patients at ICO? numeric variable (1 = Yes; 2 =No).For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

- 19. When you are in your workplace, do you wear a surgical mask? numeric variable (1 = Yes; 2 =No).
  - 20. If you are in the COVID-19area, do you wear Personal Protective Equipment (PPE)? numeric variable (1 = Yes; 2 = No, 3 = Not Applicable).
  - 21. Do you think that the Personal Protective Equipment (PPE) removal procedure is safe? numeric variable (1 = Yes; 2 = No, 3 = I don't know, 4 = Not Applicable).
  - 22. Do you feel protected by the Personal Protective Equipment (PPE) used? numeric variable (1 =Yes; 2 = No, 3 = I don't know, 4 = Not Applicable).
  - 23. Do you think that you may have been exposed to COVID-19 during personal relationships with your co-workers? numeric variable (1 = Yes; 2 = No, 3 = I don't know).
  - 24. Do you think that the protection procedures implemented during this pandemic period will benefit you in your future professional development? numeric variable (1 = Yes; 2 = No, 3 = I don't ed know)
  - 25. Do you think that the work activity carried out during this pandemic period has affected you or

25. Do you think that the work activity carried out during this pandemic period has affected you or will affect you emotionally in the future? numeric variable (1 = Yes; 2 = No, 3 = 1 don't know).
At work, do you wash your hands with soap or water or with a hydro-alcoholic solution...
26. ... before you start working? numeric variable (1 = Yes; 2 = No).
27. ... every time you enter a new workspace? numeric variable (1 = Yes; 2 = No).
28. ... before eating? numeric variable (1 = Yes; 2 = No).
29. ... after handling money, mobile phone, other utensils ...? numeric variable (1 = Yes; 2 = No).
30. ... less than 7 times during the working day? numeric variable (1 = Yes; 2 = No).
31. ... at the end of the working day? numeric variable (1 = Yes; 2 = No).
32. When you eat, do you maintain a distance ≥ 2m from your colleagues? numeric variable (1 = Yes; 2 = No).
33. Did your collegues cover thir face with their elbows when they sneeze / cough? numeric variable (1 = Yes; 2 = No).
34. ... when you get home? numeric variable (1 = Yes; 2 = No).
35. ... before eating? numeric variable (1 = Yes; 2 = No).
36. ... after handling money, mobile phone, other utensils numeric variable (1 = Yes; 2 = No).
37. ... after cleaning? numeric variable (1 = Yes; 2 = No).
38. ... after blowing your nose, sneezing or coughing? numeric variable (1 = Yes; 2 = No).
39. Do you shower and change clothes when you get home (or did you go to work)?: numeric variable (1 = Yes; 2 = No).
39. Do you wear a mask when you go shopping? numeric variable (1 = Yes; 2 = No).
40. Do you wear a cohabitant who has passed COVID-19 (with symptoms, with or without confirmation by PCR, or PCR + without symptoms)? numeric variable (1 = Yes; 2 = No).
41. Do the people you live with cover their elbows if they sneeze / cough? numeric variable (1 = Yes; 2 = No).
42. Do you use public transport t

- If "yes", continue with question 44; if "no, jump to question 46.
- 44. Which type of public transport? numeric variable (1 = bus, 2 = metro, 3 = train, 4 = taxi, 5 = bicycle(multiple answer allowed)).
- **45.** How many days a week do you use public transport? | \_ | numeric variable (1 to 7).
- **46.** Do you use private transportation to get to work? numeric variable (1 = Yes; 2 = No). If "yes", continue with question 47; if "no", jump to question 49.
- 47. Which private transport? numeric variable (1 = single use car, 2 = shared car, 3 = single use bike, 4 =shared bike, 5 = bike (multiple answer allowed)).
- 48. How many days pen weekt do /ponjour entriviate the transport?/guide linear chievariable (1 to 7).

- **49.** Do you walk the street for more than 15 minutes? numeric variable (1 = Yes; 2 = No). *If "yes", continue with question 50; if "no", jump to question 52.*
- 50. How many days a week do you go for a walk? |\_\_| numeric variable (1 to 7).
- **51.** For how many minutes a day do you go for a walk as an average: |\_\_| minutes / day numeric variable.

## D. COVID-19 tests performed

- **52.** Have you had a COVID-19 PCR test? numeric variable (1 = Yes, only one; 2 = Yes, several; 3 = No).
  - If "1", continue with question 53; if "2", jump to question 55; if "3", jump to question 59.
- **53.** COVID-19 PCR test performed on day: | *dd* | *mm* | *yy*|.
- 54. COVID-19 PCR test result numeric variable (1 = Negative; 2 = Positive).
- **55.** How many COVID-19 PCR test have you had in total? | \_ | numeric variable (1 to 10). Depending on the answer, open as many questions with the number of PCR made to ask the date and result in the same format (A1 and A2; B1 and B2; etc).
  - A1. COVID-19 PCR test performed on day: | dd | mm | yy|.
  - A2. COVID-19 PCR test result numeric variable (1 = Negative; 2 = Positive).
- 56. When you had your first COVID-19 PCR test, did you present any of these signs or symptoms?
  anumeric variable (multiple answer allowed) (1 = Febricula (>37.3°C); 2 = Fever (>38°C); 3 = Cough; 47
  anumeric variable (sorethroat); 5 = Headache; 6 = Arthromyalgia (generalized pain); 7 = Astheniage (intense fatigue); 8 = Dyspnoea (shortness of breath); 9 = Anosmia (loss of smell); 10= Nauseage vomiting; 11 = Diarrhea; 12 = Skin lesions; 13 = Myoclonus (involuntary movements); 14 = Pneumonia; 15 = Other (specify: string variable \_\_\_\_\_).
- 57. Have you had a COVID-19 rapid antibody test? numeric variable (1 = Yes; 2 = No).
- 58. COVID-19 rapid antibody test result numeric variable (1 = Negative; 2 = Positive).

## Finally, we would like to complete the information provided with information about your lifestyle.

- E. Lifestyle
  - **59.** Do you drink any alcoholic beverage at least once a week? numeric variable (1 = Yes; 2 = No). *If "yes", continue with question 60; if "no", jump to question 64.*
  - 60. How many glasses of wine do you drink every week?
  - 61. How many beers do you drink every week? |\_\_| numeric variable
  - 62. How many glasses of cognac, gin or other spirits do you drink every week? | numeric variable
  - **63.** Has your alcohol consumption changed during the pandemic compared to your consumption previously? numeric variable (1 = No, it is similar; 2 = Yes, it has increased; 3 = Yes, it has decreased).
  - **64. Regarding tobacco use:** numeric variable (1 = I have never smoked; 2 = I am a former smoker; 3 = I am a corrent smoker).

If "1" or "2", jump to question 67; If "3", continue to question 65.

- 65. How many roll-ypur-own cigarrettes do you smoke every day? |\_\_| numeric variable
- **66.** Has your tobacco consumption changed during the pandemic compared to your consumption previously? numeric variable (1 = No, it is similar; 2 = Yes, it has increased; 3 = Yes, it has decreased).

## F. End of the survey

Thank you very much for your participation. As mentioned before, all information from this survey and the tests performed is confidential and will be anonymized.

If you would like to leave us any further comments regarding the pandemic at the ICO Centers, please do so below:

67. Commentaries. Open answer, leave space for about 5 lines of text. For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Teleworking

3 4 5 6 7 8 9 10 11 12	Supplemen (always/oca
13 14 15 16 17	Sex
18 19 20 21 22 23	Age [median,
24 25 26 27 28	ICO Center
29 30 31 32 33 34	ICC Health care w
35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50	Any Comorbi Smoking histo
51 52 53 54 55 56 57 58 59 60	Cohabiting Cohabiting w Reported rRT <u>Positive of p</u> r

## Supplementary Table 1. Demographic characteristics of on-site workers (always/ocassionally) and teleworkers

	Never/ocassionally (n=981)	Always (n=230)	p-value
	n (%)	n (%)	-
Sex			
Male	240 (25)	47 (20)	
Female	736 (75)	183 (80)	0,183
Age [median, (min-max)]	43 (19-68.5)	44.9 (19-71.6)	0,015
<35y	271 (28)	38 (17)	
35-49y	429 (44)	122 (53)	
>49y	281 (29)	70 (30)	0,002
ICO Center			
ICO L'Hospitalet	684 (70)	184 (80)	
ICO Girona	182 (19)	17 (7)	
ICO Badalona	<b>103 (11)</b>	29 (13)	
ICO Tarragona / Terres de l'Ebre	12 (1)	0 (0)	< 0.000
Health care workers			
Yes	567 (59)	72 (32)	
No	402 (41)	152 (68)	< 0.000
Middle and superior technicians	187 (19)	92 (41)	0.000
Porters	17 (2)	3 (1)	
Administrative staff	90 (9)	35 (16)	
Maintenance or security stafft	29 (3)	2 (1)	
Cleaning staff	46 (5)	15 (7)	
Restoration staff	16 (2)	2 (1)	
Others	17 (2)	3 (1)	<0.0001
Any Comorbidity	142 (15)	38 (17)	0,4
Smoking history			
Never	511 (54)	126 (56)	
Ever	438 (46)	98 (44)	0,5
Past	277 (29)	66 (29)	
Current	161 (17)	32 (14)	0,6
Cohabiting	889 (91)	209 (92)	0,8
Cohabiting with covid-19	115 (14)	27 (14)	0,9
Reported rRT-PCR previous to serology	422 (84)	42 (75)	0,1
Positive of previous rRT-PCR	62 (15)	10 (24)	0,1

	<u> </u>
	<b>5 3</b>
DMIOnon	ž 2.
Sumplementary Table 2 Clinical share deviation are sided with SADS CaV 2 notitive surply UDED at these who was not a DT DCD	
Supplementary Table 2. Clinical characteristics associated with SARS-CoV-2 positive serology among those who report rRT-PCR	prevapus to study serology
(n=469).	<b>σ</b> <del>"</del>

	Total participants n (%)	SARS-CoV-2 seroprevalence n (%)	Prevalence (95%CI)	p-value	Adjusted PR (95% CI)
Reported rRT-PCR previous to serology	469 (38.0)	86 (78.2)	18.34 (15.08-22.11)	including for	05 <del>56</del> 637
Result of previous rRT-PCR				ding	2
Negative	397 (84.6)	27 (31.0)	6.80 (4.70-9.74)	for	REF
Positive	72 (15.4)	59 (68.6)	81.94 (71.31-89.23)	<0.00 J m	12.15 (7.54-19.57)
Number of symptoms(mean, standard deviation) None	1.65 (2.10) 217 (46.3)	3.08 (2.61) 21 (24.0)	9.68 (6.39-14.4)	<0.00 Elated	ni 2000 REF
1 One	61 (13)	7 (8.1)	11.48 (5.56-22.21)	ied eme	<b>1.13</b> (0.48-2.67)
2 2_3	109 (23.2)	22 (25.6)	20.18 (13.66-28.78)	tot	2.03 (1.10-3.73)
	81 (17.3)	35 (40.7)	43.21 (32.87-54.18)	e Si <0.00 단당	4.33 (2.48-7.59)
$\geq 4$ p-trend (among exposed)	01 (17.5)	JJ (TU.7)	чэ.21 ( <i>э</i> 2.07-5 <b>ч</b> .10)	ed to text and <0.00	<0.001
Reporting COVID-19 compatible symptoms when rRT-PCR was performed				ur (AE data i	
No	217 (46.3)	21 (24.0)	9.68 (6.39-14.4)	ninii	REF
Yes	251 (53.5)	64 (74.4)	25.5 (20.48-31.27)	<0.00	2.49 (1.51-4.10)
COVID-19 symptoms				mining. Al training. <0.000, Al training. <0.000, and <0.000 solution.	<u>3</u> <u>5</u>
Headache	126 (26.9)	36 (41.9)	28.57 (21.35-37.08)	< 0.00 <b>tr</b> ai.	1.87 (1.20-2.93)
Cough	119 (25.4)	37 (43.0)	31.09 (23.42-39.97)	-0.00 <b>g</b>	2.25 (1.44-3.52)
Asthenia	110 (23.5)	36 (41.9)	32.73 (24.6-42.04)	يوآ 00.0>	2.38 (1.53-3.72)
Arthromyalgia	80 (17.1)	57 (66.0)	36.25 (26.47-47.31)	<0.00 P	2.32 (1.47-3.67)
Low-grade fever (37.3°C-38°C)	73 (15.6)	26 (30.2)	35.62 (25.5-47.21)	<0.00	2.71 (1.67-4.39) 1.18 (0.65-2.13) 1.47 (0.83-2.60) 6.09 (3.86-9.60)
Odynophagia	64 (13.6)	14 (16.3)	21.88 (13.39-33.65)	0.40 <b>a</b>	1.18 (0.65-2.13)
Diarrhoea	58 (12.4)	16 (18.6)	27.59 (17.62-40.43)	0.05	1.47 (0.83-2.60)
Anosmia	42 (9)	33 (38.4)	78.57 (63.65-88.48)	<0.00 B	6.09 (3.86-9.60)
Dyspnoea	40 (8.5)	11 (12.8)	27.50 (15.91-43.2)	0.12 <b>0</b>	<b>1.56</b> (0.81-3.00)
<i>Fever (&gt;38°C)</i>	28 (6)	15 (17.4)	53.57 (35.4-70.84)	<0.00	3.06 (1.71-5.46)
Fever (>38°C) Nausea / vomiting	17 (3.6)	6 (7)	35.29 (16.75-59.66)	0.07	1.86 (0.80-4.36)
Skin lesions	8 (1.7)	1 (1.2)	12.50 (1.72-53.86)	0.66	0.74 (0.10-5.38)
Pneumonia	3 (0.6)	2 (2.3)	66.67 (15.27-95.69)	0.03	1.86 (0.80-4.36)           0.74 (0.10-5.38)           2.99 (0.71-12.63)
Myoclonus	2 (0.4)	0		0.50	5


 38
 1
 2 (0.4)
 0
 0.50
 1

 39
 Numbers do not always sum up the total due to some missing values (none of the categories present more than 5% of missing values). PR: Prevalence Ratio, CI: Confidence Interval.
 <sup>1</sup>Chi-squared test for categorical

 40
 variables (Fisher's exact test corrected for continuity) and median test for continuous variables. <sup>2</sup>Adjusted for sex, age (continuous), ICO center, care staff, telework and cohabitants
 <sup>1</sup>Chi-squared test for categorical

 41
 42
 43
 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
 <sup>4</sup>Chi-squared test for categorical

- 44 45
- 46



		BMJ Open BMJ Open BMJ Open BMJ Open BMJ Open BMJ Open BMJ Open BMJ Open	Page 3
	STR	이용 2007 (v4) Statement—Checklist of items that should be included in reports of cress-sectional studies	
Section/Topic	ltem #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract 둘 파울	3
		(b) Provide in the abstract an informative and balanced summary of what was done and what 광용 bound	3
Introduction	•	ated	
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods		and eried	
Study design	4	Present key elements of study design early in the paper	5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure w-up, and data collection	5
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	5
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifierd. Get diagnostic criteria, if applicable	7
Data sources/	8*	For each variable of interest, give sources of data and details of methods of assessment (meagurement). Describe	7
measurement		comparability of assessment methods if there is more than one group	
Bias	9	Describe any efforts to address potential sources of bias	5,6,19
Study size	10	Explain how the study size was arrived at	5
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which grothings were chosen and why	7
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8
		(b) Describe any methods used to examine subgroups and interactions	8
		(c) Explain how missing data were addressed	8
		(d) If applicable, describe analytical methods taking account of sampling strategy	NA
	ļ	(e) Describe any sensitivity analyses	NA
Results		2i q e	

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

 bmjopen-20; 1 by copyrig

aphique de l

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility,	9
		confirmed eligible, included in the study, completing follow-up, and analysed	
		(b) Give reasons for non-participation at each stage	9
		(c) Consider use of a flow diagram	6
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information (응 제공 프 confounders	9
		(b) Indicate number of participants with missing data for each variable of interest	9
Outcome data	15*	Report numbers of outcome events or summary measures	12
Main results	16	( <i>a</i> ) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their presition (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	12
		(b) Report category boundaries when continuous variables were categorized	9
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaning of the period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analy	15
Discussion		ning.	
Key results	18	Summarise key results with reference to study objectives	17
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	21
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicities of analyses, results from similar studies, and other relevant evidence	17
Generalisability	21	Discuss the generalisability (external validity) of the study results	21
Other information		arte	
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable for the original study on	22
		which the present article is based	

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in controls in case-control studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.grg/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.grobe-statement.org.

# **BMJ Open**

## COVID-19 among workers of a Comprehensive Cancer Center between first and second epidemic waves (2020): a seroprevalence study in Catalonia, Spain.

Journal:	BMJ Open
Manuscript ID	bmjopen-2021-056637.R2
Article Type:	Original research
Date Submitted by the Author:	23-Feb-2022
Complete List of Authors:	Peremiquel-Trillas , Paul; Catalan Institute of Oncology, Tobacco Control Unit Saura-Lazaro, Anna; Catalan Institute of Oncology, Tobacco Control Unit Benavente Moreno, Yolanda; Catalan Institute of Oncology Cancer Epidemiology Research Programme Casabonne, Delphinne; Catalan Institute of Oncology Loureiro, Eva; Catalan Institute of Oncology Cabrera, Sandra; Catalan Institute of Oncology Duran, Angela; Catalan Institute of Oncology Garrote, Lidia; Catalan Institute of Oncology Brao, Immaculada; Catalan Institute of Oncology Galán, Maica; Catalan Institute of Oncology Galán, Maica; Catalan Institute of Oncology Galán, Maica; Catalan Institute of Oncology Soler, Francesc; Catalan Institute of Oncology Ouríasa, Dolça; Catalan Institute of Oncology Domínguez, Maria Ángeles; Bellvitge University Hospital Albasanz-Puig, Adaia; Catalan Institute of Oncology Gudiol, Carlota; Catalan Institute of Oncology Ramírez-Tarruella, Dolors; Catalan Institute of Oncology Muniesa, Joan; Catalan Institute of Oncology Rivas, Juan; Catalan Institute of Oncology Cale, Candela; Catalan Institute of Oncology Calan, Ana; Catalan Institute of Oncology Calan, Ana; Catalan Institute of Oncology Cale, Candela; Catalan Institute of Oncology Cancer-Pont, Dolors; Hospital Duran i Reynals, Alemany, L.; Institut Catala d' Oncologia, Fernandez, Esteve; Catalan Institute of Oncology, Tobacco Control Unit
<b>Primary Subject Heading</b> :	Epidemiology
Secondary Subject Heading:	Infectious diseases, Oncology
Keywords:	Adult oncology < ONCOLOGY, Epidemiology < INFECTIOUS DISEASES, COVID-19, Epidemiology < ONCOLOGY

1		BMJ
2 3 4		Open: fi
5 6 7 8 9 10	SCHOLARONE <sup>™</sup> Manuscripts	BMJ Open: first published as 10.1136/bmjopen-2021-056637 on 21 April 2022. Downloaded from http://bmjopen.bmj.com/ on June 13, 2025 at Agence Bibliographique de I Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.
11 12 13 14 15		10.1136/bmjop rotected by co
16 17 18 19 20		en-2021-0566: ppyright, inclu
21 22 23 24 25		37 on 21 April Ense ding for uses
26 27 28 29		2022. Downlo eignement Su related to text
30 31 32 33 34		aded from htt perieur (ABES t and data mir
35 36 37 38 39		p://bmjopen.t S) . ning, Al trainin
40 41 42 43 44		omj.com/ on J ng, and simila
45 46 47 48		une 13, 2025 r technologie
49 50 51 52 53		at Agence Bi <sup>1</sup> S.
54 55 56 57 58		bliographiqu
58 59 60	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	e de l

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies



*I*, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.



# COVID-19 among workers of a Comprehensive Cancer Center between first and second epidemic waves (2020): a seroprevalence study in Catalonia, Spain.

# 4 Paula Peremiquel-Trillas\*, Anna Saura-Lázaro\*, Yolanda Benavente-Moreno, Delphine

5 Casabonne, Eva Loureiro, Sandra Cabrera, Angela Durán, Lidia Garrote, Immaculada

6 Brao, Jordi Trelis, Maica Galán, Francesc Soler, Joaquim Julià, Dolça Cortasa, M. Angeles

7 Domínguez, Adaia Albasanz-Puig, Carlota Gudiol, Dolors Ramírez, Joan Muniesa, Juan

8 Pedro Rivas, Carles Muñoz-Montplet, Ana Sedano, Àngel Plans, Beatriz Calvo-Cerrada,

9 Candela Calle, Ana Clopés, Dolors Carnicer-Pont<sup>†</sup>, Laia Alemany<sup>†</sup>, Esteve Fernández<sup>†</sup>

10 \*Contributed equally

11 <sup>†</sup>Joint senior authors

# 12 Authors' affiliations

ASL Universitat de Barcelona, Barcelona, Spain. @PeremiquelPaula. ORCID: 0000-0002-8636-1725 Cancer Epidemiology Research Programme, Cancer Epidemiology and Prevention Department,	Institut Català nme, Institut 1-9742-2725
d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain; Epidemiology and Public Health Program d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain. 0000-000	
<ul> <li>YBM Cancer Epidemiology Research Programme, Cancer Epidemiology and Prevention Department, d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain; Epidemiology and Public Health Program d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain; CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain. ORCID: 0000-0003-1422-4614</li> </ul>	nme, Institut
DC Cancer Epidemiology Research Programme, Cancer Epidemiology and Prevention Department, d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain; Epidemiology and Public Health Program d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain; CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain. ORCID: 0000-0002-7874-3707	nme, Institut
EL Computer Science Services, Technology & Physics, Institut Català d'Oncologia (ICO), L'Hosp Llobregat, Spain; Computational Science and Artificial Intelligence, Faculty of Computer Science University of Coruña (UDC), Coruña, Spain.	italet de ce of Coruña,
<ul> <li>SC Research Nursing Department, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Sp @scabrerajaime. ORCID: 0000-0003-3013-8812</li> </ul>	oain.
AD Nursing Department, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain.	
LG Nursing Department, Institut Català d'Oncologia – Badalona (ICO), Badalona, Spain.	
IB Nursing Department, Institut Català d'Oncologia – Girona (ICO), Girona, Spain.	
JT Palliative Care Department and Medical Director, Institut Català d'Oncologia (ICO), L'Hospital Llobregat, Spain. @JordiTrelis.	let de
MG Esofagogastric Tumours Functional Unit and Medical Director, Institut Català d'Oncologia (ICC L'Hospitalet de Llobregat, Spain.	)),
FS Pharmacy Service and Medical Director, Institut Català d'Oncologia – Girona (ICO), Girona, Sp	pain.
JJT Palliative Care Department and Medical Director. Institut Català d'Oncologia (ICO) Badalona, E Spain. @drijulia. ORCID: 0000-0002-1462-3167	Badalona,
DC Medical Director, Institut Català d'Oncologia -Tarragona/Terres de l'Ebre, Tarragona (ICO).	
MADL Microbiology Department. Hospital Universitari de Bellvitge; Infectious Diseases Programme, I d'Investigació Biomèdica de Bellvitge (IDIBELL); Department of Pathology Experimental Ther Universitat de Barcelona, Barcelona, Spain.	

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

# BMJ Open

2
3
4
5
6
7
, 8
•
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
23 24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58

13

14

15

16

17

18

59 60

I	AAP	Infectious Disease Department, Hospital Universitari de Bellvitge, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain. CIBER of Infectious Diseases (CIBERINFEC), Madrid, Spain. ORCID: 0000-0001-9852-5574.
(	CG	Infectious Disease Department, Hospital Universitari de Bellvitge, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain. CIBER of Infectious Diseases (CIBERINFEC), Madrid, Spain. @Carlotasway3. ORCID: 0000-0003-3095-4422
Ι	OR	Preventive Medicine Unit, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain.
J	М	Computer Science Services, Technology & Physics Department, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain.
J	PR	Computer Science Services, Technology & Physics Department, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain.
(	СММ	Technology and Physics Department, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain; Medical Physics and Radiation Protection Department, Institut Català d'Oncologia (ICO) – Girona, Girona, Spain; Department of Medical Sciences, Universitat de Girona, Girona, Spain. @CMunozMontplet. ORCID: 0000-0002-7324-8889.
A	AS	Human Resources Department, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain.
P	AC	Scientific Direction, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain. ORCID: 0000-0002- 1857-362X.
I	BCC	Occupational Health Unit, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain.
	CC	General Direction, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain. @CandelaCalle.
A	ĄР	Occupational Health Unit, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain. ORCID: 0000- 0003-3199-0361.
Ι	DCP	Cancer Prevention and Control Programme, Cancer Epidemiology and Prevention Department, Catalan Institute of Oncology (ICO), L'Hospitalet de Llobregat, Spain; Epidemiology and Public Health Programme, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain. ; CIBER of Respiratory Diseases (CIBERES). ORCID: 0000-0002-3475-8704.
Ι	LA	Cancer Epidemiology Research Programme, Cancer Epidemiology and Prevention Department, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain; Epidemiology and Public Health Programme, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain; CIBER of Epidemiology and Public Health (CIBERESP), Madrid, Spain. ORCID: 0000-0003-0945-6015.
H	ΞF	Cancer Prevention and Control Programme, Cancer Epidemiology and Prevention Department, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain; Epidemiology and Public Health Programme, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), L'Hospitalet de Llobregat, Spain; School of Medicine and Clinical Sciences, Universitat de Barcelona, Barcelona, Spain; CIBER of Respiratory Diseases (CIBERES). @StvFdz. ORCID: 0000-0003-4239-723X.
W	/ord co	ounts.
А	bstract	t: 296. Main text: 3,309. One figure, three tables, supplementary information.
Pı G	reventi ranvia	<i>condence to:</i> Prof. Esteve Fernández, MD, MPH, PhD. Tobacco Control Unit, Cancer ion and Control Programme, Institut Català d'Oncologia (ICO). Avinguda de la de l'Hospitalet, 199-203, 08908 L'Hospitalet de Llobregat, Barcelona, Spain. Phone: 2607345. Twitter: @StvFdz E-mail: <u>efernandez@iconcologia.net</u> (Prof. E. Fernández).

# ABSTRACT Objectives Cancer patients are at higher risk for severe COVID-19 infection. COVID-19

surveillance of workers in oncological centres is crucial to assess infection burden and prevent
transmission. We estimate the SARS-CoV-2 seroprevalence among health care workers
(HCW) of a comprehensive cancer centre in Catalonia, Spain, and analyse its association with
sociodemographic characteristics, exposure factors and behaviours.

- **Design** Cross-sectional study ( $21^{st}$  May  $26^{th}$  June 2020).
- 26 Setting A comprehensive cancer centre (Institut Català d'Oncologia) in Catalonia, Spain.

27 Participants All HCW (*N*=1,969) were invited to complete an online self-administered
28 epidemiological survey and provide a blood sample for SARS-CoV-2 antibodies detection.

Primary outcome measure Prevalence (%) and 95% confidence intervals (CI) of
seropositivity together with adjusted prevalence ratios (aPR) and 95%CI were estimated.

**Results** A total of 1,266 HCW filled the survey (participation rate: 64.0%) and 1,238 underwent serological testing (97.8%). The median age was 43.7 years (p25-p75: 34.8-51.0 years), 76.0% were female, 52.0% were nursing or medical staff, and 79.0% worked on-site during the pandemic period. SARS-CoV-2 seroprevalence was 8.9% (95%CI: 7.44-10.63), with no differences by age and sex. No significant differences in terms of seroprevalence were observed between onsite workers and teleworkers. Seropositivity was associated with living with a person with COVID-19 (aPR: 3.86, 95%CI: 2.49-5.98). Among on-site workers, seropositive participants were twofold more likely to be nursing or medical staff. Nursing and medical staff working in a COVID-19 area showed a higher seroprevalence than other staff (aPR: 2.45, 95% CI: 1.08-5.52).

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

**Conclusions** At the end of the first wave of the pandemic in Spain, SARS-CoV-2 42 seroprevalence among Institut Català d'Oncologia HCW was lower than the reported in other 43 Spanish hospitals. The main risk factors were sharing household with infected people and 44 contact with COVID-19 patients and colleagues. Strengthening preventive measures and health 45 education among HCW is fundamental.

46 Keywords SARS-CoV-2; COVID-19; seroprevalence; antibody; health care workers;
 47 epidemiology.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

# 48 ARTICLE SUMMARY

# Strengths and limitations

• Seroepidemiological study with a large sample size settled in a comprehensive cancer center.

**BMJ** Open

- Questionnaire completeness was very high, with no variables presenting more than 5% of missing values.
- Recall bias is possible as the data for the correlates of SARS-CoV-2 infection rely on a self-administered questionnaire.
  - The accomplishment of preventive measures might be overestimated: response and perception biases must be considered, as well as complacency bias.
    - Answers reported in the questionnaire could be influenced by the participants' knowledge regarding their COVID status.

# 61 INTRODUCTION

Frontline health care workers (HCW) dealing with COVID-19 have higher exposure to SARS-CoV-2 than the general population (1), and they can contribute to the spread of COVID-19 as per their exposure to vulnerable patients. Since the beginning of the pandemic, several studies have been published on SARS-CoV-2 infections prevalence in HCW, although with diverse results. A meta-analysis of 49 studies, including 127,480 health care workers, showed that the overall seroprevalence of SARS-CoV-2 antibodies in the European region was 8.5% (2). HCW in Spain have been highly affected: a total amount of 154,636 cases among HCW were already officially notified by December 2, 2021 at the onset of the sixth pandemic wave (3,4).

Cancer patients are vulnerable, presenting a high risk for COVID-19 infection and more severe outcomes due to their immunosuppression status (5). The pandemic has presented unprecedented professional and personal challenges for the oncology community (6). Data are lacking on the seroprevalence of SARS-CoV-2 among HCW in oncological centres, and small sample sizes limit the few published studies. The present study aims to estimate the seroprevalence of SARS-CoV-2 and associated sociodemographic and behavioural risk factors among workers of the Catalan Institute of Oncology (ICO), a Comprehensive Cancer Centre comprised of four hospitals in Catalonia (Spain), covering around 40% of the adult population in Catalonia (7).

1 2		
2 3 4	79	
5 6 7	80	PARTICIPANTS AND METHODS
8 9 10	81	Study design and setting
10 11 12	82	A cross-sectional study including blood sample collection and a self-administered
13	83	questionnaire was conducted between 21st May and 26th June 2020 in the four ICO centres
14 15 16	84	(L'Hospitalet de Llobregat, Badalona, Tarragona/Terres de l'Ebre and Girona).
17 18	85	The study population were HCW delivering care and services to patients (directly or indirectly)
19 20	86	and support staff, including those who do not deliver care but work in other tasks within the
21	87	hospital. A total of 1,969 employees of ICO were invited to participate in the study through an
22 23	88	email that allowed access to the study information. The inclusion criteria were: a) to be an
24 25	89	active worker during the epidemic period, (1st February - 26th June 2020) and b) to be aged
26	90	≥18years. The participants filled in an online epidemiological questionnaire and were
27 28	91	scheduled for serology testing by the Occupational Health Department. 1,266 HCW filled in
29 30	92	the online epidemiological questionnaire (participation rate: 64.3%) and 1,238 of them (97.8%)
31 32	93	underwent a serology test. Three participants with inconclusive serological results were
33 34	94	excluded. The final analysis included 1,235 participants (Figure 1).
35 36	95	Figure 1 about here
37 38	96	
39 40 41	97	Epidemiological questionnaire and study variables
42 43	98	An epidemiological questionnaire was programmed online to collect information regarding
44	99	sociodemographic characteristics, working information, compliance of personal protective
45 46	100	equipment (PPE) measures at work, at home and history of previous COVID-19 infection
47 48	101	(Supplemental Material). The questionnaire was developed based on previous
49 50	102	epidemiological studies conducted within the ICO centres, and a modified version was used in
51	103	another seroprevalence study performed among university personnel of the University of
52 53 54	104	Barcelona (8).
55 56	105	Sociodemographic characteristics included information on age and sex, ICO centre of
57 58 59 60	106	recruitment, presence of comorbidities, smoking history, pregnancy and cohabitants.

107 Work-related conditions included the professional category, teleworking status, type of shift,
108 working on a COVID-19 area, contact with COVID-19 cases, contact with biological samples
109 and reporting to be exposed to COVID-19.

Concerning PPE measures at work, participants were asked about feeling protected with PPE and compliance with PPE measures. Regarding the application of preventive measures outside the working setting, participants were asked if they got a shower after leaving the workplace or when arriving home, if they changed clothes after work or upon home arrival, as well as about hand washing and use of face mask when shopping. Information about COVID-19 cases and protective measures were also collected among those participants reporting cohabitants. Participants were also asked about the type of transport used to go to work. 

Participants were asked about a previous diagnosis of COVID-19 performed by rRT-PCR or
 serology test and date of diagnosis, as well as reporting COVID-19 compatible symptoms, and
 the type of symptoms.

# 28 29 120 SARS-CoV-2 laboratory testing

Serum samples from participants at L'Hospitalet, Girona and Tarragona/Terres de l'Ebre were studied at the Microbiology Department of Hospital de Bellvitge and samples from health-care workers at ICO Badalona were analysed at the MetroNord Regional Clinical Laboratory, using the same procedures and techniques in both laboratories. Detection of SARS-CoV-2 antibodies was carried out using the quantitative SARS-CoV-2 S1/S2 IgG LIAISON® test (DiaSorin, Vercelli, Italy) on the LIAISON XL platform, following the manufacturer's instructions. This test discriminates among negative (<12AU/mL; with 3.8 as IgG detection limit), equivocal (12.0–15.0AU/mL) and positive (>15.0AU/mL) subjects. In those cases in which a) IgG anti S1/S2 quantification was higher than the limit of detection (i.e.>3.8AU/mL) but did not reach the limit of discrimination (i.e.<15AU/mL) and/or b) when the HCW answered the questionnaire saying that he or she had been diagnosed of COVID-19 but IgG anti S1/S2 where lower than 15 AU/ml, an additional serological study was performed using a different antigen (N) as a target. In this case, a SARS-CoV-2 IgG test (Abbott Diagnostics, Sligo, Ireland) was run on an Architect i2000 platform. This test discriminates among negative ( $\leq 1.4$ Index (S/C)) and positive  $(\geq 1.4$  Index (S/C)) subjects. 

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

**BMJ** Open

# 137 Case definition

A seropositive case of SARS-CoV-2 was defined as seropositivity to IgG independently ofprevious self-reported results.

# 140 Patient and Public Involvement

141 No patient was involved in the study.

# 142 Statistical analysis

Crude global and by subgroups SARS-CoV-2 seroprevalence and 95% confidence intervals (CI) were calculated. Differences in the distribution of study variables between seropositive and seronegative participants were assessed using chi-squared test for categorical variables, and parametric or non-parametric tests were performed for normal and non-normal continuous variables, respectively. Prevalence ratios (PR) and 95% confidence intervals (CI) were estimated using Poisson regression models with robust variance (9). Prevalence ratios were adjusted (aPR) for statistically significant variables in the bivariate analysis and those considered relevant for the study design. Thus, adjusted models included sex, ICO centre of recruitment, age, type of HCW, teleworking and cohabitants. Linear trends for variables with ordinal categories was based in the likelihood ratio test of the model with the ordinal variable as a continuous one. P-values were based on 2-sided hypothesis tests and considered significant at p < 0.05. All analyses were conducted using Stata version 16.0 (StataCorp LP, College Station, Texas).

# 156 Ethical considerations

The present study was approved by the Hospital Universitari de Bellvitge Ethics Committee (PR205/20). The study follows the Helsinki Declaration and subsequent amendments, and Spanish data confidentiality laws (General data protection regulation Organic Law 3/2018, EU General data protection Regulation 2016/679 and Law 14/2007 for biomedical research). All participants signed an informed consent form after receiving information of the study and prior to obtaining biological samples. The biological material obtained was kept at ICO and processed under the appropriate measures to preserve the confidentiality of the results and data.

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

# **RESULTS**

A total of 1,235 HCW with serological results (Figure 1) were included in the analysis: 76.0%
were female, the median age was 43.7 years (p25-p75: 34.8-51.0 years), 52.2% were nursing
or medical staff, and 18.6% of the participants teleworked full-time during the study period
(Table 1). Up to 14.7% of the participants reported at least one comorbidity. Regarding
smoking habits, 16.0% were current smokers, and 28.2% reported to be former smokers (Table
1). Seven women were pregnant, and none of them showed seropositivity.

The overall crude SARS-CoV-2 seroprevalence was 8.9% (95%CI: 7.44-10.63), with no statistically significant differences by neither age group nor sex, and the seroprevalence for nursing and medical staff was 11.6% (95%CI: 9.37-14.34). After fully adjustment, the main determinants of higher seroprevalence included working at ICO Girona compared to workers at ICO L'Hospitalet (aPR: 1.52, 95%CI: 0.97-2.38), and nursing or medical staff compared to other groups (aPR: 2.04, 95%CI: 1.33-3.14) (**Table 1**).

8. For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

reliez onz

Page 11 of 33

**3** 13

# BMJ Open

of 33		BMJ Open		mjope by co	
able 1. Sociodemographic characteristic	cs associated with SARS-CoV-2 p	ositive serology among study	y participants ( <i>N=</i> 1,235).	bmjopen-2021-0566 d by copyright, inclu	
	Total participants	SARS-CoV-2 seroprevalence	Prevalence (95%CI)	omjopen-2021-05663 on 21 April 2022. Downloaded from http://bmjope Enseignement Superieur (ABES) . 0.02	aPR (95% CI)
	n (%)	n (%)		on 2 ng fo	
Study participants	1,235	110	8.91 (7.44-10.63)		
Sex				ses	
Male	291 (23.6)	27 (24.5)	9.28 (6.44-13.20)	eig relig	REF
Female	939 (76.0)	83 (75.5)	8.84 (7.18-10.83)	atec <u>0.82</u>	0.82 (0.53-1.28
Age [median, (p25-p75)]	43.7 (34.8-51.0)	42.8 (32.0-50.1)			0.99 (0.97-1.0
<35 years	313 (25.3)	33 (30.0)	10.54 (7.59-14.46)	vnlc t Su tex	REF
35-49 years	566 (45.8)	47 (42.7)	8.30 (6.29-10.88)	bade t ar	0.85 (0.55-1.34
>49 years	356 (28.8)	30 (27.3)	8.43 (5.95-11.80)	nd $0.5$	0.88 (0.53-1.46
ICO Center				rom r (A lata	
ICO L'Hospitalet	885 (71.7)	73 (66.4)	8.25 (6.61-10.25)		REF
ICO Girona	204 (16.5)	29 (26.4)	14.22 (10.06-19.72)	ning	1.52 (0.97-2.38
ICO Badalona	134 (10.9)	7 (6.4)	5.22 (2.51-10.56)	g, A	0.54 (0.25-1.19
ICO Tarragona / Terres de l'Ebre	12 (1.0)	1 (0.9)	8.33 (1.16-41.38)	<b>D D</b>	1.07 (0.15-7.83
Professional category				.bmj.com/ on ing, and simil	
Nursing staff <sup>1</sup>	380 (30.8)	43 (39.0)	11.32 (8.50-14.92)	ind Con	REF
Medical Staff <sup>2</sup>	265 (21.5)	32 (29.1)	12.08 (8.67-16.58)	sim V OI	1.07 (0.65-1.70
Middle and superior technicians	285 (23.1)	14 (12.7)	4.91 (2.93-8.13)	n June 13, ilar techn	0.41 (0.22-0.7
Service staff <sup>3</sup>	114 (9.2)	2 (1.8)	7.02 (3.55-13.42)	e 13 chn	0.69 (0.31-1.54
Porter	21 (1.7)	8 (7.3)	9.52 (2.39-31.16)	, 2025 Iologie	0.74 (0.17-3.24
Administrative	129 (10.4)	8 (7.3)	6.20 (3.13-11.92)	125 a	0.54 (0.25-1.16
Other	20 (1.6)	1 (0.9)	5.00 (0.70-28.26)	~ U U3	0.50 (0.07-3.7
Nursing or medical staff <sup>4</sup>	645 (52.2)	75 (68.2)	11.63 (9.37-14.34)	Agence 0.001	2.04 (1.33-3.14
Other staff <sup>5</sup>	569 (46.1)	33 (30.0)	5.80 (4.15-8.05)	Bibliographique 0.56	REF
Felework				ogra	
Never/Occasionally	981 (79.4)	86 (78.1)	8.77 (7.15-10.71)	phie	REF
Always	230 (18.6)	23 (20.9)	10.00 (6.72-14.63)	Ju 0.56	1.60 (0.98-2.59

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

		BMJ Open		bmjopen-2021. 1 by copyright	
able 1 (continued)				<u> </u>	
	Total participants	SARS-CoV-2 seroprevalence	Prevalence (95%CI)	-056637 on 21 April Ens	aPR (95% CI) <sup>8</sup>
hift work		•		37 on ding t	
Morning	545 (44.1)	49 (45.0)	8.99 (6.86-11.7)	n 21 J for	REF
Evening	140 (11.3)	10 (9.1)	7.14 (3.88-12.77)		0.56 (0.34-0.93)
Split shift (morning-evening)	417 (33.8)	38 (34.5)	9.11 (6.7-12.28)	April Ense	0.88 (0.57-1.37)
Night	88 (7.1)	10 (9.1)	11.36 (6.22-19.86)	2022. 0.83	0.95 (0.46-1.96)
Other	25 (2)	3 (2.7)	12 (3.92-31.32)	0.83 eigneme	1.15 (0.35-3.75)
Comorbidities <sup>6</sup>				Downloaded botto text and o	
None	1,054 (85.3)	99 (90.0)	9.39 (7.77-11.31)	t Su	REF
Yes	181 (14.7)	11 (10.0)	6.08 (3.4-10.64)	tan per 0.15	0.67 (0.36-1.25)
moking history		<b>`</b> ,		ieu ieu d d	· · · · · ·
Never	650 (52.6)	80 (72.7)	12.31 (9.99-15.07)	from ur (At data	REF
Past	348 (28.2)	22 (20.0)	6.32 (4.20-9.42)		0.57 (0.35-0.93)
Current	198 (16.0)		4.04 (2.03-7.87)	ning . 0.0002	
Cohabitants				у, А	,
Yes	1,119 (90.6)	95 (86.0)	8.49 (6.99-10.27)	jop I tra	REF
No	104 (8.4)	15 (13.6)	14.42 (8.88-22.57)	0.04	1.48 (0.83-2.66)
Current         Cohabitants         Yes         No         mbers do not always sum up the total due         adjusted Prevalence Ratio, CI: Confide         trising staff: nurses and nursing assistants         edical staff: resident physicians and spec         rvice staff: security, maintenance, cleani         urses, nursing assistants, resident physici         iddle and superior technicians, security, to         pmorbidities: hypertension, obesity (BMI)         orders.         ti-squared test for categorical variables (figured for sex, age (continuous), ICO ce	e to some missing values (none ence Interval, p25: 25% percent s. tialists. ing and kitchen. ians and specialists.	e of the categories present mo tile, p75: 75% percentile.	re than 5% of missing values).	tp://bmjopen.bmj.com/ on June 1: S) . Al training, and similar tech	
urses, nursing assistants, resident physici iddle and superior technicians, security, pomorbidities: hypertension, obesity (BMI orders. hi-squared test for categorical variables (fi ljusted for sex, age (continuous), ICO ce	maintenance, cleaning, kitchen $I \ge 30$ ), heart disease, liver disea Fisher's exact test corrected for	, porter, administrative, and o se, diabetes, chronic respirate continuity) and median test	other. ory disease, renal disease, cance for continuous variables.	nologies.	orders and other

Seroprevalence among on-site workers was 8.8% (95%CI: 7.15-10.71) (Table 2). Onsite workers were younger, mostly health care workers, and reported more frequently rRT-PCR previous to serology than teleworkers, but no differences were observed in sex, self-reported comorbidities, smoking history, cohabiting with COVID-19 positive case between them and teleworkers (Supplemental Material). Among this group (N=981) of professionals who never or occasionally teleworked SARS-CoV-2 seropositivity was not associated with not working in a COVID-19 area (aPR: 1.29, 95%CI: 0.81-2.06), nor being in contact with COVID-19 biological samples (aPR: 1.30, 95%CI: 0.77-2.20) nor being in contact with patients with COVID-19 (aPR: 1.09, 95%CI: 0.66-1.79) were associated with SARS-CoV-2 positivity (Table 2). On-site nursing or medical staff who worked in a COVID area had twofold SARS-CoV-2 seroprevalence than others who did not work in COVID area (aPR: 2.45, 95%CI: 1.08-5.52). Seropositivity was higher among those whom referred being exposed by interacting with colleagues (aPR: 3.26, 95%CI: 1.49-7.15). On-site workers who self-reported symptoms of COVID-19 were almost 10-fold more likely to be seropositive than those who did not (aPR: 9.5, 95%CI: 5.34-17.03). Most of the on-site workers were highly adherent to the recommendation of hand hygiene at work. Hand washing before eating or working, were followed by more than 97% of on-site workers, whereas around 24% of them reported not hand hygiene after working or a low frequency of handwashing during the workday. In relation to protective measures at work, 17.4% of the on-site workers did not feel protected with PPE, and 12.1% did not use PPE with confirmed or suspicious COVID-19 cases. About colleagues' behaviour, 2m safety distance from colleagues when having lunch was reported to be unfollowed by 14.1% (Table 2). 

45 46

	Total participants	SARS-CoV-2 seroprevalence	nclu	bmiopen-2021-056637- -value <sup>2</sup>	Adjusted PR
	n (%)	n (%)	-	6n 2	(95% CI) <sup>3</sup>
On-site workers	981 (79.4)	86 (78.1)		<b></b>	
Type of transport to work			es	pril	
Private	751 (76.6)	66 (76.7)	8.79 (6.96-11.04) eg	2022.	REF
Public	154 (15.7)	15 (17.4)	9.74 (5.95-15.54) <b>atem</b>	2	1.32 (0.74-2.36)
Private and Public	35 (3.6)	2 (2.3)	5.71 (1.43-20.19) <b>6</b>	Dov	0.63 (0.15-2.58)
Walking	37 (3.8)	3 (3.5)	8.11 (2.63-22.34) <b>5</b>	Downloaded from 0.14	0.57 (0.14-2.35)
Working in a COVID-19 area		·	8.11 (2.03-22.34) Xt an	iade	,
No	398 (40.6)	29 (33.7)	7.29 (5.11-10.29) de e	¢d f	REF
Yes	545 (55.6)	55 (63.9)	10.09 (7.83-12.92) a 🛱 🏹	<b>0</b> .14	1.29 (0.81-2.06)
Type of and COVID area <sup>1</sup>			a B	2	
Non-assisting HCW & never worked in a COVID-19 area	148 (15.1)	7 (8.0)	4.73 (2.27-9.6)	o.	REF
Non-assisting HCW & ever worked in a COVID-19 area	230 (23.4)	13 (15.1)	5.65 (3.31-9.5)	bm m	1.12 (0.44-2.82)
Assisting HCW & never worked in a COVID-19 area	244 (24.9)	22 (25.6)	5.65 (3.31-9.5) A fraining 9.02 (6.01-13.32) 12.86 (9.57-17.07)		1.81 (0.77-4.26)
Assisting HCW & ever worked in a COVID-19 area	311 (31.7)	40 (46.5)	12.86 (9.57-17.07)	0.006	2.45 (1.08-5.52)
p-trend			, íg,	<u>n</u>	0.26
Contact with COVID-19 cases			6.91 (4.63-10.18) 10.63 (8.29-13.54)	//bmiopen.bmi.com/ on June	
No	333 (33.9)	23 (26.7)	6.91 (4.63-10.18)	2	REF
Yes	536 (54.6)	57 (66.3)	10.63 (8.29-13.54) a	ة 0.07 ي	1.30 (0.77-2.20)
Contact with COVID-19 biological samples			r te	une	
No	646 (65.9)	51 (59.3)	7.89 (6.05-10.24)	 ພ	REF
Yes	282 (28.7)	30 (34.9)	10.64 (7.54-14.81) 🔒	-	1.09 (0.66-1.79)
Reporting to be exposed to COVID-19 by interacting with colleagues at work			7.89 (6.05-10.24) 10.64 (7.54-14.81)	0.17 2025 at A	
No	242 (24.7)	66 (76.7)	2.89 (1.38-5.95)	t Agence<0.0001	REF
Yes	608 (62.0)	7 (8.1)	10.86 (8.62-13.59)	<u> </u>	3.26 (1.49-7.15
Reporting COVID-19 compatible symptoms				Bib	
No	623 (63.5)	15 (17.4)	2.41 (1.46-3.96)	Bibliograf <i>&lt; 0.0001</i>	REF
Yes	306 (31.2)	68 (79.1)	22.22 (17.91-27.23)	a<0.0001	9.53 (5.34-17.03

Page 15 of 33

	Total participants	SARS-CoV-2 seroprevalence	Prevalence (95%Cla	66 37 <i>p-value</i> <sup>2</sup>	Adjusted PR (95% CI) <sup>3</sup>
Not following protection measures at work			g fo	n 2	
Felt protected with PPE	132 (17.4)	12 (16.9)	9.09 (5.23-15.34) or	$\frac{1}{P}$ 0.83	0.98 (0.51-1.88
Colleagues cover themselves with their elbows when sneezing/coughing	155 (15.8)	21 (24.4)	13.55 (9.00-19.90) Tree:	pril 0.01 20	1.70 (1.01-2.87
2m safety distance from colleagues during lunch	127 (14.1)	12 (15.6)	9.45 (5.44-15.91) ar	0.71	1.06 (0.56-1.99
Use of PPE with confirmed or suspicious COVID-19 patients	79 (12.1)	7 (10.45)	8.86 (4.28-17.46) <b>b</b> ment	<b>Dov</b> 0.63	1.01 (0.45-2.26
PPE removal safety	48 (7.3)	3 (4.6)	6.25 (2.03-17.68) 🔄 🖉	<b>no</b> 0.33	0.54 (0.17-1.74
Personal use of mask	34 (3.5)	1 (1.2)	2.94 (0.41-18.17) a e	ade 0.21	0.41 (0.06-2.99
Colleagues use of surgical mask	7 (0.7)	1 (1.2)	14.29 (1.96-58.12) a l	<b>d</b> 0.62	1.68 (0.23-12.2
lot following hand hygiene at work			ata A	om	
≤7 times during workday	233 (23.8)	15 (17.4)	6.44 (3.92-10.41)	0.13	0.71 (0.39-1.28
After money, phone and other personal tools manipulation	175 (17.8)	16 (18.6)	9.14 (5.67-14.41) <b></b>	0.89	1.00 (0.58-1.74
Every time entering in a new workspace	102 (10.4)	5 (5.8)	4.90 (2.05-11.25)	0.14 0.37	0.55 (0.22-1.37
Before working	21 (2.1)	3 (3.5)	14.29 (4.67-36.17)	<b>0.37</b>	1.72 (0.54-5.47
After finishing the workday	17 (1.7)	1 (1.2)	5.88 (0.82-32.09) <b>j</b>	0.67	0.65 (0.09-4.72
Before eating	9 (0.9)	2 (2.3)	22.22 (5.59- 57.95) <b>g</b>	<u>o</u> 0.16	2.67 (0.65-10.9

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

m/ on June 13, 2025 at Agence Bibliographique de l

d by copyrig bmjopen-20;

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

Concerning the correlates of seropositivity according to household factors for all participants (Table 3), seropositivity was associated with living with a COVID-19 positive person (aPR: 3.86, 95%CI: 2.49-5.98). Up to 17.3% of the participants did not take a shower nor change clothes upon home arrival, but the majority (99.0%) did hand hygiene. The least followed hand hygiene home practices were after money, phone and other personal tools manipulation, and after nose blowing, coughing or sneezing (23.5% and 22.7%). However, not following protection measures or hand hygiene at home were associated with a higher SARS-CoV-2 seroprevalence.

Clinical characteristics were collected for those participants (*N*=469) who reported a rRT-PCR performed previous to serology (Supplemental material). The majority of the patients with a positive serology and reporting a positive rRT-PCR presented compatible COVID-19 symptoms (74.4%). Among seropositive patients, the most common symptoms were arthromyalgia, cough, headache, asthenia and anosmia. Reporting a positive rRT-PCR when presenting compatible symptoms was associated with a threefold higher prevalence of seropositivity (aPR: 3.10, 95%CI: 1.78-5.31). An increased number of compatible symptoms was also associated with a higher seroprevalence (aPR: 7.4, 95%CI: 1.78-5.31, for presenting four or more symptoms compared to no symptoms).

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

	RS-CoV-2 positive serology	among study participan	ts (n=1,235).	-056637 or , including	
	<b>Total participants</b> <i>n</i> (%)	SARS-CoV-2 seroprevalence n (%)	Prevalence (95%CI)	g fogulue p-gulue p-gulue	Adjusted PR (95% CI
tudy participants	1,235	110	8.91 (7.44-10.63)	i S S	
Cohabitants with COVID-19 <sup>1</sup>				2022. eigne relate	
No	894 (79.9)	52 (54.7)	5.82 (4.46-7.56)	eme led	REF
Yes	141 (12.60)	34 (35.8)	24.11 (17.76-31.86)	< <b>ହ୍</b> ରିକ୍ଟିଞ୍ଚି	3.86 (2.49-5.97)
Cohabitants cover themselves with their lbow when sneezing				nloade Super ext an	
No	158 (14.1)	18 (18.9)	11.39 (7.29-17.37)	ieu d d	REF
Yes	919 (82.1)	73 (76.8)	7.94 (6.36-9.88)		0.73 (0.43-1.22)
ot following protection measures at ome <sup>4</sup>				ı <mark>http:</mark> BES) minir	
Use of face mask when shopping	17 (1.4)	2 (1.8)	11.76 (2.95-36.86)	<b>4</b> .67	0.98 (0.24-4.05)
Shower and clothes changing afterwork or upon home arrival	214 (17.3)	20 (18.2)	9.35 (6.11-14.05)	Attraining; and stimil	1.02 (0.62-1.69)
ot following hand hygiene at home <sup>4</sup>				inin <mark>b</mark>	
Upon arrival	12 (1)	2 (1.8)	16.67 (4.19-47.76)	∯.35 <u>∃</u>	1.59 (0.39-6.60)
Before eating	60 (4.9)	9 (8.2)	15.00 (7.99-26.4)	8.09 <mark>8</mark>	1.55 (0.77-3.12)
After money, phone and other personal tools manipulation	290 (23.5)	27 (24.6)	9.31 (6.46-13.24)	stinila 53 <b>U</b>	1.01 (0.65-1.58)
After cleaning	110 (8.9)	8 (7.3)	7.27 (3.68-13.88)	8.53E	0.78 (0.38-1.61)
After nose blowing	280 (22.7)	25 (22.7)	8.93 (6.1-12.88)	1990 ne	0.93 (0.58-1.48)

#### DISCUSSION

Despite the impact of COVID-19 in oncological patients (10), there are scarce SARS-CoV-2 seroprevalence studies in comprehensive cancer centres with large sample sizes. The global SARS-CoV-2 seroprevalence was 8.9% during the first wave of the COVID-19 pandemic, lower than expected, owing to the presumed higher risk among HCW. Also, it was lower than the reported estimates in two studies performed among HCW in Catalonia between March-April and May 2020, showing a seroprevalence of 11.2% (11) and 10.3% (12), respectively. In all cases, the seroprevalence was higher than in the general population, estimated to be of a maximum of 7.4% in the Barcelona metropolitan area when the study was conducted (13). Seroprevalence studies interpretation must be related to the average COVID-19 prevalence at the time of blood collection. Both of the mentioned studies were carried out earlier than ours, which was performed approximately one month later (21<sup>st</sup> May-26<sup>th</sup> June 2020), and two months after the first-wave peak in Catalonia (23<sup>th</sup> March) (14). Another explanation for this lower seroprevalence in our Centre concerns the participation: all active HCW, regardless of their teleworking status during the previous months or work absenteeism, were invited to participate, and most did (64%). In contrast, García-Basteiro's (11) and Barallat's (12) studies comprised general hospitals (10,11) and primary health care centers (12) in which the incidence could be higher than in a monographic cancer centre. 

Several studies regarding COVID-19 infections in HCW in Spain have been published, although showing diverse results. In a tertiary-care hospital in Mallorca, with low regional seroprevalence in the general population (<2%), the prevalence of infected HCW (n=2,210) was 2.8%(15). Varona et al. performed a cross-sectional study evaluating 6.038 employees from the healthcare system of 17 hospitals across four regions in Spain (Madrid, Catalonia, Galicia and Castilla-Leon), showing an 11% seropositivity for SARS-CoV-2 IgG (16). Finally, other studies in Madrid, reported a seroprevalence between 16.6% and 36.5% among HCW in areas with high COVID-19 prevalence (17-19). These studies revealed seroprevalence of SARS-CoV-2 IgG antibodies in HCW tend to be higher than in the general population, at variance according to regional COVID-19 incidence. 

The prevalence of SARS-CoV-2 antibodies among HCW has been increasingly investigated in many other countries showing a broad range of outcomes. So far, two systematic reviews estimated an overall seroprevalence of SARS-CoV-2 antibodies of 8.7% and 8.0% among 127,480 HCW and 168,200 HCW, respectively, before vaccination started (2,20). 

Seroprevalence was higher in studies conducted in North America (12.7%) compared with those conducted in Europe (8.5%), Africa (8.2) and Asia (4%) (2).

In Europe, seroprevalence rates among HCW in Germany, Denmark and Belgium were low (1.6%, 4.0% and 6.4%, respectively) (21-23). These studies were conducted during early stages of the epidemic, and therefore, they derived that infection was community-acquired. Also, the Belgian study, with a sample size of almost 30,000 HCW, notes that the high availability of PPE, high standards of infection prevention, and PCR screening in symptomatic staff, coupled with contact tracing and quarantine, might explain the relatively low seroprevalence (23). An study performed in Lombardy, Italy (24), one of the Italian regions most hit by the first epidemic wave, showed a seroprevalence of 7.4% (3.8-11.0%), similar to the observed in the Catalan studies (11,12). Sweden and the UK were the two European countries reporting the highest seropositivity rates among HCW: 19.1% and between 18.0% and 45.3%, respectively (25–27). In the UK, this high seroprevalence was settled in London during the week with the highest number of new cases in the city in the first wave, with around 15% seropositivity among the general population. In the USA, the prevalence of infection among HCW was 10.7%, despite high variation, as low as 1.1% in California (28) to 13.7% in New York State (29). 

Despite SARS-CoV-2 seropositivity rate in oncological HCW has significant implications for oncological patients, scant research has been done. The only study published with a large sample size was in Tokyo, Japan, and it showed a very low seroprevalence of 0.67% among 1,190 HCW. It was performed at the end of the first wave in Japan, between the 3<sup>rd</sup> of August and the 30<sup>th</sup> of October 2020, so this may explain the lower seroprevalence compared with our estimation. A French study performed among 663 HCW and 1,011 cancer patients, after the end of the first wave, showed also low seroprevalence both for HCW and patients (1.8% and 1.7%, respectively) (30). Other studies that have been published were based on small sample sizes and showed very variable seroprevalence rates (22,31–35). 

In our study, we found no differences in HCW seroprevalence according to sex, age and presence of comorbidities. Current or past smoking was however inversely associated to SARS-CoV-2 seroprevalence. Early studies in selected cohorts of COVID-19 patients showed a paradoxical higher risk of SARS-CoV-2 infection among non-smokers (36) whilst ever smokers showed higher risk of COVID-19 progression, including severity of the disease, Intensive Care Unit admission and death (27,28,37). 

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

It is worth mentioning that, unlike most of the other published seroepidemiological studies among HCW, the present study was performed among all the HCW of the institution, regardless they did full-time telework during the study period (21.6%). No differences by telework were found, and among all study participants the main factor associated with SARS-CoV-2 seropositivity was living with a COVID-19 case, with a times higher probability, similarly to what has been described in other studies (2,20). This finding supports the importance of community dissemination of the infection also for HCWs. 

Our study shows that among on-site HCW in an oncological centre, working as medical care staff (nursing, nursing assistant, resident physicians and specialists) in COVID-19 areas stood out as one of the main factors associated with developing SARS-CoV-2 antibodies. Published results regarding the possibility of in-hospital infection among HCW and transmission at work are controversial. Some studies did not find any relation between working in COVID unit or professional category with seropositivity (11,24) whereas other studies reported that seroprevalence was strongly associated with patient related-work (16,22,25,38). 

Contact with colleagues at work is potentially a risky situation for transmission among HCW as well as the relaxation of protective measures at the end of the working day. In our study, the on-site HCW who reported being exposed to COVID-19 by other colleagues presented an almost four-fold probability of being seropositive. Most of the HCW declared to follow the protective measures at the workplace, and no differences in seroprevalence were found according to protective measures and hand hygiene. 

Protecting HWC health is of paramount importance for reducing morbidity and mortality, reducing transmission, and maintaining the health system capacity (39). Thus international health authorities recommend screening strategies for SARS-CoV-2 infection in exposed or high-risk HCW (40) as well as massive COVID-19 vaccination (41). 

Significant differences exist in SARS-CoV-2 testing between countries, and existing programmes focus on screening symptomatic rather than asymptomatic staff. Published studies point out the fact that screening should be performed regardless of the absence of typical symptoms for COVID-19 disease. It has been demonstrated that seroconversion can occur in HCW who have suffered no previous symptoms of SARS-CoV-2 infection (42,43) as asymptomatic transmission is very relevant in SARS-CoV-2 spread (44,45). Thus, the approach for mass testing of both symptomatic and asymptomatic HCW could mitigate 

382 workforce depletion by unnecessary quarantine, reduce spread in atypical, mild, or
383 asymptomatic cases; and protect patients and health-care workforce.

Among the potential limitations of the study, some recall bias is possible as the data for the correlates of SARS-CoV-2 infection rely on a self-administered questionnaire. Also, response and perception biases must be considered, as well as complacency bias. Results, especially those regarding the accomplishment of preventive measures, might be overestimated. Answers reported in the questionnaire could be influenced by the participants' knowledge regarding their COVID status. However, this study is the first seroepidemiological study with such a large sample size settled in an oncological health centre. The sufficient sample size and high response rate (64.3%) are strengths of the study, although information regarding non-participants was not collected, and we cannot disregard a potential participation bias. However, the distribution by age and sex was similar between participants and non-participants and a possible reason for no participation is that professionals from ICO-Badalona had previously participated in a HCW county seroprevalence survey (12). Also, the fact that the information of the study and the questionnaire was published online and sent by e-mail, as well as the short period of time stablished to respond to it, could have limited the participation. Questionnaire completeness was very high, with no variables presenting more than 5% of missing values.

In conclusion, SARS-CoV-2 seroprevalence among ICO HCW at the end of the first wave of the pandemic was lower than the reported in other Catalan hospitals, but higher than among the general population living in the area. Whereas the main risk factor was living with infected people, among on-site workers, contact with colleagues was associated with SARS-CoV-2 infection. Knowing the seroprevalence rate and follow-up evaluation of persistence may help hospitals to characterize the staff at risk, rationalize their placement, prioritize the use of PPE, thereby potentially reducing the risk of infection. Follow-up studies to evaluate long term durability of antibodies among HCW will be of interest, after the introduction of COVID-19 vaccination among HCW, to better promote infection control in this group. Strengthening preventive measures and health education among HCW is fundamental, especially in oncological departments and centres.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies

Contributors EF, DCP, AP, CC, AC and AS contributed to study design. SC, AD, LG, IB, JT, MG, FS, JJT, DC, AS, BC, DR, CG and AP accrued participants and care for blood collection at ICO centres. Laboratory analyses were coordinated by MADL. The questionnaire was designed by DCP and EF, and revised by PPT, ASL, YB, DC, AP, and LA. Questionnaire's implementation was done by EL, JM, JPR, CMM. Data were analysed by YB and DC. PPT, ASL, YB, DC, LA, and EF interpreted the initial results and designed the tables. All authors contributed to interpretation of results. The first draft of the manuscript was prepared by PPT and ASL. PPT, ASL, YB, DC, LA, DC and EF were the main contributors to the writing of the manuscript. All authors assisted in manuscript review. The co-senior authors had full access to all the data in the study for interpretation and had final responsibility for manuscript generation and review, and the decision to submit for publication. EF is the guarantor. 

Funding This work was supported by the Catalan Institute of Oncology. PPT is partially supported by the Instituto de Salud Carlos III (ISCIII), Government of the Kingdom of Spain, co-funded by FEDER funds/European Regional Development Fund (ERDF) - a way to build Europe (CM19/00216). The Ministry of Universities and Research, Government of Catalonia partly supports EF and DCP (2017SGR319) and PPT, AS, YBM, DC and LA (2017SGR1085). We thank CERCA Programme / Generalitat de Catalunya for institutional support. 

Competing interests JJ received research funding from Kyowa Kirin and from Angelini Pharma for congress attendance. The Cancer Epidemiology Research Programme has received grants from Merck & Co., Roche, GSK, IDT, Hologic, and Seegene. 

Acknowledgments The authors acknowledge all the health care workers who participated in the study as well as all the ICO staff involved in the logistics of the different aspects of the study. 

Data availability statement No additional data available 

1		
2 3	42.4	
4	434	REFERENCES
5	435	1. Ng K, Poon BH, Kiat Puar TH, Shan Quah JL, Loh WJ, Wong YJ, et al. COVID-19
6 7	436	and the Risk to Health Care Workers: A Case Report. Annals of internal medicine.
8	437	2020 Jun 2;172(11):766–7.
9	438	2. Galanis P, Vraka I, Fragkou D, Bilali A, Kaitelidou D. Seroprevalence of SARS-CoV-2
10	439	antibodies and associated factors in healthcare workers: a systematic review and meta-
11	440	analysis. J Hosp Infect. 2021 Feb;108:120–34.
12	441	3. Informe nº 56. Situación de COVID-19 en España. Casos diagnosticados a partir de 10 de
13	442	mayo. Instituto de Salud Carlos III; Red Nacional de Vigilancia Epidemiológica.
14 15	443	España; 2020. Available:
16	444	https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/Enferm
17	445	edadesTransmisibles/Documents/INFORMES/Informes%20COVID-
18	446	19/Informe%20COVID-
19	447	19.%20N%c2%ba%2056_09%20de%20diciembre%20de%202020.pdf
20	448	
21 22	449	4. Centro de Coordinación de Alertas y, Emergencias Sanitarias. Actualización no 517.
22	450	Enfermedad por el coronavirus (COVID-19). 03.12.2021 [Internet]. [cited 2022 Feb 1].
24	451	Available from:
25	452	https://www.sanidad.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/docu
26	453	mentos/Actualizacion_517_COVID-19.pdf
27	454	5. Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more
28 29	455	vulnerable to SARS-CoV-2: A multicenter study during the COVID-19 outbreak.
30	456	Cancer Discovery. 2020 Jun 1;10(6):783.
31	457	6. Leung MST, Lin SG, Chow J, Harky A. COVID-19 and Oncology: Service
32	458	transformation during pandemic. Cancer Medicine. 2020 Oct 18;9(19):7161–71.
33	459	7. Institut Català d'Oncologia [Internet]. [cited 2021 Mar 19]. Available from:
34	460	http://ico.gencat.cat/ca/l_institut/
35 36	461	8. Videla S, Otero A, Martí S, Domínguez MÁ, Fabrellas N, Delgado-Hito MP, et al.
30 37	462	Prevalence of SARS-CoV-2 Infection at the University of Barcelona during the Third
38	463	COVID-19 Pandemic Wave in Spain. Int J Environ Res Public Health. 2021
39	464	Jan;18(12):6526.
40	465	9. Barros AJD, Hirakata VN. Alternatives for logistic regression in cross-sectional
41	466	studies: An empirical comparison of models that directly estimate the prevalence ratio.
42	467	BMC Medical Res Methodol. 2003 Oct 20;3:1–13.
43 44	468	10. Richards M, Anderson M, Carter P, Ebert BL, Mossialos E. The impact of the COVID-
44	469	19 pandemic on cancer care. Nature Cancer. 2020 Jun;1(6):565–7.
46	470	11. Garcia-Basteiro AL, Moncunill G, Tortajada M, Vidal M, Guinovart C, Jiménez A, et
47	471	al. Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a
48	472	large Spanish reference hospital. Nature Comm. 2020 Dec 1;11(1):1–9.
49	473	12. Barallat J, Fernández-Rivas G, -Sánchez B Q, Martinez-Caceres. Seroprevalence of
50 51	474	SARS-CoV-2 IgG Specific Antibodies among Healthcare Workers in the Northern
51 52	475	Metropolitan Area of Barcelona, Spain, after the first pandemic wave. PLoS One. 2020
53	476	Dec $28;15(12):e0244348$ .
54	477	13. Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda M, et
55	478	al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-
56	479	based seroepidemiological study. The Lancet. 2020 Aug 22;396(10250):535–44.
57 58	480	14. COVID-19 data and indicators. Sistemes d'Informació dels Serveis d'Atenció Primària- SISAP, Institut Català de la Selut, Departement de Selut, Coneralitat de Catalunya
58 59	481 482	SISAP, Institut Català de la Salut, Departament de Salut, Generalitat de Catalunya.
60	482	[Internet]. 2020 [cited 2021 Mar 19]. Available from: http://eines.portalics/covid/

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.


1			
2			
3	483	15.	Rodriguez A, Arrizabalaga-Asenjo M, Fernandez-Baca V, Lainez MP, Al Nakeeb Z,
4 5	484		Garcia JD, et al. Seroprevalence of SARS-CoV-2 antibody among healthcare workers
6	485		in a university hospital in Mallorca, Spain, during the first wave of the COVID-19
7	486		pandemic. Int J Infect Dis. 2021 Apr;105:482–6.
8	487	16.	Varona JF, Madurga R, Peñalver F, Abarca E, Almirall C, Cruz M, et al.
9	488		Seroprevalence of SARS-CoV-2 antibodies in over 6000 healthcare workers in Spain.
10	489		Int J Epidemiol. 2021 May 17;50(2):400–9.
11 12	490	17.	Galán MI, Velasco M, Casas ML, Goyanes MJ, Rodríguez-Caravaca G, Losa JE, et al.
12	491		SARS-CoV-2 Seroprevalence Among All Workers in a Teaching Hospital in Spain:
14	492		Unmasking The Risk [Internet]. medRxiv; 2020 [cited 2022 Feb 2]. p.
15	493		2020.05.29.20116731. Available from:
16	494		https://www.medrxiv.org/content/10.1101/2020.05.29.20116731v1
17	495	18.	Pérez-García F, Pérez-Zapata A, Arcos N, De la Mata M, Ortiz M, Simón E, et al.
18	496		Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection among hospital
19 20	497		workers in a severely affected institution in Madrid, Spain: A surveillance cross-
21	498		sectional study. Infect Control Hosp Epidemiol. 2021 Jul;42(7):803–9.
22	499	19.	Cantero M, Millán-Pérez R, Muñez E, Gómez-Lozano N, Anel-Pedroche J, Parra LM,
23	500		et al. SARS-COV-2 seroprevalence among all healthcare workers in a tertiary hospital
24	501		in Spain. Infectious Diseases. 2022 Jan 2;54(1):8–15.
25	502	20.	Kayı İ, Madran B, Keske Ş, Karanfil Ö, Arribas JR, Pshenichnaya N, et al. The
26 27	503		seroprevalence of SARS-CoV-2 antibodies among health care workers before the era of
28	504		vaccination: a systematic review and meta-analysis. Clin Microbiol Infect. 2021
29	505		Sep;27(9):1242–9.
30	506	21.	Korth J, Wilde B, Dolff S, Anastasiou OE, Krawczyk A, Jahn M, et al. SARS-CoV-2-
31	507		specific antibody detection in healthcare workers in Germany with direct contact to
32	508		COVID-19 patients. J Clin Virol. 2020 Jul 1;128:104437.
33 34	509	22.	Iversen K, Bundgaard H, Hasselbalch RB, Kristensen JH, Nielsen PB, Pries-Heje M, et
35	510		al. Risk of COVID-19 in health-care workers in Denmark: an observational cohort
36	511		study. Lancet Infect Dis. 2020;20(12):1401–8.
37	512	23.	Steensels D, Oris E, Coninx L, Nuyens D, Delforge ML, Vermeersch P, et al. Hospital-
38	513		Wide SARS-CoV-2 Antibody Screening in 3056 Staff in a Tertiary Center in Belgium.
39	514		JAMA. 2020;324(2):195–7.
40	515	24.	Sotgiu G, Barassi A, Miozzo M, Saderi L, Piana A, Orfeo N, et al. SARS-CoV-2
41 42	516		specific serological pattern in healthcare workers of an Italian COVID-19 forefront
43	517	~ -	hospital. BMC Pulmonary Med. 2020;20(1):1–6.
44	518	25.	Rudberg AS, Havervall S, Månberg A, Jernbom Falk A, Aguilera K, Ng H, et al.
45	519		SARS-CoV-2 exposure, symptoms and seroprevalence in healthcare workers in
46	520	•	Sweden. Nature Comm. 2020 Dec 1;11(1):1–8.
47	521	26.	Pallett SJC, Rayment M, Patel A, Fitzgerald-Smith SAM, Denny SJ, Charani E, et al.
48 49	522		Point-of-care serological assays for delayed SARS-CoV-2 case identification among
49 50	523		health-care workers in the UK: a prospective multicentre cohort study. Lancet Resp
51	524	07	Med. 2020;8(9):885–94.
52	525	27.	Houlihan CF, Vora N, Byrne T, Lewer D, Heaney J, Moore DA, et al. SARS-CoV-2
53	526		virus and antibodies in front-line Health Care Workers in an acute hospital in London:
54	527		Preliminary results from a longitudinal study [pre-print]. Available:
55 56	528	•••	medhttps://www.medrxiv.org/content/10.1101/2020.06.08.20120584v1
50 57	529	28.	Brant-Zawadzki M, Fridman D, Robinson PA, Zahn M, Chau C, German R, et al.
58	530		SARS-CoV-2 antibody prevalence in health care workers: Preliminary report of a
59	531		single center study. PLoS ONE. 2020 Nov 1;15.
60			

1			
2 3			
4	532	29.	Moscola J, Sembajwe G, Jarrett M, Farber B, Chang T, McGinn T, et al. Prevalence of
5	533		SARS-CoV-2 Antibodies in Health Care Personnel in the New York City Area. JAMA
6	534 535	30.	2020;324(9):893-5. Ladaira S. Caussat V. Badaradarff E. Cuaff A. Ballat E. Truntzer C. et al.
7 8	535 536	30.	Ladoire S, Goussot V, Redersdorff E, Cueff A, Ballot E, Truntzer C, et al. Seroprevalence of SARS-CoV-2 among the staff and patients of a French cancer centre
8 9	530 537		after first lockdown: The canSEROcov study. Eur J Cancer. 2021 May 1;148:359–70.
10	538	31.	Favara DM, McAdam K, Cooke A, Bordessa-Kelly A, Budriunaite I, Bossingham S, et
11	539	51.	al. SARS-CoV-2 Infection and Antibody Seroprevalence among UK Healthcare
12	540		Professionals Working with Cancer Patients during the First Wave of the COVID-19
13	541		Pandemic. Clin Oncol. 2021 Oct;33(10):667–75.
14 15	542	32.	Epstude J, Harsch IA. Seroprevalence of COVID-19 antibodies in the cleaning and
16	543	52.	oncological staff of a municipal clinic. GMS Hyg Infect Control. 2020;15:5–9.
17	544	33.	Fuereder T, Berghoff AS, Heller G, Haslacher H, Perkmann T, Strassl R, et al. SARS-
18	545	55.	CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at
19	546		a tertiary care centre during the COVID-19 pandemic. ESMO Open. 2020 Sep
20	547		2;5(5):e000889.
21 22	548	34.	Fong D, San Nicolò KO, Alber M, Mitterer M. Evaluating the longitudinal
23	549		effectiveness of preventive measures against COVID-19 and seroprevalence of IgG
24	550		antibodies to SARS-CoV-2 in cancer outpatients and healthcare workers. Wien Klin
25	551		Wochenschr. 2021 Apr;133(7–8):359–63.
26	552	35.	Marra A, Generali D, Zagami P, Cervoni V, Gandini S, Venturini S, et al.
27 28	553		Seroconversion in patients with cancer and oncology health care workers infected by
20	554		SARS-CoV-2. Ann Oncol. 2021 Jan;32(1):113–9.
30	555	36.	Simons D, Shahab L, Brown J, Perski O. The association of smoking status with
31	556		SARS-CoV-2 infection, hospitalisation and mortality from COVID-19: A living rapid
32	557		evidence review with Bayesian meta-analyses (version 11). Qeios. 2021 Mar 2;
33 34	558	37.	Patanavanich R, Glantz SA. Smoking is associated with COVID-19 progression: A
35	559		meta-analysis. Vol. 22, Nicotine and Tobacco Research. Oxford University Press; 2020.
36	560	• •	p. 1653–6.
37	561	38.	Korth J, Wilde B, Dolff S, Anastasiou OE, Krawczyk A, Jahn M, et al. SARS-CoV-2-
38	562		specific antibody detection in healthcare workers in Germany with direct contact to
39 40	563	20	COVID-19 patients. J Clin Virol. 2020;128:104437.
40 41	564	39.	The Lancet. COVID-19: protecting health-care workers. COVID-19 Prioritization of
42	565 566	41	Diagnostic Testing. Lancet. 2020;395: 922.
43	567	41.	The Importance of COVID-19 Vaccination for Healthcare Personnel. CDC [Internet]. [cited 2021 Mar 19]. Available from: https://www.cdc.gov/coronavirus/2019-
44	568		ncov/vaccines/recommendations/hcp.html
45	569	42.	Black JRM, Bailey C, Przewrocka J, Dijkstra KK, Swanton C. COVID-19: the case for
46 47	570	72.	health-care worker screening to prevent hospital transmission. Lancet.
48	570		2020;395(10234):1418–20.
49	572	43.	Rivett L, Sridhar S, Sparkes D, Routledge M, Jones NK, Forrest S, et al. Screening of
50	573	10.	healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in
51	574		COVID-19 transmission. eLife. 2020;9:1–20.
52 53	575	44.	Shields AM, Faustini SE, Perez-Toledo M, Jossi S, Aldera E, Allen JD, et al. SARS-
54	576		CoV-2 seroprevalence and asymptomatic viral carriage in healthcare workers: a cross-
55	577		sectional study. Thorax. 2020 Dec;75(12):1089-1094.
56	578	45.	Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L, et al. Presumed Asymptomatic Carrier
57	579		Transmission of COVID-19. JAMA. 2020;323:1406–7.
58 59	580		
60			

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

# Figure 1

Participants' flowchart in the seroprevalence survey, Catalan Institute of Oncology. 21<sup>st</sup> May-26<sup>th</sup> June 2020; Spain.



# SUPPLEMENTARY MATERIAL

Accompanying the manuscript:

# **COVID-19 among workers of a Comprehensive Cancer Center between** <page-header>The interpretation of the interpretation first and second epidemic waves (2020): a seroprevalence study in Catalonia, Spain.

**Contents:** 

- •
- •
- •

# Epidemiologic and behaviour questionnaire - ICO-Sero-COVID Study

I give my consent to participate in the study of seroprevalence of SARS-Cov-2 infection among ICO workers and related companies, which includes responding to an epidemiological survey with information on working conditions and obtaining a nasopharyngeal smear (to perform PCR test for virus detection) and/or to obtain blood sample by venipuncture (to perform serological tests for antibody determination and plasma cryopreservation at ICO biobank)

1 =Yes; 2 =No.

Thank you for participating in the COVID-19 seroprevalence survey among ICO workers. All information provided below will be treated confidentially, and all resulting results will be anonymized, with no individual data identifying participants.

# A. Socio-demographic data.

ank you for participating in the COVID-19 seroprevalence survey among ICO workers. All informations poided below will be treated confidentially, and all resulting results will be anonymized, with no individual ta identifying participants.

# B. Exposure and occupational safety measures data.

- 14. Since the beginning of Waren 2020, have you had a suspected of contributed control as COVID-19? numeric variable (1 = Yes; 2 = No).
  15. Since the beginning of March 2020, have you had a nasopharyngeal smears sample? numeric variable (1 = Yes; 2 = No).
  16. Do you belong to any of the groups considered to have an increased vulnerability to COVID -19?
  a. Cardiopathy / Hypertension numeric variable (1 = Yes; 2 = No).
  b. Respiratory disease numeric variable (1 = Yes; 2 = No).
- - c. **Hepatopathy** numeric variable (1 = Yes; 2 = No).
  - d. Nephropathy numeric variable (1 = Yes; 2 = No).
  - e. Active Cancer numeric variable (1 = Yes; 2 = No).
  - f. **Immunosuppression** numeric variable (1 = Yes; 2 = No).
  - **Diabetes mellitus** numeric variable (1 = Yes; 2 = No). g.
  - h. **Pregnancy** numeric variable (1 = Yes; 2 = No).
- **17.** Have you had contact with patients with COVID-19 infection at ICO? numeric variable (1 = Yes; 2 = No).
- **18. Have you had contact with samples of COVID-19 patients at ICO?** numeric variable (1 = Yes; 2 =No).For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

- 19. When you are in your workplace, do you wear a surgical mask? numeric variable (1 = Yes; 2 =No).
  - 20. If you are in the COVID-19area, do you wear Personal Protective Equipment (PPE)? numeric variable (1 = Yes; 2 = No, 3 = Not Applicable).
  - 21. Do you think that the Personal Protective Equipment (PPE) removal procedure is safe? numeric variable (1 = Yes; 2 = No, 3 = I don't know, 4 = Not Applicable).
  - 22. Do you feel protected by the Personal Protective Equipment (PPE) used? numeric variable (1 =Yes; 2 = No, 3 = I don't know, 4 = Not Applicable).
  - 23. Do you think that you may have been exposed to COVID-19 during personal relationships with your co-workers? numeric variable (1 = Yes; 2 = No, 3 = I don't know).
  - 24. Do you think that the protection procedures implemented during this pandemic period will benefit you in your future professional development? numeric variable (1 = Yes; 2 = No, 3 = I don °ťĈ ed know).
  - 25. Do you think that the work activity carried out during this pandemic period has affected you or

25. Do you think that the work activity carried out during this pandemic period has affected you or will affect you emotionally in the future? numeric variable (1 = Yes; 2 = No, 3 = 1 don't know).
At work, do you wash your hands with soap or water or with a hydro-alcoholic solution...
26. ... before you start working? numeric variable (1 = Yes; 2 = No).
27. ... every time you enter a new workspace? numeric variable (1 = Yes; 2 = No).
28. ... before eating? numeric variable (1 = Yes; 2 = No).
29. ... after handling money, mobile phone, other utensils ...? numeric variable (1 = Yes; 2 = No).
30. ... less than 7 times during the working day? numeric variable (1 = Yes; 2 = No).
31. ... at the end of the working day? numeric variable (1 = Yes; 2 = No).
32. When you eat, do you maintain a distance ≥ 2m from your colleagues? numeric variable (1 = Yes; 2 = No).
33. Did your collegues cover thir face with their elbows when they sneeze / cough? numeric variable (1 = Yes; 2 = No).
34. ... when you get home? numeric variable (1 = Yes; 2 = No).
35. ... before eating? numeric variable (1 = Yes; 2 = No).
36. ... after handling money, mobile phone, other utensils numeric variable (1 = Yes; 2 = No).
37. ... after cleaning? numeric variable (1 = Yes; 2 = No).
38. ... after blowing your nose, sneezing or coughing? numeric variable (1 = Yes; 2 = No).
39. Do you shower and change clothes when you get home (or did you go to work)?: numeric variable (1 = Yes; 2 = No).
40. Do you wear a mask when you go shopping? numeric variable (1 = Yes; 2 = No).
41. Do the people you live with cover their elbows if they sneeze / cough? numeric variable (1 = Yes; 2 = No).
42. Do you use a cohabitant who has passed COVID-19 (with symptoms, with or without confirmation by PCR, or PCR + without symptoms)? numeric variable (1 = Yes; 2 = No).
43. Do you use public transport to

- If "yes", continue with question 44; if "no, jump to question 46.
- 44. Which type of public transport? numeric variable (1 = bus, 2 = metro, 3 = train, 4 = taxi, 5 = bicycle(multiple answer allowed)).
- **45.** How many days a week do you use public transport? |\_\_| numeric variable (1 to 7).
- 46. Do you use private transportation to get to work? numeric variable (1 = Yes; 2 = No). If "yes", continue with question 47; if "no", jump to question 49.
- 47. Which private transport? numeric variable (1 = single use car, 2 = shared car, 3 = single use bike, 4 =shared bike, 5 = bike (multiple answer allowed)).
- 48. How many days pen weekt do / poj as and in a second rest and pot 2/ build a linear character of the other second rest and the second rest of t

# **49.** Do you walk the street for more than 15 minutes? numeric variable (1 = Yes; 2 = No). If "yes", continue with question 50; if "no", jump to question 52.

- 50. How many days a week do you go for a walk? |\_\_| numeric variable (1 to 7).
- 51. For how many minutes a day do you go for a walk as an average: |\_\_| minutes / day numeric variable.

# D. COVID-19 tests performed

- 52. Have you had a COVID-19 PCR test? numeric variable (1 = Yes, only one; 2 = Yes, several; 3 =
- **53.** COVID-19 PCR test performed on day: | dd | mm | yy|.
- **54.** COVID-19 PCR test result numeric variable (1 = Negative; 2 = Positive).
- No). If "1", continue with question 53; if "2", jump to question 55; if "3", jump to question 59. COVID-19 PCR test performed on day: | dd | mm | yy|. COVID-19 PCR test result numeric variable (1 = Negative; 2 = Positive). How many COVID-19 PCR test have you had in total? | \_ \_ | numeric variable (1 to 10). Depending on the answer, open as many questions with the number of PCR made to ask the date and result in the same format (A1 and A2; B1 and B2; etc). A1. COVID-19 PCR test performed on day: | dd | mm | yy|. A2. COVID-19 PCR test result numeric variable (1 = Negative; 2 = Positive). When you had your first COVID-19 PCR test, did you present any of these signs or symptoms? numeric variable (multiple answer allowed) (1 = Febricula (>37.3°C); 2 = Fever (>38°C); 3 = Cough; 4 = Odynophagia (sorethroat); 5 = Headache; 6 = Arthromyalgia (generalized pain); 7 = Astheniae **55.** How many COVID-19 PCR test have you had in total? |\_\_| numeric variable (1 to 10).
- 56. When you had your first COVID-19 PCR test, did you present any of these signs or symptoms numeric variable (multiple answer allowed) (1 = Febricula (>37.3°C); 2 = Fever (>38°C); 3 = Cough; 4 = Odynophagia (sorethroat); 5 = Headache; 6 = Arthromyalgia (generalized pain); 7 = Asthenia (intense fatigue); 8 = Dyspnoea (shortness of breath); 9 = Anosmia (loss of smell); 10= Nausea vomiting; 11 = Diarrhea; 12 = Skin lesions; 13 = Myoclonus (involuntary movements); 14 Pneumonia; 15 = Other (specify: string variable \_\_\_\_\_\_\_). Have you had a COVID-19 rapid antibody test? numeric variable (1 = Yes; 2 = No). COVID-19 rapid antibody test result numeric variable (1 = Negative; 2 = Positive). /, we would like to complete the information provided with information about your lifestyle. Covid (1 = Yes; 2 = No). COVID-19 rapid antibody test result numeric variable (1 = Negative; 2 = No). If "yes", continue with question 60; if "no", jump to question 64. How many glasses of wine do you drink every week? |\_\_\_| numeric variable How many glasses of cognac, gin or other spirits do you drink every week? |\_\_\_| numeric variable How many glasses of cognac, gin or other spirits do you drink every week? |\_\_\_| numeric variable Has your alcohol consumption changed during the pandemic compared to your consumption previously? numeric variable (1 = No, it is similar; 2 = Yes, it has increased; 3 = Yes, it has decreased). How many roll-ypur-own cigarrettes do you smoke every day? |\_\_\_| numeric variable Has your tobacco consumption changed during the pandemic compared to your consumption previously? numeric variable (1 = No, it is similar; 2 = Yes, it has increased; 3 = Yes, it has decreased). How many roll-ypur-own cigarrettes do you smoke every day? |\_\_\_| numeric variable Has your tobacco consumption changed during the pandemic compared to your consumption previously? numeric variable (1 = No, it is similar; 2 = Yes, it has increased; 3 = Yes, it has decreased). = Odynophagia (sorethroat); 5 = Headache; 6 = Arthromyalgia (generalized pain); 7 = Asthenia
- 57. Have you had a COVID-19 rapid antibody test? numeric variable (1 = Yes; 2 = No).
- **58.** COVID-19 rapid antibody test result numeric variable (1 = Negative; 2 = Positive).

# Finally, we would like to complete the information provided with information about your lifestyle.

- E. Lifestyle
  - **59.** Do you drink any alcoholic beverage at least once a week? numeric variable (1 = Yes; 2 = No).
  - **60. How many glasses of wine do you drink every week?** I numeric variable
  - **61. How many beers do you drink every week?** |\_\_| numeric variable
  - 62. How many glasses of cognac, gin or other spirits do you drink every week? |\_\_| numeric variable
  - 63. Has your alcohol consumption changed during the pandemic compared to your consumption
  - 64. Regarding tobacco use: numeric variable (1 = I have never smoked; 2 = I am a former smoker; 3 = I

- 65. How many roll-ypur-own cigarrettes do you smoke every day? |\_\_| numeric variable
- 66. Has your tobacco consumption changed during the pandemic compared to your consumption decreased).

# F. End of the survey

Thank you very much for your participation. As mentioned before, all information from this survey and the tests performed is confidential and will be anonymized.

If you would like to leave us any further comments regarding the pandemic at the ICO Centers, please do so below:

67. Commentaries. Open answer, leave space for about 5 lines of text. For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Supplementary Table 1. Demographic characteristics of on-sit	e workers
(always/ocassionally) and teleworkers	

	Teleworkin		
	Never/ocassionally (n=981)	p-value	
	n (%)	n (%)	p ratae
Sex			
Male	240 (25)	47 (20)	
Female	736 (75)	183 (80)	0,183
Age [median, (min-max)]	43 (19-68.5)	44.9 (19-71.6)	0,015
<35y	271 (28)	38 (17)	
35-49y	429 (44)	122 (53)	
>49y	281 (29)	70 (30)	0,002
ICO Center			
ICO L'Hospitalet	684 (70)	184 (80)	
ICO Girona	182 (19)	17 (7)	
ICO Badalona	<b>103 (11)</b>	29 (13)	
ICO Tarragona / Terres de l'Ebre	12 (1)	0 (0)	<0.0001
Health care workers			
Yes	567 (59)	72 (32)	
No	402 (41)	152 (68)	<0.0001
Middle and superior technicians	187 (19)	92 (41)	
Porters	17 (2)	3(1)	
Administrative staff	90 (9)	35 (16)	
Maintenance or security stafft	29 (3)	2 (1)	
Cleaning staff	46 (5)	15 (7)	
Restoration staff	16 (2)	2 (1)	
Others	17 (2)	3 (1)	<0.0001
Any Comorbidity	142 (15)	38 (17)	0,4
Smoking history			
Never	511 (54)	126 (56)	
Ever	438 (46)	98 (44)	0,5
Past	277 (29)	66 (29)	
Current	161 (17)	32 (14)	0,6
Cohabiting	889 (91)	209 (92)	0,8
Cohabiting with covid-19	115 (14)	27 (14)	0,9
<b>Reported rRT-PCR previous to serology</b>	422 (84)	42 (75)	0,1
Positive of previous rRT-PCR	62 (15)	10 (24)	0,1

Supplementary Table 2. Clinical characteristics associated with SARS-CoV-2 positive serology among those who report rRT-PCR prevaus to study serology (n=469).

Page 32 of 33

( <b>n</b> =4	<b>169).</b>				j ci	
1 2		Total participants n (%)	SARS-CoV-2 seroprevalence n (%)	Prevalence (95%CI)		Adjusted PR (95% CI) <sup>2</sup>
3						0 5 6 7 7
	orted rRT-PCR previous to serology	469 (38.0)	86 (78.2)	18.34 (15.08-22.11)	including for	ば マ
	ult of previous rRT-PCR				ng f	REF
6	Negative	397 (84.6)	27 (31.0)	6.80 (4.70-9.74)	<u>e</u>	REF
7 8	Positive	72 (15.4)	59 (68.6)	81.94 (71.31-89.23)		12.15 (7.54-19.57)
~	<b>nber of symptoms</b> (mean, standard deviation)	1.65 (2.10)	3.08 (2.61)		:o:0 1.000 €.	
10 11	None	217 (46.3)	21 (24.0)	9.68 (6.39-14.4)		REF
11	One	61 (13)	7 (8.1)	11.48 (5.56-22.21)	ed t	<b>5</b> 1.13 (0.48-2.67)
12	2-3	109 (23.2)	22 (25.6)	20.18 (13.66-28.78)	lo nt	2.03 (1.10-3.73)
13	≥ 3 ≥4	81 (17.3)	35 (40.7)	43.21 (32.87-54.18)	<0.00 H g	4.33 (2.48-7.59)
14 15	 p-trend (among exposed)	01 (17.5)	55 (40.7)	+3.21 (32.07-3 <del>+</del> .10)	<pre>&lt;0.00 Enseignement Superior </pre>	<0.001
<sup>16</sup> Rep	orting COVID-19 compatible symptoms when '-PCR was performed				aur (ABES) . I data mining, Al training, Al training, and s <0.000 and s <0.000 and s <0.000 and s	from
18	No	217 (46.3)	21 (24.0)	9.68 (6.39-14.4)	nini S	REF
19 20	Yes	251 (53.5)	64 (74.4)	25.5 (20.48-31.27)	<0.00	2.49 (1.51-4.10)
20 21 CO	VID-19 symptoms				≥ t	
22	Headache	126 (26.9)	36 (41.9)	28.57 (21.35-37.08)	<0.00 trai	1.87 (1.20-2.93)
23	Cough	119 (25.4)	37 (43.0)	31.09 (23.42-39.97)	<0.00	2.25 (1.44-3.52)
24	Asthenia	110 (23.5)	36 (41.9)	32.73 (24.6-42.04)	بور <0.00>	2.38 (1.53-3.72)
25 26	Arthromyalgia	80 (17.1)	57 (66.0)	36.25 (26.47-47.31)	<0.00 <b>Å</b>	2.32 (1.47-3.67)
20	Low-grade fever (37.3°C-38°C)	73 (15.6)	26 (30.2)	35.62 (25.5-47.21)	< 0.00	<b>2</b> .71 (1.67-4.39)
28	Odynophagia	64 (13.6)	14 (16.3)	21.88 (13.39-33.65)	0.40 <b>a</b>	1.18 (0.65-2.13)
29	Diarrhoea	58 (12.4)	16 (18.6)	27.59 (17.62-40.43)	0.05	1.47 (0.83-2.60)
30	Anosmia	42 (9)	33 (38.4)	78.57 (63.65-88.48)	<0.00	۵.09 (3.86-9.60)
31 32	Dyspnoea	40 (8.5)	11 (12.8)	27.50 (15.91-43.2)	0.12 <b>0</b>	1.18 (0.65-2.13)         1.47 (0.83-2.60)         6.09 (3.86-9.60)         1.56 (0.81-3.00)
33	Fever $(>38^{\circ}C)$	28 (6)	15 (17.4)	53.57 (35.4-70.84)	<0.00	3.06 (1.71-5.46)
34	Nausea / vomiting	17 (3.6)	6 (7)	35.29 (16.75-59.66)		
35	Skin lesions	8 (1.7)	1 (1.2)	12.50 (1.72-53.86)	0.66	0.74 (0.10-5.38)
36	Pneumonia	3 (0.6)	2 (2.3)	66.67 (15.27-95.69)	0.03	2.99 (0.71-12.63)
37 3 <del>8</del>	Myoclonus	2 (0.4)	0		0.50	1.86 (0.80-4.36) 0.74 (0.10-5.38) 2.99 (0.71-12.63)
20						

39 Numbers do not always sum up the total due to some missing values (none of the categories present more than 5% of missing values). PR: Prevalence Ratio, CI: Confidence Interva 40 variables (Fisher's exact test corrected for continuity) and median test for continuous variables. <sup>2</sup> Adjusted for sex, age (continuous), ICO center, care staff, telework and cohabitants 41 42 43 For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

ßо

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

- 44 45
- 46



		BMJ Open BMJ Open BMJ Open BMJ Open BMJ Open BMJ Open BMJ Open BMJ Open	Page 3		
STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of cress-sectional studies					
Section/Topic	ltem #	Recommendation	Reported on page #		
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract 둘 파울	3		
		(b) Provide in the abstract an informative and balanced summary of what was done and what 광용 bound	3		
Introduction	•	ated			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	5		
Objectives	3	State specific objectives, including any prespecified hypotheses	5		
Methods		anded			
Study design	4	Present key elements of study design early in the paper	5		
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure w-up, and data collection	5		
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	5		
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifierd. Get diagnostic criteria, if applicable	7		
Data sources/	8*	For each variable of interest, give sources of data and details of methods of assessment (meagurement). Describe	7		
measurement		comparability of assessment methods if there is more than one group			
Bias	9	Describe any efforts to address potential sources of bias	5,6,19		
Study size	10	Explain how the study size was arrived at	5		
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which grothings were chosen and why	7		
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	8		
		(b) Describe any methods used to examine subgroups and interactions	8		
		(c) Explain how missing data were addressed	8		
		(d) If applicable, describe analytical methods taking account of sampling strategy	NA		
	ļ	(e) Describe any sensitivity analyses     a	NA		
Results		2i q e			

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

 bmjopen-20; 1 by copyrig

aphique de l

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, exagin de for eligibility,	9
		confirmed eligible, included in the study, completing follow-up, and analysed දි දී	
		(b) Give reasons for non-participation at each stage	9
		(c) Consider use of a flow diagram	6
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information 5 mo potential confounders	9
		(b) Indicate number of participants with missing data for each variable of interest	9
Outcome data	15*	Report numbers of outcome events or summary measures	12
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	12
		(b) Report category boundaries when continuous variables were categorized	9
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaning reting period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analy	15
Discussion		ning Sping	
Key results	18	Summarise key results with reference to study objectives $\ge$ $\exists$ .	17
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	21
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	17
Generalisability	21	Discuss the generalisability (external validity) of the study results	21
Other information		ar te	
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable for the original study on	22
		which the present article is based	

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in controls in case-control studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.grg/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.grobe-statement.org.